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A B S T R A C T
Background
Trigger finger is a common clinical disorder, characterised by pain and catching as the patient flexes and extends digits because of
disproportion between the diameter of flexor tendons and the A1 pulley. The treatment approach may include non-surgical or surgical
treatments. Currently there is no consensus about the best surgical treatment approach (open, percutaneous or endoscopic approaches).
Objectives
To evaluate the effectiveness and safety of different methods of surgical treatment for trigger finger (open, percutaneous or endoscopic
approaches) in adults at any stage of the disease.
Search methods
We searched CENTRAL, MEDLINE, Embase and LILACS up to August 2017.
Selection criteria
We included randomised or quasi-randomised controlled trials that assessed adults with trigger finger and compared any type of surgical
treatment with each other or with any other non-surgical intervention. The major outcomes were the resolution of trigger finger, pain,
hand function, participant-reported treatment success or satisfaction, recurrence of triggering, adverse events and neurovascular injury.
Data collection and analysis
Two review authors independently selected the trial reports, extracted the data and assessed the risk of bias. Measures of treatment
effect for dichotomous outcomes calculated risk ratios (RRs), and mean differences (MDs) or standardised mean differences (SMD) for
continuous outcomes, with 95% confidence intervals (CIs). When possible, the data were pooled into meta-analysis using the random-
effects model. GRADE was used to assess the quality of evidence for each outcome.
Main results
Fourteen trials were included, totalling 1260 participants, with 1361 trigger fingers. The age of participants included in the studies
ranged from 16 to 88 years; and the majority of participants were women (approximately 70%). The average duration of symptoms
ranged from three to 15 months, and the follow-up after the procedure ranged from eight weeks to 23 months.
The studies reported nine types of comparisons: open surgery versus steroid injections (two studies); percutaneous surgery versus steroid
injection (five studies); open surgery versus steroid injection plus ultrasound-guided hyaluronic acid injection (one study); percutaneous
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surgery plus steroid injection versus steroid injection (one study); percutaneous surgery versus open surgery (five studies); endoscopic
surgery versus open surgery (one study); and three comparisons of types of incision for open surgery (transverse incision of the skin in
the distal palmar crease, transverse incision of the skin about 2-3 mm distally from distal palmar crease, and longitudinal incision of
the skin) (one study).
Most studies had significant methodological flaws and were considered at high or unclear risk of selection bias, performance bias,
detection bias and reporting bias. The primary comparison was open surgery versus steroid injections, because open surgery is the
oldest and the most widely used treatment method and considered as standard surgery, whereas steroid injection is the least invasive
control treatment method as reported in the studies in this review and is often used as first-line treatment in clinical practice.
Compared with steroid injection, there was low-quality evidence that open surgery provides benefits with respect to less triggering
recurrence, although it has the disadvantage of beingmore painful. Evidence was downgraded due to study design flaws and imprecision.
Based on two trials (270 participants) from six up to 12 months, 50/130 (or 385 per 1000) individuals had recurrence of trigger finger
in the steroid injection group compared with 8/140 (or 65 per 1000; range 35 to 127) in the open surgery group, RR 0.17 (95% CI
0.09 to 0.33), for an absolute risk difference that 29% fewer people had recurrence of symptoms with open surgery (60% fewer to 3%
more individuals); relative change translates to improvement of 83% in the open surgery group (67% to 91% better).
At one week, 9/49 (184 per 1000) people had pain on the palm of the hand in the steroid injection group compared with 38/56 (or 678
per 1000; ranging from 366 to 1000) in the open surgery group, RR 3.69 (95% CI 1.99 to 6.85), for an absolute risk difference that
49% more had pain with open surgery (33% to 66% more); relative change translates to worsening of 269% (585% to 99% worse)
(one trial, 105 participants).
Because of very low quality evidence from two trials we are uncertain whether open surgery improve resolution of trigger finger in the
follow-up at six to 12 months, when compared with steroid injection (131/140 observed in the open surgery group compared with
80/130 in the control group; RR 1.48, 95% CI 0.79 to 2.76); evidence was downgraded due to study design flaws, inconsistency and
imprecision. Low-quality evidence from two trials and few event rates (270 participants) from six up to 12 months of follow-up, we are
uncertain whether open surgery increased the risk of adverse events (incidence of infection, tendon injury, flare, cutaneous discomfort
and fat necrosis) (18/140 observed in the open surgery group compared with 17/130 in the control group; RR 1.02, 95% CI 0.57
to 1.84) and neurovascular injury (9/140 observed in the open surgery group compared with 4/130 in the control group; RR 2.17,
95% CI 0.7 to 6.77). Twelve participants (8 versus 4) did not complete the follow-up, and it was considered that they did not have a
positive outcome in the data analysis. We are uncertain whether open surgery was more effective than steroid injection in improving
hand function or participant satisfaction as studies did not report these outcomes.
Authors’ conclusions
Low-quality evidence indicates that, compared with steroid injection, open surgical treatment in people with trigger finger, may result
in a less recurrence rate from six up to 12 months following the treatment, although it increases the incidence of pain during the first
follow-up week. We are uncertain about the effect of open surgery with regard to the resolution rate in follow-up at six to 12 months,
compared with steroid injections, due high heterogeneity and few events occurred in the trials; we are uncertain too about the risk of
adverse events and neurovascular injury because of a few events occurred in the studies. Hand function or participant satisfaction were
not reported.
P L A I N L A N G U A G E S U M M A R Y
Surgery for trigger finger
Background
Trigger finger is clinically characterised by pain and catching during finger movements. Classically, the initial treatment is non-
surgical using nonsteroidal anti-inflammatory drugs, splinting and corticosteroid injection, and may require surgical treatment if the
conventional treatment fails. Although it is a common condition, there is no consensus about the best surgical treatment approach
(by skin incision and direct vision of the hand structures (open); approaches via needle or blade introduced through the skin, with no
direct vision of the hand structures (percutaneous); or via a flexible tube with a light camera attached to it (endoscopic).
Study characteristics
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This Cochrane Review is current to August 2017. We included 14 randomised controlled trials involving 1260 participants, totalling
1361 trigger fingers. Two studies compared open surgery versus steroid injections, five studies compared percutaneous surgery versus
steroid injection, one study compared open surgery versus steroid injection plus hyaluronic acid injection, one study compared
percutaneous surgery plus steroid injection versus steroid injection, five studies compared percutaneous surgery versus open surgery,
one study compared endoscopic surgery versus open surgery and one study compared three types of skin incision to open surgery. The
majority of participants were female (about 70%); they were aged between 16 and 88 years; and the mean follow-up of participants after
the procedure was eight weeks to 23 months. Due to space constraints, the reporting of all results was limited to the main comparison
- open surgery versus steroid injection - because open surgery is the oldest and the most widely used treatment method and considered
as standard surgery, whereas steroid injection is the least invasive control treatment method as reported in the studies in this review and
is often used as first-line treatment in clinical practice.
Key results
Based on two trial (270 participants), compared with the steroid injection procedure:
Resolution of trigger finger (lessening of symptoms with no recurrence):
• 92 out of 100 people had resolution of symptoms with open surgery.
• 61 out of 100 people had resolution of symptoms with steroid injection.
Incidence of pain, assessed as the presence or absence of pain after the procedure was performed (at one week):
• 49% more people had pain with open surgery (33% to 66% more).
• 68 out of 100 people had pain with open surgery.
• 19 out of 100 people had pain with steroid injection.
Recurrence of the trigger finger (from six to 12 months):
• 29% fewer people had recurrence of symptoms with open surgery (60% fewer to 3% more).
• 7 out of 100 people had recurrence of symptoms with open surgery.
• 39 out of 100 people had recurrence of symptoms with steroid injection.
Adverse events:
Adverse events including infections, tendon injuries, cutaneous discomfort, flare or fat necrosis at the procedure site, or neovascular
events were uncommon in either treatment group.
No study reported hand function or participant-reported treatment success or satisfaction.
Quality of the evidence
Very low quality evidence from two trials means we are uncertain whether open surgery improve resolution of trigger finger in
comparison with steroid injection, due the risk of bias in the design of the studies, inconsistencies between studies and the small number
of participants in studies. Low-quality evidence from two trials shows that open surgery may result in fewer recurrences of trigger
finger compared with steroid injection procedure, although it increases the incidence of pain during the first week after the procedure.
Evidence was downgraded to ’low’ due to the risk of bias in the design and the small number of participants. No studies measured
functional improvement or participant satisfaction in the comparison between open surgery and steroid injection. We are uncertain
whether there is a difference in the risk of adverse events or neurovascular injury between treatments, as few events occurred in the
studies.
Only low and very low-quality evidence was found for other comparisons so we are uncertain if percutaneous surgery has any benefits
over steroid injection, or if open surgery is better than steroid plus hyaluronic acid, or if one type of surgery is better than another.
3Surgery for trigger finger (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Open surgery versus steroid injection for treating trigger finger
Patient or population: pat ients with trigger f inger
Settings: hospital
Intervention: open surgery
Comparison: steroid inject ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Steroid injection Open surgery
Resolution of symp-
toms
(af ter one or more in-
ject ions)
Follow-up: 6 to 12
months
615 per 1000 911 per 1000
(486 to 1000)
RR 1.48
(0.79 to 2.76)
270
(2 RCTs)
⊕©©©
VERY
LOW 1,2,3
Absolute dif f erence:
28% more had resolu-
t ion of symptoms with
open surgery (2% fewer
to 58% more); relat ive
change: 48%more (21%
fewer to 176% more).
The NNTH n/ a4.
Pain
Proport ion with pain on
the palm of the hand
Follow-up: 1 week
184 per 1000 678 per 1000
(366 to 1000)
RR 3.69
(1.99 to 6.85)
105
(1 RCT)
⊕⊕©©
LOW 1,3
Absolute risk dif f er-
ence: 49% more people
had pain with surgery
(33% to 66% more),
and the relat ive per-
cent change translates
to worsening of 269%
(585% to 99% worse).
The NNTH was 3 (95%
CI 1 to 5)
Function
Not measured
See comment See comment See comment - See comment Not measured in any
trial.4
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Participant global as-
sessment of success
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Recurrence
Follow-up: range 6 to 12
months
385 per 1000 65 per 1000
(35 to 127)
RR 0.17
(0.09 to 0.33)
270
(2 RCTs)
⊕⊕©©
LOW 1,3
Absolute risk dif f er-
ence: 29% fewer peo-
ple had recurrence
with open surgery (60%
fewer to 3% more),
and the relat ive per-
cent change translates
to improvement of 83%
(67% to 91% better).
NNTB 4 (95%CI 3 to 4)
Adverse events
(infect ion, tendon or
pulley injury, f lare, cu-
taneous discomfort , f at
necrosis)
Follow-up: range 6 to 12
months
131 per 1000 133 per 1000
(75 to 241)
RR 1.02 (0.57 to 1.84) 270
(2 RCTs)
⊕⊕©©
LOW 1,3
Absolute risk dif f er-
ence: 0% (3% fewer to
4% more), and the rel-
at ive percent change
translates to worsening
of 2% (43% better to
84% worse). The NNTH
n/ a4.
Neurovascular injury
Follow-up: range 6 to 12
months
31 per 1000 67 per 1000
(22 to 208)
RR 2.17 (0.7 to 6.77) 270
(2 RCTs)
⊕⊕©©
LOW 1,3
Absolute risk dif f er-
ence: 2% more people
had neurovascular in-
jury with open surgery
(6% fewer to 11%more)
; relat ive change: 117%
more (30% fewer to
577%more). The NNTB
n/ a4.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The trials had methodological f laws: risk of detect ion bias.
2Inconsistency: heterogeneity was high.
3Imprecision: the total number of events was small, or the 95% conf idence interval includes both open surgery and steroid
inject ion groups, or the 95% conf idence interval includes both no clinical ef fect, and ‘‘appreciable benef it ’’ in favour of the
open surgery group.
4Number needed to treat to benef it (NNTB), or harm (NNTH) not applicable (n/ a) when result is not stat ist ically signif icant. NNT
for dichotomous outcomes calculated using Cates NNT calculator (http:/ / www.nntonline.net/ visualrx/ ). NNT for cont inuous
outcomes calculated using Wells Calculator (CMSG editorial of f ice).
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B A C K G R O U N D
Flexor tendons of the hands slide inside osteofibrous tunnels (pul-
leys) (Akhtar 2005; Doyle 1975; Doyle 1977; Doyle 1988; Doyle
1989; Jones 1988). Trigger finger is a common clinical disor-
der, characterised by catching or snapping as the patient flexes
and extends digits because of a disproportion between the diam-
eter of flexor tendons and the A1 pulley (Akhtar 2005; Eastwood
1992; Sato 2012; Wolfe 2005). The gliding of the flexor tendons
can cause adaptive changes that lead to stenosis of the A1 pulley
(Sampson 1991). The friction caused in the flexor tendons when
passing through the stenotic pulley can change the fibres, form-
ing an intratendinous lump (Hueston 1972). The clinical mani-
festation may vary from an occasional snapping to finger locked
in flexion (Akhtar 2005; Peters-Veluthamaningal 2009; Quinnell
1980), although sometimes locking in extension, hence an in-
ability to achieve flexion of the affected finger, can also occur
(Hueston 1972). The presence of pain is common, ranging from
severe tomild discomfort, often in the palm, on themetacarpopha-
langeal (MCP) joint or on the proximal interphalangeal (PIP) joint
(Eastwood 1992; Ryzewicz 2006).
Description of the condition
Trigger finger has an incidence of about 2.6% in the general popu-
lation (Strom 1977). It is one of the most common causes of pain
and disability in the hand (Akhtar 2005; Wolfe 2005). It is four to
six times more frequent in women, and can occur at any age, but
it more often affects the dominant hand of people in their fifties
(Fleisch 2007; Sato 2012; Weilby 1970). The most affected digits
are the thumb, ring and middle finger; the index finger is almost
always the least involved (Blyth 1996; Ragoowansi 2005; Weilby
1970). It is not uncommon for a person to have multiple trigger
digits (Ryzewicz 2006; Sheikh 2014). Notta 1850 first described
this disease many years ago. Although histological changes of A1
pulley and synovial proliferation have been identified as factors
that prompt trigger finger, the exact aetiology is still unknown
(Quinnell 1980; Sampson 1991; Sato 2012). Some diseases are as-
sociated with trigger finger, such as gout, carpal tunnel syndrome,
DeQuervain’s disease, diabetes, amyloidosis andmucopolysaccha-
ridosis, as a consequence of connective tissue metabolism changes
(Akhtar 2005; Ryzewicz 2006; Turowski 1997); in the population
of diabetic patients, for example, the incidence of trigger digits
reaches 10% (Stahl 1997). The patient may start feeling pain on
the palm or in the proximal interphalangeal joint without trig-
gering of the digit; these symptoms may disappear or increase in
severity, leading to pain and hand dysfunction and they can re-
sult in stiffness of the affected fingers’ PIP joint (Ryzewicz 2006).
Quinnell 1980 classified trigger finger into five types: type zero
(0), with normal motion; type I, uneven movement; type II, trig-
ger finger that is actively corrected; type III, trigger finger that
needs an external force for unlocking; and type IV, with a fixed
deformity.
Description of the intervention
The initial treatment for trigger finger is conservative and
involves activity modification, non-steroidal anti-inflammatory
drugs, splinting (Patel 1992), and corticosteroid injection (Kazuki
2006; Murphy 1995; Ring 2008). A Cochrane Review sum-
marised the efficacy of corticosteroid injections for trigger finger
in adults. Corticosteroid injection with lidocaine was more effec-
tive than lidocaine alone; however, only two small studies were
included on this review. The risk of adverse events was uncertain
(Peters-Veluthamaningal 2009).
However, some studies reported recurrence rate up to 48% af-
ter corticosteroid treatment (Kazuki 2006; Rhoades 1984; Ring
2008). For any stage of the disease, the initial treatment is conser-
vative; however, if tendinous obstruction symptoms are not satis-
factorily relieved through conservative treatments, the A1 pulley is
sharply incised longitudinally, through an open (Fahey 1954; Paul
1992), percutaneous (Bain 1995; Cebesoy 2007; Eastwood 1992;
Gilberts 2001; Lorthioir 1952; Pope 1995), or endoscopic (Pegoli
2008) surgical approach. Surgical treatment for trigger finger has
a reported success rate of up to 97% (Gilberts 2001; Pegoli 2008;
Turowski 1997).
The open surgical method involves skin incision, dissection of
the neurovascular bundles, and identification and incision of the
A1 pulley under direct vision, which arguably minimises the in-
jury risk to other structures (Akhtar 2005; Fahey 1954; Turowski
1997).
Lorthioir 1952 first described the percutaneous method using
a small tenotome. Eastwood 1992 used a needle in the proce-
dure. Nowadays the technique consists of cutting the A1 pulley
by a percutaneous insertion of a small instrument (e.g. needle or
hook knife) under local anaesthesia (Gulabi 2014; Guler 2013;
Rojo-Manaute 2012a). Some argue that this approach may in-
crease the risk of damaging the neurovascular bundle, flexor ten-
don and capsule, but the approach is gaining acceptance due to the
convenience of surgically treating trigger finger with no incision
(Cebesoy 2007; Gilberts 2001 Gulabi 2014; Huang 2015).
Endoscopic release consists of two small incisions through which
a type of fibre-optic endoscope (camera) passes (Pegoli 2008). The
pulley is identified and is opened by a small lamina adapted to the
endoscope (Pegoli 2008). This procedure is the least common due
to its costs and greater learning curve (Pegoli 2008).
How the intervention might work
The pulleys are fibrous tissue bands that maintain the flexor ten-
dons in a constant connection to the joint axis of motion; the A1
pulley begins on the volar plate of the MCP joint, from which
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about two-thirds of its fibres emerge, while its remaining portion is
attached to the base of the proximal phalanx (Doyle 1988). People
with trigger finger exhibit a pulley stenosis A1 and changes in the
fibres of the flexor tendons, with the formation of an intratendi-
nous node and consequent rebound or blocking of the movement
of the affected finger (Hueston 1972), and the surgical treatment
consists of sectioning the pulley A1while preserving the flexor ten-
dons to restore the coordinated movement of the finger (Akhtar
2005; Paul 1992). Surgical treatment can be performed through
open, percutaneous or endoscopic surgery. Studies of open surgery
have reported that the method has the advantage of directly visu-
alizing the structures, allowing a complete section of the A1 pulley
with minimum risk of injury to the flexors, tendon and neurovas-
cular bundles (Paul 1992; Turowski 1997), although complica-
tions such as surgical site infection and hypertrophic scar or pain
have been reported as potential disadvantages (Thorpe 1988). The
advantages described for percutaneous surgery are the option to
perform a surgical procedure without incising the skin, early return
to activities (3.9 days on average) and quick implementation of
the technique (seven minutes on average), but disadvantages such
as risk of neurovascular injury, or injury to flexor tendons or the
joint capsule have been reported, because these structures could
not be visualized (Cebesoy 2007; Gilberts 2001; Huang 2015).
Some studies, however, have described cutaneous parameters of
the palmar surface that serve as reference to locate the A1 pulley
(Fiorini 2011; Wilhelmi 2001). In endoscopic surgery the pulley
A1 section is performed under indirect visualization with a camera
introduced through the skin, and the absence of scar contraction,
early return to activities and quick execution of the procedure (4½
minutes on average) were reported as the main advantages of the
technique; on the other hand, the high cost and long learning
curve were reported as disadvantages (Pegoli 2008).
Why it is important to do this review
Trigger digit is one of the most common forms of tenosynovitis,
and affectsmostlymiddle-agedwomen’s hands (Sato 2012;Weilby
1970). It can lead to long-term pain, deformity and disability
(Akhtar 2005; Eastwood 1992). Despite its high frequency, there
is no consensus about the best surgical approach to treat it.
This review summarises the available evidence in the literature of
surgical interventions, considering safety and benefits of treatment
as measured by resolution of the condition, pain, hand function,
patient satisfaction, frequency of recurrence of triggering, adverse
events and neurovascular injury.
O B J E C T I V E S
To evaluate the effectiveness and safety of different methods of
surgical treatment for trigger finger (open, percutaneous or endo-
scopic approaches) in adults at any stage of the disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included any randomised or quasi-randomised (not strictly
random: e.g. by date of birth, hospital record number, alternation)
controlled trials of surgical treatment for trigger finger.
Types of participants
We included all studies involving adults who had been diagnosed
with trigger finger. Any trials exclusively including adolescents or
children were excluded. Studies that included children were only
included if the proportion of children was less than 10%, or data
were presented separately for adults.
This review assessed only adults because the physiopathology,
treatment timing and techniques are different in children.
Types of interventions
Surgical treatment for trigger finger was considered, including
open, percutaneous or endoscopic techniques.
All control interventions were eligible, including non-surgical in-
terventions (use of splinting, physiotherapy and corticosteroids
infiltration), placebo, no interventions (’wait and see’) and any
other therapy (including different surgical interventions).
We included studies with co-interventions, as long as the effect of
surgery could be assessed (i.e. we excluded trials that used the same
surgery in two treatment arms plus a co-intervention in one arm).
Studies that included co-interventions as a comparator were as-
sessed separately from studies with a single comparator (e.g. open
surgery versus percutaneous surgery plus steroid injection were as-
sessed separately from trials comparing open surgery and percuta-
neous surgery).
Types of outcome measures
We considered for inclusion studies that included at least one of
the following outcome measures.
Major outcomes
1. Resolution of trigger finger (as defined in the trials).
2. Pain. Severity of pain or tenderness at the base of the digit
on the palm of the hand, or incidence of pain as a dichotomous
outcome. Preference was given to reports of the severity of pain
measured using validated pain scales (visual analogue scale (VAS)
or numerical rating scale).
3. Functional status of the hand (using validated instruments
to measure hand function, e.g. Disability of the Arm, Shoulder
and Hand questionnaire, or DASH).
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4. Participant-reported treatment success or satisfaction (either
reported as a proportion with success, or using validated
questionnaires).
5. Frequency of recurrence of triggering or locking of the
affected fingers.
6. Number of patients experiencing any adverse event (e.g.
superficial infection, deep infection and adherence).
7. Neurovascular injury.
Timing of outcomes measurement
If there were available data, we extracted outcomes at the following
time periods: short-term follow-up (up to three months following
treatment); intermediate follow-up (more than three months and
up to six months after the end of treatment); and long-term (more
than six months after the end of treatment). When multiple time
points (e.g. one, six, eight and 12 weeks’ follow-up) were reported
in the trials, we extracted all available data and reported the re-
sults; however in the analysis of the different comparison groups
of the studies that reported results in the same period of time,
we grouped the data using the time period reported in the publi-
cations. When different time periods were reported in studies of
the same analysis group, we used the longest time period reported
in each study for the outcomes ’resolution’, ’hand function’, ’pa-
tient satisfaction’, ’recurrence of trigger finger’, ’adverse events’ and
’neurovascular injury’ for the short-term, intermediate-term and
long-term periods. For the pain outcome we used the shortest time
period reported in the short-term; however in the intermediate
and long term we carried out the analyses using the longest time
period reported. To prepare the ’Summary of findings’ tables we
reported the data using the longest time period assessed in each
study for the outcomes ’resolution’, ’hand function’, ’patient sat-
isfaction’, ’recurrence of trigger finger’, ’adverse events’ and ’neu-
rovascular injury’; while for the outcome ’pain’, we reported the
shortest time period assessed in the studies, as we believe that the
pain assessment in the period closest to the date of the procedure
is very important for patients deciding between the various types
of treatment, and is different from the other outcomes, in which
the longest period of time is the most important factor in the ther-
apeutic decision.
Search methods for identification of studies
Electronic searches
Our search strategy followed Cochrane Musculoskeletal Group
(CMSG) methods used in reviews. We searched the Cochrane
Central Register of Controlled Trials (CENTRAL; 2017, Issue 7)
in the Cochrane Library (searched 16 August 2017), MEDLINE
(1946 to 02 August 2017), Embase (1947 to 02 August 2017)
and Latin American and Caribbean Health Sciences (LILACS,
1982 to 02 August 2017) (Appendix 1; Appendix 2; Appendix
3; Appendix 4; Appendix 5). We set no restrictions based on lan-
guage, publication status or publication date.
In MEDLINE (Ovid), the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials (sensitivity and preci-
sion-maximising version) (Lefebvre 2009) was combined with the
subject-specific search (Appendix 2). TheMEDLINE strategy was
adapted appropriately for the other databases.
We also searched the registries ClinicalTrials.gov (U.S. National
Institute of Health) and World Health Organization (WHO)
International Clinical Trial Registry Platform for ongoing and re-
cently completed studies (15 September 2017) (Appendix 6;
Appendix 7).
Searching other resources
We checked the reference lists of included articles, reviews and
textbooks for possible relevant studies.
Data collection and analysis
The intended methodology for data collection and analysis was
described in our published protocol (Ventin 2014), which was
based on the one explained in theCochraneHandbook for Systematic
Reviews of Interventions (Higgins 2011a).
Selection of studies
Two review authors (HFJ and MJT) independently screened title
and abstract of studies thatmet the inclusion criteria for this review.
They resolved differences by discussion and consensus and, when
necessary, by discussion with the third review author (JCB).
Data extraction and management
Two review authors (HFJ and MJT) used a piloted data extraction
form to independently collect data, including the following.
• Study design and duration, funding sources and details of
trial registration.
• Place of study, number of participants assigned and
assessed, inclusion criteria, exclusion criteria, age, gender, side,
affected digits and classification of trigger finger.
• Characteristics of study interventions including timing of
intervention, duration of treatment, type of surgery (open,
percutaneous or endoscopic) or conservative interventions
(steroid only or steroid plus hyaluronic acid injection),
rehabilitation and any co-interventions.
• Characteristics of study outcomes such as duration of
follow-up, loss to follow-up and outcomes reported in the
studies.
We included nine comparisons: open surgery versus steroid injec-
tion; percutaneous surgery versus steroid injection; open surgery
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versus steroid injection plus hyaluronic acid injection guided by
ultrasound; percutaneous surgery plus steroid injection versus
steroid injection; percutaneous surgery versus open surgery; en-
doscopic surgery versus open surgery; open surgery by transver-
sal incision of the skin about 2-3 mm distally from distal palmar
crease versus open surgery by longitudinal incision of the skin at
the level of the A1-pulley without crossing the distal palmar crease
proximal; open surgery by transversal incision of the skin in the
distal palmar crease versus open surgery by longitudinal incision
of the skin at the level of the A1-pulley without crossing the dis-
tal palmar crease proximal; and open surgery by transversal inci-
sion of the skin in the distal palmar crease versus open surgery by
transversal incision of the skin about 2-3 mm distally from distal
palmar crease.
We considered as the primary comparison ’Open surgery versus
steroid injection’, because open surgery is the oldest and most
traditional method of treatment for trigger finger, while steroid
injection is the least invasive method reported in the included
studies.
A third review author (JCB) resolved all initial differences of opin-
ion. There was no blinding for the study author, institution or
journal at this stage.
Two review authors (HFJ and MJT) entered data into Review
Manager 5 (RevMan 5) (ReviewManager 2014).We sent requests
to the primary trial authors of the 14 studies to clarify any omitted
data or study characteristics (Aref 2014; Bamroongshawgasame
2010; Callegari 2011; Chao 2009; Dierks 2008; Gilberts 2001;
Hansen 2017; Kloeters 2016; Maneerit 2003; Nikolaou 2017;
Pegoli 2008; Sato 2012; Singh 2005; Zyluk 2011), but only one
author responded to the e-mail (Sato 2012), informing us about
the exact number of the thumbs, index, long, ring and little fingers
included in each comparison group of the study.
Assessment of risk of bias in included studies
Two independent review authors (HFJ and ML) assessed the risks
of bias of the included studies. As recommended by Cochrane’s
’Risk of bias’ tool (Higgins 2011a), the following methodological
domains were assessed.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment: was considered blinding
separately for subjective self-reported outcomes (e.g. resolution
of symptoms, pain, function, treatment success or patient
satisfaction, recurrence) and objective outcomes (e.g. adverse
events, neurovascular injury).
5. Incomplete outcome data.
6. Selective reporting.
7. Other bias, such as major baseline imbalance, risk of bias
associated with care providers and differences in rehabilitation.
Each of these criteria was explicitly judged as described byHiggins
2011a into one of these categories: low risk of bias; high risk of bias;
and unclear risk of bias (either lack of information or uncertainty
over the potential for bias). When necessary, authors recorded and
resolved by consensus their disagreements regarding the risk of
bias for domains.
Measures of treatment effect
We calculated the risk ratios (RRs) with 95% confidence intervals
(CIs) for dichotomous outcomes. We calculated mean differences
(MDs) with 95% CIs for continuous outcomes (pain and hand
function). We planned to calculate standardised mean differences
(SMDs) for continuous outcomes if they were pooled on different
scales, but it was not necessary.
We also presented the absolute per cent difference and relative per
cent change from baseline for all outcomes in the ’Comments’
column of the ’Summary of findings’ table. For outcomes that dif-
fer statistically between treatment groups, we expressed estimate
effects as the number needed to treat for an additional beneficial
outcome (NNTB) and the number needed to treat for an addi-
tional harmful outcome (NNTH).
For dichotomous outcomes, we calculated the absolute risk dif-
ference using the risk difference statistic in RevMan 5 software
(Review Manager 2014), and expressed the result as a percentage.
For continuous outcomes, we calculated the absolute benefit as
the improvement in the intervention group minus the improve-
ment in the control group, in the original units, expressed as a
percentage.
We calculated the relative per cent change for dichotomous data as
RR − 1 and expressed as a percentage. For continuous outcomes,
we calculated the relative difference in the change from baseline
as the absolute benefit divided by the baseline mean of the control
group, expressed as a percentage.
For dichotomous outcomes, we calculatedNNTBorNNTHfrom
the event rate in the control group (unless we knew the population
event rate) using the Visual Rx NNT calculator (Cates 2008); we
used RR when adverse events were assessed and we used the odds
ratio when beneficial events were assessed. For continuous out-
comes, NNTB was calculated using the Wells calculator software
available at the CMSG editorial office (www.cochranemsk.org).
Theminimal clinically important difference (MCID) for each out-
come was determined for input into the calculator; we assumed
that a difference of 1.5 points on a 10-point pain scale between
groups is clinically important. For function, we would have as-
sumed a difference of 10 points on the 100-point DASH score is
clinically important.
Unit of analysis issues
The unit of randomisation was usually the individual participants.
Exceptionally, as in the case of trials including people with more
than one finger assessed, we assessed the trial data for fingers, in-
stead of individual participants. We planned to identify studies
that randomise or allocate clusters (e.g. many fingers) but do not
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account for clustering analysis, and when possible, re-analyse such
studies by calculating effective sample sizes according to the meth-
ods described in Higgins 2011b, but that was not necessary be-
cause none carried out cluster-allocation studies.
Dealing with missing data
We attempted to extract outcomes for all participants randomised
to any intervention. In case there was insufficient information
relative to estimate effects, such as number of participants, means,
measures of uncertainty (standard deviation or error), or number
of events and participants, we tried to contact authors of included
studies.
For dichotomous outcomes, we used number randomised as de-
nominator, making the assumption that any participants missing
at the end of treatment did not have a positive outcome (e.g. for
the outcome ’number of patients experiencing any adverse event’,
we assumed any missing participants had an adverse event).
For continuous outcomes with no standard deviation reported, we
planned to calculate standard deviations if possible from standard
errors, P values, or confidence intervals, according to the methods
outlined in Higgins 2011b; if this was not possible we considered
imputing missing standard deviations from other trials of the same
meta-analysis.
When impossible to acquire missing data, we addressed the po-
tential impact of missing data on the findings of the review in the
Discussion section.
Assessment of heterogeneity
We estimated the presence of heterogeneity across the included
studies with visual examination of the forest plot generated from
meta-analysis of studies initially considered appropriate for pool-
ing. We assessed the degree of statistical heterogeneity based on
the test for heterogeneity and the I² statistic. We interpreted the
values as follows: 0% to 40% might not be important; 30% to
60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; and 75% to 100% shows con-
siderable heterogeneity (Deeks 2011).
Assessment of reporting biases
We planned to draw funnel plots from primary outcomes to assess
the potential publication bias (small-study effects), if more than
10 studies were included in the meta-analyses. However, due to
the small number of studies included in each comparison it was
not possible to perform this type of analysis. We also assessed the
presence of bias for small studies in the overall meta-analysis by
checking whether the random-effects estimate of the intervention
effect is more efficient than the fixed-effect estimate (Sterne 2011).
Data synthesis
For results of comparable groups of studies - with similar partici-
pants, the same intervention and comparator, and using the same
outcome measure - we pooled outcomes in a meta-analysis using
the random-effects model as a default, as we expected some vari-
ation in the surgery and comparators.
GRADE and ’Summary of findings’ tables
We presented the main results (resolution of trigger finger, sever-
ity of pain, functional status of the hand DASH, participant-
reported treatment success, frequency of recurrence of triggering,
adverse events and neurovascular injury) of the review in ’Sum-
mary of findings’ tables in order to improve the readability of the
review. The ’Summary of findings’ tables provide key informa-
tion concerning the quality of evidence, the magnitude of effect of
the interventions examined (open, percutaneous and endoscopic
approach) and the sum of available data on the main outcomes
(Schünemann 2011). GRADEproGDT software was used to pro-
vide an overall grading of the quality of the evidence (GRADEpro
GDT).
Subgroup analysis and investigation of heterogeneity
Had sufficient data been available, we planned to conduct a sub-
group analysis to determine different estimated effects across dif-
ferent age ranges (i.e. younger adults (< 65 years) or older people
(65 years and older)); the presence or absence of comorbidities (in-
cluding carpal tunnel syndrome, diabetes, gout,DeQuervain’s dis-
ease, mucopolysaccharidosis, amyloidosis and rheumatoid arthri-
tis); and at different follow-up times (i.e. short-term (up to three
months), intermediate-term (more than three months and up to
six months) or long-term follow-up (greater than six months)).
Due to lack of data in included studies it was not possible to per-
form subgroup analysis for age or presence of comorbidities. It
was possible to carry out a subgroup analysis by different follow-
up times for some comparisons (see Effects of interventions).
Sensitivity analysis
We performed a sensitive analysis to investigate the robustness of
the treatment effect to allocation concealment, by removing the
trials that reported inadequate or unclear allocation concealment
from meta-analysis to see if this changes the overall treatment
effect. And we also investigated the effect of imputation of missing
data (e.g. imputation of standard deviation).
R E S U L T S
Description of studies
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See:Characteristics of included studies; Characteristics of excluded
studies and Characteristics of ongoing studies.
Results of the search
The search strategy was completed in August 2017. We found
a total of 402 records from the following databases: Cochrane
Musculoskeletal Group Specialised Register (4 records); Cochrane
Central Register of Controlled Trials (95); MEDLINE (100); Em-
base (120); LILACS (24); ClinicalTrials.gov (20); and the WHO
International Clinical Trials Registry Platform (39).
We also found three potentially eligible studies from other sources
(one from the studies thatwere included in other published reviews
and two by means of automatic search of Google Scholar related
to a previous publication on the topic of trigger finger (Fiorini
2011)).
The search result was our identification of 52 bibliographic ci-
tations for potentially includable studies, for which we obtained
full reports. We finally included 14 studies in this review, from
a total of 28 published reports. The included studies were pub-
lished between 2001 and 2017 (Aref 2014; Bamroongshawgasame
2010; Callegari 2011; Chao 2009; Dierks 2008; Gilberts 2001;
Hansen 2017; Kloeters 2016; Maneerit 2003; Nikolaou 2017;
Pegoli 2008; Sato 2012; Singh 2005; Zyluk 2011). Only three tri-
als had a published protocol (Hansen 2017; Nikolaou 2017; Sato
2012).
In total there are 14 included studies, 15 excluded studies and
three ongoing studies (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Characteristics of the 14 included studies can be found in
Characteristics of included studies.
Thirteen studies included in the review reported the results in a
single publication (Bamroongshawgasame 2010; Callegari 2011;
Chao 2009; Dierks 2008; Gilberts 2001; Hansen 2017; Kloeters
2016; Maneerit 2003; Nikolaou 2017; Pegoli 2008; Sato 2012;
Singh 2005; Zyluk 2011). One study reported the results in two
publications (Aref 2014).
All trials were reported in English.
Design of the studies
Eleven studies were reported as randomised trials -
Bamroongshawgasame 2010,Callegari 2011,Chao 2009,Gilberts
2001, Hansen 2017, Kloeters 2016, Maneerit 2003, Nikolaou
2017, Pegoli 2008, Sato 2012 and Zyluk 2011 - and three were
quasi-randomised (Aref 2014; Dierks 2008; Singh 2005). In Aref
2014 and Singh 2005 the patients were randomised to either per-
cutaneous surgery or steroid injection using their birth year, and in
Dierks 2008 the patients were randomised to either open or percu-
taneous surgery using their patient numbers. All studies had two
intervention groups, except Kloeters 2016 and Sato 2012 which
had three intervention groups. All 14 studies were single-centre
trials. Aref 2014 took place in Iran; Bamroongshawgasame 2010
and Maneerit 2003 in Thailand; Callegari 2011 and Pegoli 2008
in Italy; Chao 2009 in China; Dierks 2008 in Germany; Gilberts
2001 andKloeters 2016 in theNetherlands;Hansen 2017 inDen-
mark; Nikolaou 2017 in Greece; Sato 2012 in Brazil; Singh 2005
in Malaysia; and Zyluk 2011 in Poland.
Sample sizes
The 14 trials enrolled a total of 1260 participants, totalling at
least 1361 fingers: a study enrolled 115 participants with a 20
follow-up loss, but the authors did not describe what the totality
of fingers involved in the study represented in the loss of these
20 participants (Zyluk 2011). The total follow-up loss in 14 trials
was 2.9% (37 participants).
Participants
Age and gender
The age of participants included in the studies ranged from 16
to 88 years. Callegari 2011 assessed participants aged between
35 and 70 years; Dierks 2008 included adults with ages ranging
between 18 and 80 years; Gilberts 2001, Hansen 2017, Kloeters
2016 and Nikolaou 2017 included participants aged 18 years or
older; Sato 2012 enrolled participants older than 15 years of age;
Aref 2014, Chao 2009, Maneerit 2003 and Singh 2005 reported
the inclusion of adult participants, but did not specify their age;
Bamroongshawgasame 2010, Pegoli 2008 and Zyluk 2011 did not
report age as an inclusion criterion, but all participants in these
three studies were adults over 18 years of age. Most participants
were women (approximately 70%), but the exact number was not
calculated because the studies of Gilberts 2001, Maneerit 2003
andSato 2012 reported gender in relation to the number of fingers,
while the others related the number of participants.
Affected digits
Ten studies (Aref 2014; Bamroongshawgasame 2010; Callegari
2011; Chao 2009; Gilberts 2001; Kloeters 2016; Maneerit 2003;
Pegoli 2008; Sato 2012; Singh 2005) published data regarding
which digits were affected in the assigned participants, totalling
1002 digits, of which 385 (38%) were thumbs, 89 (9%) index,
286 (29%) middle, 205 (20%) ring and 37 (4%) little finger.
Zyluk 2011 reported data regarding which digits were affected in
the assessed participants, totalling 105 digits, of which 39 (37%)
were thumbs, 1 (1%) index, 22 (21%) middle, 35 (33%) ring
and 8 (8%) little; Hansen 2017 published the percentage of each
affected finger, but was not explicit if the data were referring to
the assigned participants (165 digits) or assessed participants (153
digits);Hansen 2017 reported that 39%of the digits were thumbs,
5% index, 25% middle, 25% ring and 6% little.
Dierks 2008 andNikolaou 2017 assigned a total of 68participants,
but they did not report data on which fingers were affected in these
participants.
Types/classification of trigger finger
All trials assessed only participants with trigger finger. Aref 2014,
Chao 2009, Hansen 2017, Kloeters 2016, Maneerit 2003, Sato
2012 and Singh 2005 used the classification of Quinnell 1980 to
characterise the participants: while Kloeters 2016,Maneerit 2003,
Sato 2012 and Singh 2005 used gradation from 0 to IV, Aref
2014, Chao 2009 and Hansen 2017 gradated triggering from I to
V, Bamroongshawgasame 2010, Callegari 2011, Nikolaou 2017
and Zyluk 2011 used the classification of Froimson 1993, which
corresponds to a change in the classification of Quinnell 1980.
Dierks 2008, Gilberts 2001 and Pegoli 2008 did not use any kind
of classification.
Timing of intervention
Eleven studies reported data on the timing of intervention
(Bamroongshawgasame 2010; Callegari 2011; Chao 2009;
Dierks 2008; Gilberts 2001; Hansen 2017; Kloeters 2016;
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Maneerit 2003; Nikolaou 2017; Sato 2012; Zyluk 2011).
Bamroongshawgasame 2010, Kloeters 2016 and Nikolaou 2017
reported that the participants had presented trigger finger symp-
toms for at least three months; Callegari 2011 reported an average
time of 3.5 months (range: 1 to 6 months). Two studies reported
that the participants had, on average, shown symptoms for four
months (Chao 2009; Maneerit 2003). Dierks 2008 reported that
the participants subjected to percutaneous surgery had, on aver-
age, shown symptoms for seven months (range: 1 to 36), while
in the group subjected to open surgery, the average had been 12
months (range: 1 to 60 months). Gilberts 2001 reported that on
average the timing of intervention had been six months (range: 1
to 24 months) in the group subjected to percutaneous surgery and
12 months (range: 1 to 144 months) in the open surgery group.
Hansen 2017 reported that the average time for performing inter-
vention after the beginning of symptoms was four months in the
open surgery group and fivemonths in the steroid injection group.
Sato 2012 reported average time of 15months in the percutaneous
surgery group, 10.5 months in the open surgery group and 11.8
months in the steroid injection group. Zyluk 2011 reported that
the average time for performing intervention after the beginning
of symptoms was five months in the percutaneous surgery group
and six months in the steroid injection group. Three studies did
not report any data on the timing of intervention (Aref 2014;
Pegoli 2008; Singh 2005).
Interventions
Based on surgical intervention methods, we grouped the studies
in nine comparison groups:
Comparison 1: open surgery versus steroid injection (Hansen 2017;
Sato 2012). Follow-up data were available for 269 participants,
totalling 270 fingers (140 with open surgery and 130 with steroid
injection). In total 12 participants (12 digits) were follow-up loss
in Hansen 2017: seven participants (seven digits) did not receive
allocated intervention - six in open surgery group and one in
steroid injection group -, and five participants (five fingers) did
not complete the follow-up - two in the open surgery group and
three in the steroid injection group.
Comparison 2: percutaneous surgery versus steroid injection (Aref
2014; Chao 2009; Sato 2012; Singh 2005; Zyluk 2011). Follow-
up data were available for 344 participants, totalling 368 fingers
(176 with percutaneous surgery and 192 with steroid injection).
Two studies had follow-up loss (Chao 2009; Zyluk 2011). InChao
2009 three participants (four fingers) did not complete the follow-
up, with one participant (one finger) in the percutaneous surgery
group and two participants (three fingers) in the steroid injection
group. In Zyluk 2011 20 participants did not complete the follow-
up, in which 12 were in the percutaneous surgery group and eight
in the steroid injection group.
Comparison 3: open surgery versus steroid injection plus ultra-
sound-guided hyaluronic acid injection (Callegari 2011). Follow-
up data were available for 30 participants, totalling 30 fingers (15
with open surgery and 15 with steroid injection plus ultrasound-
guided hyaluronic acid injection).
Comparison 4: percutaneous surgery plus steroid injection versus
steroid injection (Maneerit 2003). Follow-up data were available
for 113 participants, totalling 125 fingers (65 with percutaneous
surgery plus steroid injection and 60 with steroid injection). Two
participants (two fingers), with one in each group, did not com-
plete the follow-up.
Comparison 5: percutaneous surgery versus open surgery (
Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001;
Nikolaou 2017; Sato 2012). Follow-up data were available for 402
participants, totalling 429 fingers (215 with percutaneous surgery
and 214 with open surgery).
Comparison 6: endoscopic surgery versus open surgery (Pegoli
2008). Follow-up data were available for 200 participants, to-
talling 231 fingers (114with endoscopic release and 117with open
surgery).
Comparison 7: open surgery by transversal incision of the skin
about 2-3 mm distally from the distal palmar crease versus open
surgery by longitudinal incision of the skin at the level of the A1-
pulley without crossing the proximal distal palmar crease (Kloeters
2016). Follow-up data were available for 20 participants, totalling
21 fingers (10 with open surgery by transversal incision of the
skin about 2-3 mm distally from distal palmar crease and 11 open
surgery by longitudinal incision of the skin).
Comparison 8: open surgery by transversal incision of the skin
in the distal palmar crease versus open surgery by longitudinal
incision of the skin at the level of the A1-pulley without crossing
the distal palmar crease proximal (Kloeters 2016). Follow-up data
were available for 20 participants, totalling 22 fingers (11 with
open surgery by transversal incision of the skin in the distal palmar
crease and 11 open surgeries by longitudinal incision of the skin).
Comparison 9: open surgery by transversal incision of the skin in
the distal palmar crease versus open surgery by transversal incision
of the skin about 2-3 mm distally from distal palmar crease (
Kloeters 2016). Follow-up data were available for 20 participants,
totalling 21 fingers (11 with open surgery by transversal incision
of the skin in the distal palmar crease and 10 open surgeries by
transversal incision of the skin about 2-3 mm distally from distal
palmar crease).
Outcome measures
The trials varied in their follow-up times. Twelve studies stipulated
follow-up time points (Bamroongshawgasame 2010; Callegari
2011; Chao 2009; Dierks 2008; Gilberts 2001; Hansen 2017;
Kloeters 2016; Nikolaou 2017; Pegoli 2008; Sato 2012; Singh
2005; Zyluk 2011); one trial reported mean follow-up of 23
months (six to 42 months) and was considered long term
(Maneerit 2003); one trial did not clearly specify the follow-
up period, but reported weekly evaluations of the participants
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in the first six weeks and cases of recurrence with up to nine
months of follow-up (long term) (Aref 2014). Five trials were short
term (Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001;
Nikolaou 2017; Pegoli 2008); Bamroongshawgasame 2010 re-
ported follow-up data for eight weeks, while Dierks 2008, Gilberts
2001; Nikolaou 2017 and Pegoli 2008 conducted follow-up to
12 weeks. Two trials presented data for six months (intermediate
term) (Sato 2012; Zyluk 2011). Five trials related follow-up data
for one year (long term) (Callegari 2011; Chao 2009; Hansen
2017; Kloeters 2016; Singh 2005).
Major outcomes
Resolution of trigger finger
Resolution of trigger finger was assessed by ten trials (
Bamroongshawgasame 2010; Callegari 2011; Chao 2009; Dierks
2008; Gilberts 2001; Hansen 2017; Maneerit 2003; Nikolaou
2017; Pegoli 2008; Sato 2012). The resolution definition was
heterogeneous among the studies and some authors reported
it as “successful treatment”, “healing” or “satisfactory results”.
Bamroongshawgasame 2010 considered successful trigger finger
treatment as the relief of pain and the cessation of finger locking
after the procedure. Callegari 2011 considered satisfactory results
as the remission of symptoms within six weeks, with no recur-
rence within six months. Chao 2009 and Maneerit 2003 con-
sidered as satisfactory the participants who progressed with pain
score lower than or equal to one (VAS scale) and cessation of trig-
gering. Dierks 2008 considered successful treatment as the com-
plete relief of symptoms. Gilberts 2001 assessed the success of the
treatment as the cessation of triggering, with no recurrence during
follow-up (three months). Hansen 2017 considered cure if cessa-
tion of blockage was maintained after 12 months of the treatment.
Nikolaou 2017 reported resolution as the “success rate” per digit
after the procedure. Pegoli 2008 considered resolution as the dis-
appearance of triggering after the procedure. Sato 2012 described
trigger finger healing as the remission of symptoms with the cessa-
tion of blockage with no recurrence within six months. Aref 2014,
Kloeters 2016, Singh 2005 and Zyluk 2011 did not evaluate this
primary endpoint.
Severity or incidence of pain
Thirteen trials reported pain (Aref 2014; Bamroongshawgasame
2010; Callegari 2011; Chao 2009; Dierks 2008; Gilberts 2001;
Hansen 2017; Maneerit 2003; Nikolaou 2017; Pegoli 2008;
Sato 2012; Singh 2005; Zyluk 2011), but only eight studies as-
sessed pain in the hand after the procedure and published data
(Bamroongshawgasame 2010; Callegari 2011; Chao 2009; Dierks
2008; Hansen 2017; Maneerit 2003; Sato 2012; Zyluk 2011);
only two studies assessed it through continuous measurements
and reported complete data (Chao 2009; Dierks 2008). Aref 2014
reported that pain was assessed using the VAS scale, but did not
report the data. Bamroongshawgasame 2010 used a zero to three
score scale, but the data reported in an inaccurate chart was in-
complete as it did not report the exact values and standard
deviations. Callegari 2011, Chao 2009,Maneerit 2003 and Zyluk
2011 used a VAS scale with a range of 0 to 10 cm, but Callegari
2011, Maneerit 2003 and Zyluk 2011 did not report the stan-
dard deviations. Dierks 2008 assessed pain using a 1 to 6 scale.
Hansen 2017 reported that pain was assessed using a 1 to 10 scale,
but did not report the standard deviations. Sato 2012 reported
pain where the procedure was performed (topical pain), assessed
through dichotomized “yes or no” (presence or absence of pain).
Gilberts 2001, Nikolaou 2017 and Pegoli 2008 reported the av-
erage postoperative pain duration in days. Singh 2005 reported
pain assessment but did not describe what method was used and
did not report the data. Kloeters 2016 did not measure any this
outcome.
Functional status of the hand
Only three trials - Callegari 2011, Kloeters 2016 and Nikolaou
2017 - evaluated functional status of the hand by validated in-
struments, and they used Disabilities of the Arm, Shoulder and
Hand (DASH or QuickDASH) questionnaire; Callegari 2011
and Kloeters 2016 used the DASH questionnaire, while Nikolaou
2017 assessed the data using the QuickDASH questionnaire.
Kloeters 2016 reported complete data about DASH, informing
the respective standard error means to eachDASH score; Callegari
2011 and Nikolaou 2017 did not report any variance measure.
Aref 2014, Bamroongshawgasame 2010,Chao2009,Dierks2008,
Gilberts 2001, Hansen 2017, Maneerit 2003, Pegoli 2008, Sato
2012, Singh 2005 and Zyluk 2011 did not evaluate this outcome.
Participant-reported treatment success or satisfaction
Only four trials assessed post-treatment patient satisfaction
(Aref 2014; Bamroongshawgasame 2010; Callegari 2011;
Singh 2005), but two trials reported the data incompletely
(Bamroongshawgasame 2010; Callegari 2011), and two tri-
als did not report the data (Aref 2014; Singh 2005).
Bamroongshawgasame 2010 measured patient satisfaction using
a 0 to 3 score (0 = unsatisfied, 1 = somewhat satisfied, 2 = satisfied
and 3 = very satisfied), and Callegari 2011 used a visual satisfaction
scale (SVAS) gradated from 0 to 10. The other ten trials did not
assess participant-reported treatment success or satisfaction (Chao
2009; Dierks 2008; Gilberts 2001; Hansen 2017; Kloeters 2016;
Maneerit 2003; Nikolaou 2017; Pegoli 2008; Sato 2012; Zyluk
2011).
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Frequency of recurrence of triggering or locking of the affected
fingers
Eight studies reported direct data on the recurrence of trigger finger
(Aref 2014; Bamroongshawgasame 2010; Callegari 2011; Gilberts
2001; Hansen 2017; Sato 2012; Singh 2005; Zyluk 2011). Aref
2014, Bamroongshawgasame 2010, Gilberts 2001, Hansen 2017
and Singh 2005 reported the recurrence of triggering, but did not
define it. Callegari 2011 considered recurrence as the return of any
degree of triggering after a full remission period of trigger finger.
Sato 2012 defined recurrence (relapse) as the return of finger lock-
ing within six months of follow-up. Zyluk 2011 considered recur-
rence of triggering as the return to the baseline grade of triggering,
after a period of total or partial improvement. Two studies did not
evaluate the recurrence of triggering as a study outcome, but pub-
lished indirect data on it (Chao 2009; Dierks 2008): Chao 2009
reported on participants who again experienced pain and relapse
of triggering after a period of remission of the symptoms, whichwe
consider as recurrence; Dierks 2008 reported that all participants
had relief from the symptoms for 12 weeks (final study follow-up).
Kloeters 2016, Maneerit 2003, Nikolaou 2017 and Pegoli 2008
did not report or provide data on recurrence.
Number of patients experiencing any adverse event
All assessed trials referred to some adverse event, except Kloeters
2016 which did not publish any data about adverse event. Aref
2014 assessed finger stiffness, tendon bowstringing (pulley in-
jury), dysaesthesia, and skin atrophy or skin hypopigmentation.
Bamroongshawgasame 2010 assessed A2 pulley injury. Callegari
2011 assessed abnormal flexion of the finger and algodystrophic
syndrome after the procedure. Chao 2009 assessed infection and
tendon bowstringing (pulley injury). Dierks 2008 observed tran-
sient inflammation. Gilberts 2001 assessed haematoma and dif-
fuse swelling of the operated digit, and adherence of flexor tendon.
Hansen 2017 assessed infection, tendon bowstringing (pulley in-
jury), digit flare after procedure, fat necrosis in digit and tendon
rupture. Maneerit 2003 assessed infection and partial loss of flex-
ion of the finger after treatment. Pegoli 2008 assessed infection and
dysaesthesia. Nikolaou 2017 assessed infection and partial loss of
movement in operated digit. Sato 2012 assessed the presence of in-
fection and rupture of the flexor tendon after the procedure. Singh
2005 assessed stiffness of the fingers, tendon bowstringing (pulley
injury), and dysaesthesia. Zyluk 2011 measured the active range
of motion of the fingers; the authors reported on infection and
algodystrophic syndrome incompletely as they stated that there
was no case in which these complications occurred in the steroid
injection group, but the authors did not mention whether these
complications occurred in the percutaneous surgery group.
Neurovascular injury
Nine trials assessed neurovascular injury, although Zyluk
2011 only reported data on one of the comparison groups
(Bamroongshawgasame 2010; Chao 2009; Dierks 2008; Gilberts
2001; Hansen 2017; Maneerit 2003; Pegoli 2008; Sato 2012;
Zyluk 2011). Five studies did not assess neurovascular injury
(Aref 2014; Callegari 2011; Kloeters 2016; Nikolaou 2017; Singh
2005).
Excluded studies
We excluded 15 studies because they did not fulfil our inclusion
criteria. The reasons for exclusion are supplied in Characteristics
of excluded studies.
Studies awaiting classification
There are no studies awaiting classification.
Ongoing studies
Our search regarding ongoing trials (15 September 2017)
found 20 records on Clinicaltrials.gov (U.S. National Institute
of Health) and 39 records on the World Health Organization
(WHO) International Clinical Trial Registry Platform, a total of
59 records. Excluding the duplicate registers (N = 20) and studies
related to other subjects (N = 30), six did not fulfil our inclu-
sion criteria, leaving three trials (NTR1135;TCTR20140529001;
TCTR20150416001) to be included in an update of this review.
The ongoing study NTR1135 is a multicentre randomised trial
with two intervention groups. This ongoing study is taking place
in the Netherlands and it should enrol a total of 490 participants.
The ongoing study TCTR20140529001 is a single-centre ran-
domised trial with two intervention groups. This ongoing study
is taking place in Thailand and it should enrol a total of 128 par-
ticipants.
The ongoing study TCTR20150416001 is a single-centre ran-
domised trial with two intervention groups. This ongoing study
is taking place in Thailand and it should enrol a total of 51 par-
ticipants.
We report the details of the ongoing studies in Characteristics of
ongoing studies.
Risk of bias in included studies
The 14 trials had many methodological flaws and were considered
at high risk of bias (Figure 2, Figure 3 and Characteristics of
included studies).
17Surgery for trigger finger (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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When we estimated the presence of bias for small studies in the
overall meta-analysis by checking whether the results of the out-
comes change in the analyses using random-effects or fixed-effect
(Sterne 2011), there were changes in five analyses in two com-
parisons - one analysis in the comparison between open surgery
and steroid injection, and four analyses in the comparison of per-
cutaneous surgery versus steroid injection -, and there were no
changes in results in the other seven comparisons. In comparison
1 (open surgery versus steroid injection) the outcome resolution of
symptoms (six to 12 months) did not differ between groups in the
random-effects analysis (RR 1.48, 95% CI 0.79 to 2.76) and was
favourable to the open surgery group in the fixed-effect analysis
(RR 1.51, 95% CI 1.31 to 1.73) (Analysis 1.1). In comparison 2
(percutaneous surgery versus steroid injection) the outcome res-
olution of symptoms (six to 12 months) did not differ between
groups in the random-effects analysis (RR 2.11, 95% CI 0.31 to
14.51) and was favourable to the percutaneous surgery group in
the fixed-effect analysis (RR 1.77, 95% CI 1.48 to 2.12) (Analysis
2.1). Short-term pain (one month) showed no difference between
groups in the random-effects analysis (RR−1.80, 95% CI−5.72
to 2.12), but was favourable to the percutaneous surgery group
in the fixed-effect analysis (RR −1.46, 95% CI −1.81 to−1.11)
(Analysis 2.2.1). The outcome recurrence (range six to 12months)
showed no difference between groups in the random-effects anal-
ysis (RR 0.57, 95% CI 0.21 to 1.59), but was favourable to the
percutaneous surgery group in the fixed-effect analysis (RR 0.60,
95% CI 0.37 to 0.96) (Analysis 2.4). Adverse event ’partial loss
of movement’ showed no difference between groups in the ran-
dom-effects analysis (RR 3.09, 95% CI 0.87 to 10.97) and was
favourable to the steroid injection group in the fixed-effect analysis
(RR 2.93, 95% CI 1.41 to 6.07) (Analysis 2.5.2).
Allocation
Chao 2009 and Zyluk 2011 described that the generation of ran-
dom sequence was accomplished by selecting number one or two
from sealed envelopes in the presence of a witness and in Sato
2012 it was done by means of a six-sided die with two sides rep-
resenting one of the three treatments, drawn prior to beginning
the study by a person not involved in the research; in Hansen
2017 the generation of the random sequence was done by using
the Research Randomizer software (Research Randomizer). Three
trials were considered quasi-randomised (Aref 2014; Dierks 2008;
Singh 2005); Aref 2014 and Singh 2005 allocated participants
based on their year of birth; in Dierks 2008 they were allocated
by the register number. The seven remaining trials did not pro-
vide enough information about how the random sequence gen-
eration was done (Bamroongshawgasame 2010; Callegari 2011;
Gilberts 2001; Kloeters 2016; Maneerit 2003; Nikolaou 2017;
Pegoli 2008).
Allocation concealment before the assignment was adequate for
Chao 2009, Gilberts 2001, Hansen 2017, Nikolaou 2017, Sato
2012 and Zyluk 2011 (sealed envelopes). Aref 2014, Dierks 2008
and Singh 2005 were quasi-randomised. Bamroongshawgasame
2010, Callegari 2011, Kloeters 2016, Maneerit 2003 and Pegoli
2008 did not describe their allocation concealment methods.
Blinding
We considered all trials to be at high risk of performance bias
(Aref 2014; Bamroongshawgasame 2010; Callegari 2011; Chao
2009; Dierks 2008; Gilberts 2001; Hansen 2017; Kloeters 2016;
Maneerit 2003; Nikolaou 2017; Pegoli 2008; Sato 2012; Singh
2005; Zyluk 2011). Since all of the included studies compared
different surgical techniques with or without corticoid injection, it
was not possible to provide blind treatment. The participants were
not blinded in any of the trials regarding the procedure performed.
Detection bias was considered blinding separately for self-reported
subjective outcomes (e.g. resolution of symptoms, pain, function,
patient satisfaction, recurrence) and objective outcomes (e.g. ad-
verse events, neurovascular injury). Twelve trials did not blind
the assessors for self-reported subjective outcomes and they were
considered at high risk of bias (Aref 2014; Bamroongshawgasame
2010; Callegari 2011; Chao 2009; Dierks 2008; Gilberts 2001;
Hansen 2017; Kloeters 2016; Maneerit 2003; Pegoli 2008; Sato
2012; Singh 2005); two trials blinded the assessors to the self-re-
ported subjective outcomes and theywere considered at low risk of
bias (Nikolaou 2017; Zyluk 2011). Twelve trials did not blind the
assessors for objective outcomes and they were considered at high
risk of bias (Aref 2014; Bamroongshawgasame 2010; Callegari
2011; Chao 2009; Dierks 2008; Gilberts 2001; Hansen 2017;
Maneerit 2003; Nikolaou 2017; Pegoli 2008; Sato 2012; Singh
2005); only one trial blinded the assessors to the objective out-
comes and it was considered as at low risk of bias (Zyluk 2011). It
was possibly because Zyluk 2011 compared percutaneous surgery
(using needle, without incision) with steroid injection. One trial
(Kloeters 2016) did not assess or report any objective outcome
and was considered unclear risk of bias.
Incomplete outcome data
We judged trials to be at low risk of bias if follow-upwas completed
by more than 80% of participants, missing data were balanced
in the groups and an intention-to-treat analysis was described for
the primary outcomes. Ten trials were considered at low risk of
attrition bias (Bamroongshawgasame 2010; Callegari 2011; Chao
2009; Dierks 2008; Gilberts 2001; Hansen 2017;Maneerit 2003;
Nikolaou 2017; Pegoli 2008; Sato 2012); and one was at high risk
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(Zyluk 2011). Aref 2014, Kloeters 2016 and Singh 2005 were at
unclear risk.
Bamroongshawgasame 2010, Callegari 2011, Dierks 2008,
Gilberts 2001, Nikolaou 2017, Pegoli 2008 and Sato 2012 re-
ported no losses to follow-up. Chao 2009, Hansen 2017 and
Maneerit 2003 were judged to be at low risk of bias because the
data loss was small and balanced in both groups; in Chao 2009
the data loss was one (2%) and three (6%) respectively, in per-
cutaneous surgery and steroid injection groups; in Hansen 2017
eight participants (9%) in open surgery group and four (5%) in
steroid injection group were allocated to treatment, but they did
not receive the allocated treatment or they did not complete to
follow up of 12 months; and in Maneerit 2003 the data loss was
one (1.5%) and one (1.6%) respectively in percutaneous surgery
plus steroid injection and steroid injection groups.
Zyluk 2011 was judged as high risk despite a follow-up loss of
17% (20/115 participants), because the loss in the percutaneous
surgery group was significantly higher than in the steroid injection
group, 12 (22%) and eight (13%) respectively, and the intention-
to-treat analysis was not carried out. Aref 2014, Kloeters 2016
and Singh 2005 were judged as unclear risk because they did not
clearly report if there was a follow-up loss of participants during
the study.
Selective reporting
Only one trial (Hansen 2017) was considered at low risk regarding
reporting bias; Hansen 2017 published the protocol before the
recruitment of participants began and always followed the proto-
coled methodology.
Eleven trials did not publish a prior protocol specifying the study’s
results of interest and were considered at high risk of bias (Aref
2014; Bamroongshawgasame 2010; Callegari 2011; Chao 2009;
Dierks 2008;Gilberts 2001; Kloeters 2016;Maneerit 2003; Pegoli
2008; Singh 2005; Zyluk 2011). Aref 2014 and Singh 2005 did
not report results of interest, such as resolution, pain and func-
tional status of the hand; Bamroongshawgasame 2010, Gilberts
2001 and Pegoli 2008 did not assess functional status of the hand
and assessed pain through non-validated measures. Callegari 2011
reported incomplete outcomes of pain and functional status of the
hand because, although the VAS and DASH values were pro-
vided, the respective standard deviations were not provided. Chao
2009 and Dierks 2008 did not assess functional status, an out-
come of interest in the review. Kloeters 2016 did not assess results
of interest, such as resolution and pain. Maneerit 2003 did not
assess the functional hand status and incompletely reported pain,
because although the VAS value was provided, the standard devia-
tion value was not reported. Zyluk 2011 did not assess resolution
and functional hand status, and pain were reported incompletely,
because although the VAS value was provided, the standard devi-
ation value was not reported.
Two trials (Nikolaou 2017; Sato 2012) were considered as unclear
risk of bias. Nikolaou 2017 published the study on February 18,
2017, after the protocol was published on July 6, 2016, but was
considered as uncertain risk of bias for having submitted the fi-
nalized study for evaluation by the editorial board of the journal
on July 4, 2016, two days prior to the publication of the protocol.
Sato 2012 was considered as unclear risk of bias because although
its protocol was available before the publication of the trial, the
study protocol was published on 4 October 2010 and the study
started on 1November 2002 and was concluded on 3March 2007
(Sato 2012).
Other potential sources of bias
Three trials were considered at low risk for ’other bias’ (
Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001). Three
trials were considered at high risk of other potential bias (Callegari
2011; Kloeters 2016; Pegoli 2008). Rehabilitation differences were
reported in Callegari 2011. Kloeters 2016 and Pegoli 2008 pre-
sented imbalance between groups: inKloeters 2016 there was a sig-
nificant difference in baseline DASH scores between groups, and
in Pegoli 2008 there was baseline imbalance between the groups
regarding the presence of associated diseases (38% in the open
surgery group and 14% in the endoscopic surgery group), which
were operated concomitantly with trigger finger.
Eight trials were considered at unclear risk of other biases (Aref
2014; Chao 2009; Hansen 2017;Maneerit 2003; Nikolaou 2017;
Sato 2012; Singh 2005; Zyluk 2011); Aref 2014, Nikolaou 2017
and Singh 2005 did not provide data on baseline balance, reha-
bilitation and care providers; Chao 2009, Hansen 2017, Maneerit
2003 and Sato 2012 reported no information on rehabilitation or
care providers, or both. Zyluk 2011 did not report any data about
rehabilitation.
Effects of interventions
See: Summary of findings for the main comparison Open
surgery versus steroid injection for treating trigger finger;
Summary of findings 2 Percutaneous surgery versus steroid
injection for treating trigger finger; Summary of findings 3Open
surgery versus steroid injection plus hyaluronic acid injection
guided by ultrasound for treating trigger finger; Summary of
findings 4 Percutaneous surgery plus steroid injection compared
to steroid injection for trigger finger; Summary of findings
5 Percutaneous surgery versus open surgery for treating trigger
finger; Summary of findings 6 Endoscopic surgery versus open
surgery for treating trigger finger; Summary of findings 7
Open surgery by transverse incision of the skin about 2-3 mm
distally from distal palmar crease compared to open surgery by
longitudinal incision of the skin for trigger finger; Summary of
findings 8 Open surgery by transverse incision of the skin in the
distal palmar crease compared to open surgery by longitudinal
incision of the skin for trigger finger; Summary of findings 9
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Open surgery by transverse incision of the skin in the distal palmar
crease compared to open surgery by transverse incision of the skin
about 2-3 mm distally from distal palmar crease for trigger finger
We considered as comparison any surgical intervention versus an-
other surgical intervention or versus any conservative interven-
tion: open surgery versus steroid injection; percutaneous surgery
versus steroid injection; open surgery versus steroid injection plus
hyaluronic acid injection guided by ultrasound; percutaneous
surgery plus steroid injection versus steroid injection; percuta-
neous surgery versus open surgery; endoscopic surgery versus open
surgery; open surgery by transversal incision of the skin about 2-
3 mm distally from distal palmar crease versus open surgery by
longitudinal incision of the skin at the level of the A1-pulley with-
out crossing the distal palmar crease proximal; open surgery by
transversal incision of the skin in the distal palmar crease versus
open surgery by longitudinal incision of the skin at the level of the
A1-pulley without crossing the distal palmar crease proximal; and
open surgery by transversal incision of the skin in the distal palmar
crease versus open surgery by transversal incision of the skin about
2-3 mm distally from distal palmar crease. We considered as pri-
mary comparison ’open surgery versus steroid injection’, because
open surgery is the oldest surgical method used for the treatment
of trigger finger, while the steroid injection is the least invasive
method reported in the studies included.
We present all outcomes in the ’Summary of findings’ tables
(Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7; Summary of findings 8; Summary of findings 9).
Comparison 1: open surgery versus steroid injection
Two trials reported outcomes for the comparison of open surgery
versus steroid injection (Hansen 2017; Sato 2012). Hansen 2017
performed the ultrasonic guided infiltration, while Sato 2012 per-
formed infiltration without the use of ultrasound. The most rel-
evant data regarding this comparison are shown in Summary of
findings for the main comparison.
Resolution of trigger finger
The combined analysis of the results of Hansen 2017 and Sato
2012 comparing the open surgery and steroid injection groups
(after one or more injections) showed no differences between the
two comparison groups (131/140 versus 80/130; RR 1.48, 95%
CI 0.79 to 2.76; I² = 95%), although the two individual studies
showed favourable individual results for open surgery but high
heterogeneity due to lack of overlapping confidence intervals (see
Analysis 1.1). Hansen 2017 had 12 participants (8 versus 4) lost
to follow-up and was considered as a resolution failure.
When the results were subgrouped by time periods (short, inter-
mediate or long term) for exploratory purposes, the subgroup tri-
als showed differences between groups (Chi² = 17.14, df = 2 (P
= 0.0002), I² = 88.3%) (see Analysis 1.7) (Hansen 2017; Sato
2012). Hansen 2017 assessed the results comparing open surgery
with short-term infiltration and the results analysis showed no dif-
ference between groups (76/84 versus 68/81; RR 1.08, 95% CI
0.96 to 1.21); Sato 2012 reported intermediate-term results and
the data analysis showed differences in favour of the open surgery
group when compared with steroid injections (56/56 versus 42/
49; RR 1.17, 95% Cl 1.04 to 1.31); in the long-term assessment
the results analysis of Hansen 2017, comparing open surgery with
infiltration, showed difference in favour of the open surgery group
(75/84 versus 38/81; RR 1.90, 95%CI 1.49 to 2.43) (see Analysis
1.7).
Severity or incidence of pain
Hansen 2017 and Sato 2012 reported pain. Hansen 2017 assessed
by a numerical rating scale from 1 to 10 (1 = no pain, and 10 =
worst imaginable pain) and reported the median and interquartile
range (IQR) before treatment and after three and 12 months fol-
low-up, but did not report the mean and standard deviation; the
median in baseline was 6 (IQR=5-7) in both groups; no difference
between groups was reported in Hansen 2017 at three months
follow-up, with median 1 (IQR = 1-2) in the open surgery group
and 1 (IQR 1-1) in the steroid injection group; at 12 months
follow-up differences in favor of the open surgery group was re-
ported in Hansen 2017, that found median 1 (IQR 1-1) in the
open surgery group and 3 (IQR = 1-5) in the steroid injection
group (P < 0.05). Analyses were realized using the median as an
approximate for the mean, and the IQR to estimate an approx-
imate standard deviations: the results’ analyses of Hansen 2017
comparing open surgery and steroid injection groups showed no
differences between the two comparison groups in short-term (at
three months follow-up) (MD 0.00, 95% CI −0.23 to 0.23, 1 to
10-point scale where 1 means no pain and 10 worst imaginable
pain), but it was favourable to open surgery group in long-term
(at 12 months follow-up) (MD -2.00, 95% CI −2.68 to -1.32),
with clinically significant differences (Analysis 1.3).
Sato 2012 assessed the presence of pain in the palm of the hand
after the procedure, and the results analysis showed significantly
more participants feeling pain in the palm of the hand in the open
surgery group than in the steroid injection group in short-term
follow-up at one week (38/56 versus 9/49; RR 3.69, 95% CI 1.99
to 6.85), but no significant difference between groups was found
in intermediate-term follow-up at six months (0/56 versus 4/49;
RR 0.10, 95% CI 0.01 to 1.77) (Analysis 1.2).
Function or disability
No data about function or disability was assessed in Hansen 2017
or Sato 2012.
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Participant-reported treatment success or satisfaction
No data about patient satisfaction was assessed in Hansen 2017
or Sato 2012.
Recurrence of triggering
The pooled results analysis of Hansen 2017 and Sato 2012 showed
a significant difference in favour of the open surgery group when
compared with the steroid injection group at the end of follow-
up (8/140 versus 50/130; RR 0.17, 95% CI 0.09 to 0.33; Chi² =
0.59, df = 1 (P = 0.44); I² = 0% ) (see Analysis 1.4). Hansen 2017
had a loss of follow-up of 12 participants (8 versus 4), which we
considered as recurrence events.
When the results were subgrouped by time of outcome measure-
ment (short, intermediate or long term) for exploratory purposes,
no trial was short term in this comparison. One trial was inter-
mediate term and marginal differences were identified in favour
of the open surgery group (0/56 versus 7/49; RR 0.06, 95% CI
0.00 to 1.00) (see Analysis 1.8) (Sato 2012). In the long term as-
sessment the results analysis of Hansen 2017 showed a significant
difference in favour of the open surgery group (8/84 versus 43/
81; RR 0.18, 95% CI 0.09 to 0.36) (see Analysis 1.8).
Adverse events
No significant differences between open surgery and steroid in-
jection groups were noted in the combined results from Hansen
2017 and Sato 2012 for adverse events (18/140 versus 17/130; RR
1.02, 95% CI 0.57 to 1.84) (see Analysis 1.5). Twelve participants
(8 versus 4) did not complete the follow-up in Hansen 2017, and
were considered as adverse events in the data analysis.
Analyses by types of adverse events indicated that no significant
difference between groups was observed for infection (11/140 ver-
sus 4/130; RR 2.65, 95%CI 0.88 to 7.99); there was no tendon or
pulley injury in both groups (0/56 versus 0/49; risk ratio could not
be estimated); there was no significant difference in the groups for
flare around procedure site (8/84 versus 15/81; RR 0.51, 95% CI
0.23 to 1.15) and for fat necrosis at the procedure site (8/84 versus
6/81; RR 1.29, 95% CI 0.47 to 3.54), but there was significant
differences in favour of the steroid injection group for cutaneous
discomfort around procedure site after 12 months (15/84 versus
4/81; RR 3.62, 95% CI 1.25 to 10.44) (see Analysis 1.5).
Neurovascular injury
Only one case of neurovascular injury was reported in the com-
bined results of two studies (Hansen 2017; Sato 2012), which oc-
curred in the open surgery group, however Hansen 2017 had a
loss of follow-up of 12 participants (8 versus 4), which we con-
sidered as neurovascular injury in the analysis. No statistically sig-
nificant differences between the two groups were observed in the
combined results analysis of Hansen 2017 and Sato 2012 (9/140
versus 4/130; RR 2.17, 95% CI 0.70 to 6.77) (see Analysis 1.6).
Comparison 2: percutaneous surgery versus steroid
injection
Five studies reported outcomes comparingpercutaneous surgery to
steroid injection (Aref 2014; Chao 2009; Sato 2012; Singh 2005;
Zyluk 2011). The most relevant information on the outcomes of
this comparison is classified in Summary of findings 2.
Resolution of trigger finger
Two studies assessed the resolution and the combined analysis of
the results comparing the percutaneous surgery and steroid injec-
tion groups (after one or more injections) showed no differences
between the two comparison groups in six to 12months follow-up
(89/92 versus 54/99; RR 2.11, 95% CI 0.31 to 14.51; I² = 98%),
although the two individual studies showed favourable individual
results for percutaneous surgery but high heterogeneity due to lack
of overlapping confidence intervals (see Analysis 2.1) (Chao 2009;
Sato 2012). Chao 2009 had four participants (1 versus 3) lost to
follow-up and was considered as a resolution failure.
When the results were subgrouped by time periods (short, in-
termediate or long term) for exploratory purposes, the subgroup
trial showed differences between groups (Chi² = 30.82, df = 2 (P
< 0.00001), I² = 93.5%). Chao 2009 assessed the results com-
paring percutaneous surgery with short-term infiltration and the
results analysis showed differences in favour of the percutaneous
surgery group (43/47 versus 21/50; RR 2.18, 95% CI 1.55 to
3.05). Sato 2012 reported intermediate-term results and the data
analysis showed differences in favour of the percutaneous surgery
group when compared with steroid injections (45/45 versus 42/
49; RR 1.16, 95% Cl 1.03 to 1.31). In the long-term assessment
the results analysis of Chao 2009, comparing percutaneous surgery
with one or more infiltrations, showed difference in favour of the
percutaneous surgery group (44/47 versus 12/50; RR 3.90, 95%
CI 2.37 to 6.42) (see Analysis 2.7).
Severity or incidence of pain
Chao 2009, Sato 2012 and Zyluk 2011 reported pain. Two trials
assessed pain using VAS score and the combined results’ analy-
sis showed no difference between groups in the short-term (MD
−1.80, 95% CI −5.72 to 2.12; I² = 99%, 0 to 10-point scale
where 0 means no pain and 10 severe pain) (see Analysis 2.2)
(Chao 2009; Zyluk 2011); although no statistical difference was
found between the groups, a decrease of 1.8 point in the VAS
score could correspond to a clinical improvement in favour of per-
cutaneous surgery. The study of Zyluk 2011 did not report the
standard deviation, but was included in themeta-analysis with the
same standard deviation reported by Chao 2009, as foreseen in the
protocol by Ventin 2014. Zyluk 2011 reported significantly less
pain in the percutaneous surgery group in the intermediate term,
although the differences between the VAS scores are not clinically
significant (mean VAS score at pre-treatment and six months were
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respectively 3.5 and 0.4 for the percutaneous surgery group and
3.9 and 1.3 for the injection group; the standard deviation and P
value were not reported). Chao 2009 assessed pain usingVAS score
in the long term (one year) and the results’ analysis was favourable
to percutaneous surgery (MD -6.50, 95% CI -7.25 to−5.75, 0 to
10-point scale), with clinically significant differences (see Analysis
2.2).
Sato 2012 assessed the presence of pain in the palm of the hand
after the procedure and the results’ analysis was favourable to the
steroid injection group in short-term follow-up at one week (30/
45 versus 9/49; RR 3.63, 95% CI 1.94 to 6.78); no significant
difference between groups was found in the intermediate-term
follow-up at six months (0/45 versus 4/49; RR 0.12, 95% CI 0.01
to 2.18) (see Analysis 2.3).
Function or disability
Function or disability was not measured by any instrument in Aref
2014, Chao 2009, Sato 2012, Singh 2005 or Zyluk 2011.
Participant-reported treatment success or satisfaction
No trial reported data about patient satisfaction.
Recurrence of triggering
Five trials reported triggering recurrence and the analysis of the
combined results showed no differences between groups (22/189
versus 40/203; RR 0.57, 95% CI 0.21 to 1.59; I² = 62%) (Aref
2014; Chao 2009; Sato 2012; Singh 2005; Zyluk 2011); two trials
had a pooled loss of follow-up of 24 participants (13 versus 11),
which we considered as recurrence events (see Analysis 2.4) (Chao
2009; Zyluk 2011).
When the results’ analysis was sub-grouped for follow-up, we ob-
served no differences between the groups in the short term (12/58
versus 8/67; RR 1.73, 95% CI 0.76 to 3.94), in the intermediate
term (12/103 versus 21/116; RR 0.37, 95% CI 0.02 to 5.50; I² =
73%) and in the long term (10/86 versus 19/87; RR 0.55; 95%
CI 0.10 to 2.99; I² = 71%); the test for differences between sub-
groups showed no difference between the two interventions (Chi²
= 2.30, df = 2 (P = 0.32), I² = 12.9%) (see Analysis 2.8).
Adverse events
The pooled results of five studies showed no statistically significant
difference between the two groups in the analysis of total adverse
events (26/189 versus 18/203; RR 1.58, 95%CI 0.91 to 2.75; I² =
0%) (Aref 2014; Chao 2009; Sato 2012; Singh 2005; Zyluk 2011);
(see Analysis 2.5). Two studies had a total of 24 participants (13
versus 11) with follow-up loss, which were considered as adverse
events (Chao 2009; Zyluk 2011).
Analyses by kinds of adverse events indicated no differences be-
tween the groups for infection (1/92 versus 3/99; RR 0.35, 95%
CI 0.04 to 3.29), partial loss of movement (23/97 versus 8/104;
RR 3.09, 95% CI 0.87 to 10.97) and tendon or pulley injury (3/
131 versus 3/136; RR 1.00, 95% CI 0.21 to 4.81). Dysaesthesia
was reported only in the steroid injection group, but there were
no differences between the two comparison groups (0/39 versus
4/37; RR 0.20, 95% CI 0.02 to 1.67), and also skin atrophy or
hypopigmentation (0/25 versus 3/25; RR 0.14, 95% CI 0.01 to
2.63) (see Analysis 2.5).
Neurovascular injury
No neurovascular injury cases of the participants who completed
the follow-up were reported in the combined results of two studies
(Chao 2009; Sato 2012), although four participants in the study
of Chao 2009 did not complete the follow-up andwere considered
as having neurovascular injury. The analysis of the combined data
showed no difference between the two groups (1/92 versus 3/99;
RR 0.35, 95% CI 0.04 to 3.29) (see Analysis 2.6).
Comparison 3: open surgery versus steroid injection
plus hyaluronic acid injection guided by ultrasound
Only one trial reported the outcomes comparing open surgery to
steroid injection plus ultrasound-guided hyaluronic acid injection
(Callegari 2011). The main information on this comparison is in
Summary of findings 3.
Resolution of trigger finger
The results’ analysis of Callegari 2011 showed no significant dif-
ference between the two groups at the six-month follow-up (15/
15 versus 14/15; RR 1.07, 95% CI 0.89 to 1.28) and at the one-
year follow-up (15/15 versus 11/15; RR 1.35, 95% CI 0.98 to
1.85) (see Analysis 3.1).
Severity of pain
Callegari 2011 assessed pain using the VAS score (VAS score: 0
to 10 points, where 0 means no pain and 10 severe pain), which
found no statistically significant differences between the two inter-
mediate-term groups (mean VAS in both groups was one point in
sixmonths and four points in the pre-treatment). The results could
not be analysed because the standard deviation of VAS was not
reported. There was no clinically significant difference between
the pre-treatment groups and those with six months of follow-up.
Function or disability
The DASH scores (DASH score: 0% to 100%, where 0% means
no disability and 100% means the most severe disability) at six
months (intermediate-term), without a variance measure, were
reported in Callegari 2011, which described a mean difference
(MD) of 11% in the open surgery group and 13% in the injection
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group. The pre-treatment DASH scores were 33% in the open
surgery group and 31% in the injection group. There was no
clinically significant difference between the pre-treatment groups
and with six months of follow-up.
Participant-reported treatment success or satisfaction
Callegari 2011 measured patient satisfaction using the scoring sys-
tem SVAS (Satisfaction Visual Analogue Scale: 0 to 10 points,
where 0means totally unsatisfied and 10 completely satisfied), but
did not report the standard deviation; an average difference of 0.2
was found (8.4 in the open surgery group versus 8.2 in the injec-
tion group) with three months of follow-up and 0.4 (7.8 in open
surgery group versus 7.4 in injection group) with six months of
follow-up. There was no clinically significant difference between
the pre-treatment groups and those with six months of follow-up.
Recurrence of triggering
There was no significant difference between the two groups in
the results analysis for recurrence of trigger finger at six months
of follow-up (0/15 versus 0/15; risk ratio could not be estimated)
and at one year of follow-up (0/15 versus 3/15; RR 0.14, 95% CI
0.01 to 2.55) in Callegari 2011 (see Analysis 3.2).
Adverse events
No statistically significant differences were observed between the
open surgery and injection groups in the data analysis of the total
adverse events in Callegari 2011 (3/15 versus 1/15; RR 3.00, 95%
CI 0.35 to 25.68); analysis by type of adverse events indicated that
algodystrophic syndrome occurred only in the open surgery group
(1/15 versus 0/15; RR 3.00, 95% CI 0.13 to 68.26). The partial
loss of movement was more common in the open surgery group
(2/15 versus 1/15; RR 2.00, 95% CI 0.20 to 19.78) (see Analysis
3.3).
Neurovascular injury
No data about neurovascular injury was reported by Callegari
2011.
Comparison 4: percutaneous surgery plus steroid
injection versus steroid injection
Only one study reported results comparing percutaneous surgery
plus steroid injection versus steroid injection (Maneerit 2003).
The most relevant data regarding the outcome of this comparison
are grouped in Summary of findings 4.
Resolution of trigger finger
Maneerit 2003 reported long-term results comparing percuta-
neous surgery plus steroid injection versus one or more steroid
injections, and the analysis of the results was favourable to the
percutaneous surgery plus steroid injection group (59/66 versus
36/61; RR 1.51, 95% Cl 1.21 to 1.90) (see Analysis 4.1). Two
participants (1 versus 1) did not complete follow-up and were
considered as resolution failure in the data analysis.
Severity of pain
In Maneerit 2003 no significant differences between the short-
term groups were found (mean VAS score zero to 10-scale at two
weeks was 0.4 versus 0.3, with pre-treatment score of five in both
groups; reported P > 0.05). Maneerit 2003 did not report the
standard deviation, making it impossible to analyse the data. The
difference of 0.1 point score between the groups is not a clinically
significant difference.
Function or disability
No data about function or disability were assessed in Maneerit
2003.
Participant-reported treatment success or satisfaction
Nodata about patient satisfaction were assessed inManeerit 2003.
Recurrence of triggering
No data about recurrence of triggering were reported by Maneerit
2003.
Adverse events
The data analysis of all adverse events inManeerit 2003 showed no
significant differences between the groups (2/66 versus 2/61; RR
0.92, 95% CI 0.13 to 6.36) (see Analysis 4.2). Two participants
(1 versus 1) did not complete the follow-up and were considered
as adverse events in the data analysis.
Analyses by kinds of adverse events did not differ between groups
for infection (1/66 versus 2/61; RR 0.46, 95% CI 0.04 to 4.97)
and partial loss of movement (2/66 versus 1/61; RR 1.85, 95% CI
0.17 to 19.87) (see Analysis 4.2). The test for subgroup differences
showed no difference between the two groups (Chi² = 0.65, df =
1 (P = 0.42), I² = 0%) (see Analysis 4.2).
Neurovascular injury
No neurovascular injury was reported byManeerit 2003 in partic-
ipants who concluded the follow-up but two participants (1 versus
1) did not complete follow-up and were considered as having neu-
rovascular injury in the results analysis; there were no statistical
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differences between the two comparison groups (1/66 versus 1/
61; RR 0.92, 95% CI 0.06 to 14.46) (see Analysis 4.3).
Comparison 5: percutaneous surgery versus open
surgery
Five studies reported data comparing percutaneous surgery versus
open surgery (Bamroongshawgasame 2010; Dierks 2008; Gilberts
2001; Nikolaou 2017; Sato 2012). Nikolaou 2017 performed
the percutaneous surgery guided by ultrasound, while in the
other studies percutaneous surgery was performed without ul-
trasound visibility (Bamroongshawgasame 2010; Dierks 2008;
Gilberts 2001; Sato 2012).The main information on the outcome
of this comparison is in Summary of findings 5.
Resolution of trigger finger
Pooled data from five trials showed no significant difference in
overall resolution at endpoint between the two groups (213/215
versus 213/214; RR 1.00, 95% CI 0.97 to 1.02; Chi² = 1.60, df =
4 (P = 0.81); I² = 0% ) (see Analysis 5.1) (Bamroongshawgasame
2010; Dierks 2008; Gilberts 2001; Nikolaou 2017; Sato 2012).
When the results were sub-grouped by time of outcome mea-
surement (short, intermediate or long term) for exploratory pur-
poses, four trials were short term and no statistically signifi-
cant differences were identified between the two groups for res-
olution (168/170 versus 157/157; RR 1.00, 95% CI 0.97 to
1.02; Chi² = 1.56, df = 3 (P = 0.67); I² = 0%) (see Analysis
5.6) (Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001;
Nikolaou 2017). Only one trial was intermediate term and no
statistically significant difference was identified between the two
groups for resolution (45/45 versus 56/56; RR 1.00, 95% CI 0.96
to 1.04) (see Analysis 5.6) (Sato 2012). In this comparison no trial
was long term.
Severity or incidence of pain
Five trials reported pain (Bamroongshawgasame 2010; Dierks
2008; Gilberts 2001; Nikolaou 2017; Sato 2012). Data from
Bamroongshawgasame 2010 on treatment pain were reported in-
completely and shown by figure; therefore the results of this trial
were not entered into the meta-analysis. The author reported no
pain in both groups after six weeks.
The results’ analysis of Dierks 2008 indicated no significant dif-
ferences between percutaneous and open surgery groups at one
week (MD 0.30, 95% CI −0.34 to 0.94; 1- to 6-point scale) or
12 weeks (MD 0.00, 95% CI −0.52 to 0.52; 1- to 6-point scale)
(see Analysis 5.2). These differences are not clinically significant.
Gilberts 2001 assessed the mean duration of postoperative pain
and reported 5.7 days (range 3 to 60) in the open surgery group
and 3.1 days (range 0 to 21) in the percutaneous surgery group
(P = 0.039). Nikolaou 2017 reported the mean time of analgesic
use in days, which was 2.9 days in the open surgery group and 3.5
days in the group treated with percutaneous surgery (P > 0.05).
Sato 2012 assessed the presence of pain in the palm of the hand
after the procedure and the results’ analysis showed no significant
differences between the groups in the short term, after a week of
follow-up (30/45 versus 38/56; RR 0.98, 95% CI 0.75 to 1.29)
(see Analysis 5.3). In the intermediate time, the results’ analysis of
Sato 2012 showed no difference between the two groups too, at
six months of follow-up (0/45 versus 0/56; risk ratio could not be
estimated) (see Analysis 5.3).
Function or disability
OnlyNikolaou 2017 reported data on function or disability of the
hand, accessing the QuickDASH scores preoperatively and after
the procedure, without a variance measure. The pre-treatment
QuickDASH scores were 43.2 in the open surgery group and 45.5
in the percutaneous surgery group; in the follow-up after two, four
and 12 weeks the QuickDASH scores were 8.2, 1.3 and 0 in the
open surgery group, and 7.5, 0.5 and 0 in the percutaneous surgery
group, respectively. There was no clinically significant difference
between groups in all periods accessed (P > 0.05).
No data about function or disability was assessed in
Bamroongshawgasame 2010, Dierks 2008, Gilberts 2001 or Sato
2012.
Participant-reported treatment success or satisfaction
Only Bamroongshawgasame 2010 assessed patient satisfaction
and reported inaccurately, through a graphic representation, that
100% of patients in both groups were satisfied after three weeks
of treatment (80/80 versus 80/80).
Other four trials did not assess any data for this outcome (Dierks
2008; Gilberts 2001; Nikolaou 2017; Sato 2012).
Recurrence of triggering
Four trials reported the recurrence of trigger finger and the com-
bined data from these studies showed no significant differences be-
tween the percutaneous and open surgery groups at the end of fol-
low-up (0/199 versus 1/198; RR 0.28, 0.01 to 6.83) (see Analysis
5.4) (Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001;
Sato 2012). When the studies were assessed for explanatory pur-
poses, we observed that three trials did not show any cases of recur-
rence in both groups (0/145 versus 0/152) (Bamroongshawgasame
2010; Dierks 2008; Sato 2012). Only one trial reported the re-
currence of triggering after two months in the open surgery group
(0/54 versus 1/46) (Gilberts 2001). Bamroongshawgasame 2010,
Dierks 2008 and Gilberts 2001 observed short-term results, while
Sato 2012 observed intermediate-term results.
When the results were subgrouped by time of outcome measure-
ment (short, intermediate or long-term) for exploratory purposes,
three trials were short-term and no differences between the groups
was observed (0/154 versus 1/142; RR 0.28, 95%CI 0.01 to 6.83)
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(Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001). One
trial was intermediate-term and no differences was foud between
groups (0/45 versus 0/56; risk ratio could not be estimated) (see
Analysis 5.7) (Sato 2012). No trial was long-term in this compar-
ison.
No data about recurrence of triggering were assessed in Nikolaou
2017.
Adverse events
No significant differences between percutaneous and open surgery
groups were noted in the combined results for adverse events from
five trials (Bamroongshawgasame 2010; Dierks 2008; Gilberts
2001; Nikolaou 2017; Sato 2012), and no heterogeneity was ob-
served (I² = 0%) (3/215 versus 3/214; RR 0.80, 95% CI 0.17 to
3.68) (see Analysis 5.5).
Analyses by types of adverse events indicated that in both treatment
groups there was no infection (0/61 versus 0/72; risk ratio could
not be estimated), no partial loss of movement (0/16 versus 0/
16; risk ratio could not be estimated), as well as tendon or pulley
injury (0/125 versus 0/136; risk ratio could not be estimated).
There was swelling, inflammation or haematoma in both groups
and no significant differences (2/74 versus 2/62; RR 0.80, 95%CI
0.12 to 5.30; Chi² = 0.76, df = 1 (P = 0.38); I² = 0%). Adherence
only occurred in the open surgery group (0/54 versus 1/46; RR
0.28, 95% CI 0.01 to 6.83). Other adverse events not specified
by an author occurred in the percutaneous surgery group (1/54
versus 0/46; RR 2.56, 95% CI 0.11 to 61.45) (see Analysis 5.5)
(Gilberts 2001).
Neurovascular injury
Combined data from four trials reported no neurovascular in-
jury in both groups (0/199 versus 0/198) (Bamroongshawgasame
2010; Dierks 2008; Gilberts 2001; Sato 2012).
No data about neurovascular injury was reported by Nikolaou
2017.
Comparison 6: endoscopic surgery versus open
surgery
Only one study compared endoscopic surgery versus open surgery
(Pegoli 2008). The relevant data on the main outcomes of this
comparison are listed in Summary of findings 6.
Resolution of trigger finger
The results’ analysis of Pegoli 2008 indicated no significant differ-
ences in resolution between endoscopic and open surgery groups
(114/114 versus 117/117; RR 1.00; 95% CI 0.98 to 1.02) (see
Analysis 6.1).
Pain
Pegoli 2008 assessed the duration of pain, in days, and reported
that the average pain time after the procedure was 23 days in the
endoscopic surgery group and 45 days in the open surgery group.
Function or disability
No data about function or disability were assessed in Pegoli 2008.
Participant-reported treatment success or satisfaction
No data about patient satisfaction were assessed in Pegoli 2008.
Recurrence of triggering
There were no cases of recurrence of triggering in either group (0/
114 versus 0/117).
Adverse events
No significant differences between endoscopic and open surgery
groups were noted in the results’ analysis for all adverse events in
Pegoli 2008, although a higher number of complications was re-
ported in the endoscopic surgery group when compared with the
open surgery group (8/114 versus 3/117; RR 2.74, 95% CI 0.74
to 10.06) (see Analysis 6.2). Pegoli 2008 assessed dysaesthesia and
infection events and all of the adverse event cases reported corre-
sponded to dysaesthesia, while no infection cases were observed
in either group (see Analysis 6.2).
Neurovascular injury
Pegoli 2008 reported neurovascular injury only in the endoscopic
surgery group and no significant differences between groups were
noted in the results analysis (1/114 versus 0/117; RR 3.08, 95%
CI 0.13 to 74.79) (see Analysis 6.3).
Comparison 7: open surgery by transverse incision of
the skin about 2-3 mm distally from distal palmar
crease versus open surgery by longitudinal incision of
the skin at the level of the A1-pulley without crossing
the distal palmar crease proximal
Only one study compared open surgery by transverse incision of
the skin about 2-3 mm distally from distal palmar crease versus
open surgery by longitudinal incision of the skin at the level of
the A1-pulley without crossing the proximal distal palmar crease
(Kloeters 2016).
Kloeters 2016 assessed data on function or disability of the hand
by DASH score. No data on resolution of trigger finger, pain,
patient satisfaction, recurrence, adverse events or neurovascular
injury were assessed in the trial.
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The DASH scores (DASH score: 0 to 100, where 0 means no
disability and 100 means the most severe disability) and respective
mean standard error at preoperative baseline, and at one, three
and 12 months follow-up were reported in Kloeters 2016. Ana-
lyzes of the results showed that although the baseline preopera-
tive values of the DASH score were significantly lower in the
open surgery group by transverse incision of the skin about 2-3
mm distally from distal palmar crease, no significant difference
between the groups was observed at one (MD −1.50, 95% CI
−19.19 to 16.19; 0- to 100-point scale), three (MD−2.00, 95%
CI−16.45 to 12.45; 0- to 100-point scale) and 12months follow-
up (MD −8.90, 95% CI −23.35 to 5.55; 0- to 100-point scale)
(see Analysis 7.1).
Comparison 8: open surgery by transverse incision of
the skin in the distal palmar crease versus open
surgery by longitudinal incision of the skin at the level
of the A1-pulley without crossing the distal palmar
crease proximal
Only one study compared open surgery by transverse incision of
the skin in the distal palmar crease versus open surgery by longi-
tudinal incision of the skin at the level of the A1-pulley without
crossing the proximal distal palmar crease (Kloeters 2016).
Kloeters 2016 assessed data on function or disability of the hand by
DASH score. No data regarding resolution of trigger finger, pain,
patient satisfaction, recurrence, adverse events or neurovascular
injury were assessed in the trial.
The DASH scores and respective standard error mean at preop-
erative baseline, and at one, three and 12 months follow-up were
reported in Kloeters 2016. The analyzes of the results showed that
there was no significant difference between the two comparison
groups in the follow-up with one (MD 5.20, 95% CI −16.67 to
27.07; 0- to 100-point scale), three (MD 1.60, 95% CI −15.27
to 18.47; 0- to 100-point scale) and 12 months (MD 3.10, 95%
CI −21.28 to 27.48; 0- to 100-point scale) (see Analysis 8.1).
Comparison 9: open surgery by transverse incision of
the skin in the distal palmar crease versus open
surgery by transverse incision of the skin about 2-3
mm distally from distal palmar crease
Only one study compared open surgery by transverse incision
of the skin in the distal palmar crease versus open surgery by
transverse incision of the skin about 2-3 mm distally from distal
palmar crease (Kloeters 2016).
Kloeters 2016 assessed data on function or disability of the hand by
DASH score. No data regarding resolution of trigger finger, pain,
patient satisfaction, recurrence, adverse events or neurovascular
injury were assessed in the trial.
The DASH scores and respective standard error of the mean at
preoperative baseline, and at one, three and 12 months follow-
up were reported in Kloeters 2016. The analyzes of the results
showed that although the baseline preoperative values of the
DASH score were significantly lower in the open surgery group by
transverse incision of the skin about 2-3 mm distally from distal
palmar crease, no significant difference between the groups was
observed at one (MD 6.70, 95% CI −13.67 to 27.07; 0- to 100-
point scale), three (MD 3.60, 95% CI −12.84 to 20.04; 0- to
100-point scale) and 12 months follow-up (MD 12.00, 95% CI
−8.84 to 32.84; 0- to 100-point scale) (see Analysis 9.1).
Sensitivity analyses
Three quasi-randomised trials were considered at high risk of
selection bias (Aref 2014; Dierks 2008; Singh 2005). Five ran-
domised trials were considered at unclear allocation concealment
(Bamroongshawgasame 2010; Callegari 2011; Kloeters 2016;
Maneerit 2003; Pegoli 2008). We were unable to perform the sen-
sitivity analyses in Comparisons 3, 4, 6, 7, 8 and 9, since they cor-
responded to only one trial. In Comparison 1 (open surgery versus
steroid injection) all studies (Hansen 2017; Sato 2012) were low
risk of selection bias, and no change in the analyses was observed
for all the outcomes analysed (resolution, pain, frequency of re-
currence, adverse events and neurovascular injury) (see Analysis
1.1; Analysis 1.2; Analysis 1.3; Analysis 1.4; Analysis 1.5; Analysis
1.6). When we removed the studies with high or uncertain risk
of bias in Comparison 2 (percutaneous surgery versus steroid in-
jection) there was no change in the analyses for the outcomes of
resolution, pain or neurovascular injury (see Analysis 2.1; Analysis
2.2; Analysis 2.3; Analysis 2.6). In the analysis of the recurrence
outcome we observed that in the final assessment of follow-up (six
to 12 months) there were no significant differences between the
two groups either in the analysis of all trials (RR 0.57, 95% CI
0.21 to 1.59), or in the analysis after removing Aref 2014 and
Singh 2005 (RR 0.23, 95% CI 0.03 to 2.08) (see Analysis 2.4).
We only found a change in the recurrence results in the long-term
subgroup (more than six months), which had initially shown no
difference between groups (RR 0.55, 95% CI 0.10 to 2.99) and
was then favourable to the percutaneous surgery group (RR 0.09,
95% CI 0.01 to 0.66), after removing the studies Aref 2014 and
Singh 2005 (see Analysis 2.8.3). When we analysed the outcome
of adverse events there were no result changes, which remained
with no significant difference between groups, both in the analysis
for total adverse events with all studies (RR 1.58, 95% CI 0.91
to 2.75), or after removing the studies Aref 2014 and Singh 2005
(RR 1.14, 95% CI 0.25 to 5.14) (see Analysis 2.5). In Compari-
son 5 (percutaneous surgery versus open surgery) the data analyses
with all studies were similar to the analyses after the removal of
studies with high or uncertain risk of bias (Bamroongshawgasame
2010; Dierks 2008), which remained with no differences between
the comparison groups for all the outcomes analysed (resolution,
pain, frequency of recurrence and adverse events) (see Analysis
5.1; Analysis 5.2; Analysis 5.3; Analysis 5.4; Analysis 5.5). The
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resolution at the end of treatment (two- to six-months’ follow-
up) with all studies included (RR 1.00, 95% CI 0.97 to 1.02)
remained with no difference between groups after removing the
studies Bamroongshawgasame 2010 and Dierks 2008 (RR 1.00,
95% CI 0.97 to 1.04) (see Analysis 5.1); the same outcome was
observed for adverse events, which remained with no significant
difference between groups in the analysis with all studies included
(RR 0.80, 95% CI 0.17 to 3.68) and after removing the two stud-
ies (Bamroongshawgasame 2010;Dierks 2008) (RR 0.57, 95%CI
0.10 to 3.25) (see Analysis 5.5). The pain outcome was assessed
by only one study and the outcome frequency of recurrence did
not change (see Analysis 5.2; Analysis 5.3; Analysis 5.4).
We also investigated the effect of imputation of incomplete out-
come data on the results. In Comparison 1 the outcome resolution
continued with no significant differences between the two groups
when the results between open surgery versus steroid injection
were compared at the end of follow-up (six to 12 months) for the
best-case scenario (RR 1.48, 95% CI 0.82 to 2.68) and for the
worst-case scenario (RR 1.48, 95% CI 0.79 to 2.76). No data loss
was observed in the analyses of the incidence of pain on the palm
of the hand. Hansen 2017 reported data about severity of pain
and provided the median and the IQR, but they did not report
the mean and standard deviation; the sensitivity analysis for data
loss showed no change in the outcome for pain (1 to 10 scale),
which remained with no significant difference between groups in
a short follow-up time (three months) as well as when we consid-
ered the results based on the median and IQR reported in Hansen
2017 (open surgery group: median 1, IQR 1 to 2; steroid injection
group: mean 1, IQR 1 to 1; P > 0.05), as in the analyses of results
using an approximate mean and an approximate SD (MD 0.00,
95% CI −0.23 to 0.23); there was no change in the results in the
long term follow-up (12months), which remained favorable to the
open surgery group as well as when we considered the results based
on the median and IQR reported in Hansen 2017 (open surgery
group: median 1, IQR 1 to 1; steroid injection group: mean 3,
IQR 1 to 5; P < 0.05), as in the analyses of results that showed
approximate mean and SD (MD -2.00, 95% CI−2.68 to -1.32).
There was no change in the results for the outcome recurrence at
endpoint (six to 12 months) which remained favourable to open
surgery group in the worst-case scenario (RR 0.17, 95% CI 0.09
to 0.33), and in the best-case scenario (RR 0.03, 95% CI 0.00 to
0.19). There were no changes in the results of total adverse events,
which remained unchanged between treatment groups at both the
worst (RR 1.02, 95% CI 0.57 to 1.84) and best-case scenario (RR
0.74, 95%CI 0.34 to 1.60). There were also no changes in the out-
come results of neurovascular injury, which remained unchanged
between groups in both the worst-case scenario (RR 2.17, 95%CI
0.70 to 6.77), and best-case scenario (RR 2.89, 95% CI 0.12 to
70.03). In Comparison 2 the outcome resolution continued with
no significant differences between the two groups when the results
between percutaneous surgery versus steroid injection were com-
pared at the end of follow-up (six months to one year) for the best-
case scenario (RR 1.91, 95% CI 0.42 to 8.63) and for the worst-
case scenario (RR 2.11, 95% CI 0.31 to 14.51). We observed a
change in the pain outcome (VAS) in which the analysis with all
studies included showed no difference between the two groups in
the short term (MD −1.80, 95% CI −5.72 to 2.12), while after
removing one study - Zyluk 2011 - that did not report the stan-
dard deviation, we observed that the result was then favourable
to the percutaneous surgery group (MD −3.80, 95% CI −4.34
to −3.26). There was no change in the results for the outcome
recurrence at endpoint (six to 12 months) which continued with
no difference between the two groups in the worst-case scenario
(RR 0.57, 95%CI 0.21 to 1.59), and in the best-case scenario (RR
0.30, 95% CI 0.07 to 1.39). The results also did not change for
the outcome adverse events, which continued with no difference
between the two groups in the worst-case scenario (RR 1.58, 95%
CI 0.91 to 2.75), and in the best-case scenario (RR 1.43, 95% CI
0.68 to 2.99). Comparison 3 (open surgery versus steroid injec-
tion plus ultrasound-guided hyaluronic acid injection) consisted
of only one study, which assessed the outcomes pain (VAS), func-
tional status of the hand (DASH) and patient satisfaction but did
not report the standard deviations, and therefore the data could
not be assessed (Callegari 2011). The sensitivity analysis for data
loss in Comparison 4 (percutaneous surgery plus steroid injec-
tion versus steroid injection) showed no difference in the outcome
resolution of symptoms after one or more injections, which re-
mained favourable to treatment with percutaneous surgery in the
worst-case scenario (RR 1.51, 95% CI 1.21 to 1.90) and in the
best-case scenario (RR 1.50, 95% CI 1.21 to 1.86). There was
also no change in total adverse events, which remained with no
significant difference between groups in the worst-case scenario
(RR 0.92, 95% CI 0.13 to 6.36), and in the best-case scenario
(RR 0.92, 95% CI 0.06 to 14.46). The analysis of Comparison
5 (percutaneous surgery versus open surgery) showed data loss
for the assessment of pain and patient satisfaction in the study of
Bamroongshawgasame 2010, which reported these outcomes only
through figures, with inaccurate values and without standard
deviation data. Comparisons 6, 7, 8 and 9 had no data loss.
29Surgery for trigger finger (Review)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Percutaneous surgery versus steroid injection for treating trigger finger
Patient or population: pat ients with trigger f inger
Settings: hospital
Intervention: percutaneous surgery
Comparison: steroid inject ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Steroid injection Percutaneous surgery
Resolution of symp-
toms
(af ter 1 or more injec-
t ions)
Follow-up: range 6 to 12
months
545 per 1000 1000 per 1000
(169 to 1000)
RR 2.11
(0.31 to 14.51)
191
(2 RCTs)
⊕©©©
VERY LOW 1,2,3
Absolute dif f erence:
42% more had resolu-
t ion of symptoms with
percutaneous surgery
(15% fewer to 98%
more); relat ive change:
111% more (69% fewer
to 1351%more)
NNTB n/ a4
Pain
(Visual analogue scale:
0 to 10 points)
Follow-up: 1 month
The mean pain in the
control group was 2.7
The mean pain in the
intervent ion group was
1.8 lower (5.72 lower to
2.12 higher)
222
(2 RCTs)
⊕©©©
VERY LOW 1,2,3
Abso-
lute reduct ion: 18%pain
reduct ion with percu-
taneous surgery (57%
reduct ion to 21% in-
crease), and the relat ive
percent change trans-
lates to improvement of
25% (29%worse to 78%
better)5. NNTB n/ a4
Although a decrease of
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1.8 in the VAS score
(VAS: 0 to 10 points;
where 0 mean no pain
and 10 severe pain)
may correspond to clin-
ical improvement, there
was no stat ist ical dif -
f erence between the
groups and some par-
t icipants’ pain wors-
ened)
Function
Not measured
See comment See comment - See comment Not measured in any
trial.
Participant global as-
sessment of success
Not measured
See comment See comment - See comment Not measured in any
trial.
Recurrence
Follow-up: range 6 to 12
months
197 per 1000 112 per 1000
(41 to 313)
RR 0.57
(0.21 to 1.59)
392
(5 RCTs)
⊕©©©
VERY LOW 2,3,6
Absolute risk dif f er-
ence: 9% fewer peo-
ple had recurrence with
percutaneous surgery
(19% fewer to 2%more)
, and the relat ive per-
cent change translates
to improvement of 43%
(59% worse to 79% bet-
ter). The NNTB n/ a4.
Adverse events
(infect ion, part ial loss
of movement, tendon
or−0 injury, dysaesthe-
sia, and skin atrophy or
hypopigmentat ion)
Follow-up: range 6 to 12
months
89 per 1000 140 per 1000
(81 to 244)
RR 1.58
(0.91 to 2.75)
392
(5 RCTs)
⊕©©©
VERY LOW 3,6
Ab-
solute risk dif f erence:
3%more people had ad-
verse events with per-
cutaneous surgery (5%
fewer to 11% more),
and the relat ive percent
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change translates to
worsening of 58% (9%
better to 175% worse).
The NNTH n/ a4.
Neurovascular injury
Follow-up: range 6 to 12
months
30 per 1000 11 per 1000
(1 to 100)
RR 0.35
(0.04 to 3.29)
191
(2 RCTs)
⊕⊕©©
LOW 1,3
Absolute dif f erence:
fewer than 1% had neu-
rovascular injury with
percutaneous surgery
(5% fewer to 3% more)
; relat ive change: 65%
fewer (229% fewer to
96% more). The NNTB
n/ a4.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The two trials had methodological f laws; they did not blind the outcome assessor, and they had select ive report ing or unclear
risk for incomplete outcome data.
2Inconsistency: heterogeneity was high.
3Imprecision: the total number of events was small, or the 95% conf idence interval includes both percutaneous surgery and
steroid inject ion groups, or the 95% conf idence interval includes both no clinical ef fect, and ‘‘appreciable benef it ’’ in favour of
the steroid inject ion group.
4Number needed to treat for an addit ional benef icial outcome (NNTB), or for an addit ional harmful outcome (NNTH) not
applicable (n/ a) when result is not stat ist ically signif icant. NNT for dichotomous outcomes calculated using Cates NNT
calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous outcomes calculated using Wells Calculator (CMSG editorial
of f ice).
5Basis for assumed risk was the mean baseline risk f rom the studies in the meta-analysis.
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6The f ive trials had methodological f laws; two were quasi-randomised; four did not blind the outcome assessor and three had
unclear risk for incomplete outcome data (one trial had follow-up loss 17%, but ’intent ion to treat analysis’ was not done; two
trials did not report the follow-up loss); four trials had select ive report ing. We opted by double downgrade.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Open surgery versus steroid injection plus hyaluronic acid injection guided by ultrasound for treating trigger finger
Patient or population: pat ients with trigger f inger
Settings: hospital
Intervention: open surgery
Comparison: steroid inject ion plus hyaluronic acid inject ion guided by ultrasound
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Steroid injection plus
hyaluronic acid injec-
tion guided by ultra-
sound
Open surgery
Resolution of symp-
toms
Follow up: 12 months
733 per 1000 990 per 1000
(719 to 1000)
RR 1.35
(0.98 to 1.85)
30
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute dif f erence:
27% more had res-
olut ion of symptoms
with open surgery (3%
to 50% more); relat ive
change: 35% more (2%
fewer to 85% more).
The NNTB n/ a3.
Pain
(short-term)
Not measured
See comment See comment - See comment Pain in 6-month follow-
up was assessed by
visual analogue scale
(VAS: 0 to 10 points;
where 0 means no pain
and 10 severe pain), but
the authors failed to re-
port any measurement
of variance: standard
deviat ion, standard er-
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rors, P values, or con-
f idence intervals. The
VAS score was 1 point
(range 0 to 2) in open
surgery group, and 1
point (range 0 to 3) in
steroid plus hyaluronic
acid inject ion group.
This is not clinically sig-
nif icant
Function
Not measured
See comment See comment - See comment Funct ional status of the
hand in follow-up of 6
months was assessed
by DASH score, but the
authors failed to re-
port any measurement
of variance. The DASH
score was 11%(range 7
to 16) in open surgery
group and 13% (range
7 to 20) in steroid
plus hyaluronic acid in-
ject ion group; it t rans-
lates to absolute im-
provement of 2%(DASH
score: 0 to 100%; where
0 means no disability
and 100 the most se-
vere disability) in the
open surgery group.
This is not a clinically
signif icant dif f erence
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Participant global as-
sessment of success
Not measured
See comment See comment - See comment Pat ient sat isfact ion in
follow-up was at 6
months assessed by
sat isfact ion visual ana-
logue scale (SVAS: 0
to 10 points; where
0 means totally un-
sat isf ied and 10 com-
pletely sat isf ied), but
the authors failed to re-
port any measurement
of variance: standard
deviat ion, standard er-
rors, P values, or con-
f idence intervals. The
SVAS score was 7.8
points (3 to 10 range) in
the open surgery group,
and 7.4 points (2 to 10
range) in steroid plus
hyaluronic acid injec-
t ion group; it t ranslates
to absolute improve-
ment of 0.4 point in
the open surgery group.
This is not a clinically
signif icant dif f erence
Recurrence
Follow-up: 12 months
200 per 1000 28 per 1000
(2 to 510)
RR 0.14
(0.01 to 2.55)
30
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 20% fewer peo-
ple had recurrence
with open surgery (42%
fewer to 2% more),
and the relat ive per-
cent change translates
to improvement of 86%
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(99% worse to 155%
better). The NNTB n/ a
3.
Adverse events
(part ial loss of move-
ment, algodystrophic
syndrome)
Follow-up: 12 months
67 per 1000 200 per 1000
(23 to 1000)
RR 3.00
(0.35 to 25.68)
30
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 13% more peo-
ple had adverse events
with open surgery (11%
fewer to 37% more),
and the relat ive per-
cent change translates
to worsening of 200%
(2468% worse to 65%
better). The NNTH n/ a
3.
Neurovascular injury
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The trial had methodological f laws; it did not describe how random sequence generat ion was created and whether allocat ion
concealment was done; the outcome assessor was not blinded, and it had select ive report ing. We opted by double
downgrade.
2Imprecision: the total number of events was small, or the 95% conf idence interval includes both no clinical ef fect, and
‘‘appreciable benef it ’’ in favour of the open surgery group, or the 95% conf idence interval includes both open surgery and
steroid inject ion plus hyaluronic acid inject ion groups.
3Number needed to treat for an addit ional benef icial outcome (NNTB), or for an addit ional harmful outcome (NNTH) not
applicable (n/ a) when result is not stat ist ically signif icant. NNT for dichotomous outcomes calculated using Cates NNT
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calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous outcomes calculated using Wells Calculator (CMSG editorial
of f ice).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Percutaneous surgery plus steroid injection versus steroid injection for treating trigger finger
Patient or population: pat ients with trigger f inger
Settings: hospital
Intervention: percutaneous surgery plus steroid inject ion
Comparison: steroid inject ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Steroid injection Percutaneous surgery
plus steroid injection
Resolution of symp-
toms
(af ter 1 or more injec-
t ions)
Follow up: range 6 to 42
months
590 per 1000 891 per 1000
(714 to 1000)
RR 1.51
(1.21 to 1.90)
127
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute dif f erence:
30% more had resolu-
t ion of symptoms with
percutaneous surgery
plus steroid inject ion
(16% to 45% more); rel-
at ive change: 51%more
(21% to 90% more).
NNTB 4 (95%CI 3 to 6)
Pain
(short-term)
Not measured
See comment See comment See comment - See comment Pain in follow-up of 2
weeks was assessed by
visual analogue scale
(VAS: 0 to 10 points;
where 0 means no pain
and 10 severe pain),
but the authors failed
to report any measure-
ment of variance: stan-
dard deviat ion, stan-
dard errors, P values,
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or conf idence intervals.
The VAS score was 0.
4 point in percutaneous
surgery plus steroid in-
ject ion group, and 0.3
point in steroid injec-
t ion group; it t ranslates
to absolute worsening
of 0.1 point in the per-
cutaneous surgery plus
steroid inject ion group.
This is not a clinically
signif icant dif f erence
Function
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Participant global as-
sessment of success
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Recurrence
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Adverse events
(infect ion, part ial loss
of movement)
Follow-up: range 6 to 42
months
33 per 1000 30 per 1000
(4 to 209)
RR 0.92
(0.13 to 6.36)
127
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 0% (6% fewer
to 6% more); relat ive
percentage change: 8%
fewer (536% fewer to
87% more). The NNTB
n/ a3.
Neurovascular injury
Follow-up: range 6 to 42
months
16 per 1000 15 per 1000
(1 to 237)
RR 0.92
(0.06 to 14.46)
127
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 0% (4% fewer
to 4% more); relat ive
percentage change: 8%
fewer (1346% fewer to
94% more). The NNTB4
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n/ a3.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The trial had methodological f laws; it did not describe how random sequence generat ion was created and whether allocat ion
concealment was done; the outcome assessor was not blinded and it had select ive report ing. We opted by double
downgrade.
2Imprecision: the total number of events was small, or the 95% conf idence interval includes both percutaneous surgery plus
steroid inject ion, and steroid inject ion groups.
3Number needed to treat to benef it (NNTB), or harm (NNTH) not applicable (n/ a) when result is not stat ist ically signif icant. NNT
for dichotomous outcomes calculated using Cates NNT calculator (http:/ / www.nntonline.net/ visualrx/ ). NNT for cont inuous
outcomes calculated using Wells Calculator (CMSG editorial of f ice).
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Percutaneous surgery versus open surgery for treating trigger finger
Patient or population: pat ients with trigger f inger
Settings: hospital
Intervention: percutaneous surgery
Comparison: open surgery
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Open surgery Percutaneous surgery
Resolution of symp-
toms
Follow-up: range 2 to 6
months
995 per 1000 995 per 1000
(965 to 1000)
RR 1.00
(0.97 to 1.02)
429
(5 RCTs)
⊕⊕©©
LOW 1
Absolute risk dif f er-
ence: 0% (3% fewer
to 2% more); relat ive
percentage change: 0%
(3% fewer to 2% more).
NNTB n/ a2.
Pain
(1 to 6 scale)
Follow-up: 1 week
The mean pain short
term (1 to 6 scale) in
the control group was
2.5
The mean pain short
term (1 to 6 scale) in the
intervent ion group was
0.3 higher (0.34 lower
to 0.94 higher)
- 36
(1 RCT)
⊕©©©
VERY LOW 3,4
Absolute risk dif f er-
ence: 6% increase in
pain with percutaneous
surgery (7% reduct ion
to 19% increase), and
the relat ive percent
change translates to
worsening of 7% (22%
worse to 8% better)5.
NNTH n/ a2.
The dif ference of 0.
3 points in the pain
score (pain score: 1 to 6
points; where 1 means
no pain and 6 extreme
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pain) is not clinically
signif icant
Function
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Participant global as-
sessment of success
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Recurrence
Follow-up: range 2 to 6
months
5 per 1000 1 per 1000
(0 to 34)
RR 0.28
(0.01 to 6.83)
397
(4 RCTs)
⊕⊕©©
VERY LOW 4,6
Absolute risk dif f er-
ence: 0% (2% fewer to
2% more); relat ive per-
centage change: 72%
fewer (583% fewer to
99% more). The NNTB
n/ a2.
Adverse events
(infect ion, part ial loss
of movement, tendon
or pulley injury, oedema
or inf lammation or
hematoma, adherence)
Follow-up: range 2 to 6
months
14 per 1000 11 per 1000
(2 to 52)
RR 0.80
(0.17 to 3.68)
429
(5 RCTs)
⊕©©©
VERY LOW 1,4
Absolute risk dif f er-
ence: 0% (2% fewer to
2% more); relat ive per-
centage change: 20%
fewer (268% fewer to
83% more). The NNTB
n/ a2.
Neurovascular injury
Follow-up: range 2 to 6
months
0 per 1000 0 per 1000
(0 to 0)
Could not be est imated 397
(4 RCTs)
⊕©©©
VERY LOW 4,6
There was no injury in
both groups.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1All f ive trials had methodological f laws; one was quasi-randomised; three had adequate concealed treatment allocat ion, and
one did not describe how this allocat ion concealment was done; the subject ive outcomes assessor was blinded in one,
and no trial blinded the object ive outcomes assessor; select ive report ing was observed in three trials. We choe to double
downgrade.
2Number needed to treat to benef it (NNTB), or harm (NNTH) not applicable (n/ a) when result is not stat ist ically signif icant.
NNT for dichotomous outcomes calculated using Cates NNT calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous
outcomes calculated using Wells Calculator (CMSG editorial of f ice).
3This quasi-randomised trial had bias in the random sequence generat ion and allocat ion concealment; the outcome assessor
was not blinded, and it had select ive report ing. We opted by double downgrade.
4Imprecision: the total number of events was small, or the 95% conf idence interval includes both no clinical ef fect and
‘‘appreciable benef it ’’ in favour of the open surgery group, or the 95% conf idence interval includes both percutaneous and
open surgery.
5Basis for assumed risk was the mean baseline risk f rom the study in the meta-analysis.
6 The four trials had methodological f laws; one was quasi-randomised; only two had adequate concealed treatment allocat ion,
and one did not describe how this allocat ion concealment was done; the outcome assessor was not blinded and three had
select ive report ing in the trial. We opted by double downgrade.
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Endoscopic surgery versus open surgery for treating trigger finger
Patient or population: pat ients with trigger f inger
Settings: hospital
Intervention: endoscopic surgery
Comparison: open surgery
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Open surgery Endoscopic surgery
Resolution of symp-
toms
Follow-up: 3 months
1000 per 1000 1000 per 1000
(980 to 1000)
RR 1.00
(0.98 to 1.02)
231
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 0% (2% fewer
to 2% more); relat ive
percentage change: 0%
(2% fewer to 2% more).
The NNTB n/ a3.
Pain
(short-term)
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Function
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Participant global as-
sessment of success
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
Recurrence
Not measured
See comment See comment See comment - See comment Not measured in any
trial.
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Adverse events
(infect ion, dysaesthe-
sia)
Follow-up: 3 months
26 per 1000 70 per 1000
(19 to 258)
RR 2.74
(0.74 to 10.06)
231
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif -
ference: 4% more
people had adverse
events with endoscopic
surgery (1% fewer to
10% more), and the rel-
at ive percent change
translates to worsening
of 174%(906%worse to
26% better). The NNTH
n/ a3.
Neurovascular injury
Follow-up: 3 months
0 per 1000 0 per 1000
(0 to 0)
RR 3.08
(0.13 to 74.79)
231
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute dif f erence: 1%
more had neurovas-
cular injury with en-
doscopic surgery (2%
fewer to 3%more); rela-
t ive change: 208%more
(87% fewer to 7379%
more). The NNTH n/ a3.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The trial had methodological f laws; the authors did not describe how randomisat ion sequence was created and whether
allocat ion concealment was done; the outcome assessor was not blinded and the trial had select ive report ing. We chose
to double downgrade.
2Imprecision: the total number of events was small, or the 95%conf idence interval includes both open surgery and endoscopic
surgery groups.
3Number needed to treat for an addit ional benef icial outcome (NNTB), or for an addit ional harmful outcome (NNTH) not
applicable (n/ a) when result is not stat ist ically signif icant. NNT for dichotomous outcomes calculated using Cates NNT
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calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous outcomes calculated using Wells Calculator (CMSG editorial
of f ice).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Open surgery by transverse incision of the skin about 2-3 mm distally from distal palmar crease compared to open surgery by longitudinal incision of the skin for trigger
finger
Patient or population: pat ients with trigger f inger
Setting: hospital
Intervention: open surgery by transverse incision of the skin about 2-3 mm distally f rom distal palmar crease
Comparison: open surgery by longitudinal incision of the skin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Open surgery by longi-
tudinal incision of the
skin
Open surgery by trans-
verse incision of the
skin about 2-3 mm dis-
tally from distal palmar
crease
Resolution of symp-
toms
Not measured
See comment See comment - See comment Not measured in any
trial.
Pain
(short-term)
Not measured
See comment See comment - See comment Not measured in any
trial.
Function
(DASH score: 0 to 100
points)
Follow-up: 12 months
The mean DASH score
in the control group was
15.3
The mean DASH score
in the intervent ion
group was 8.9 lower
(23.35 lower to 5.55
higher)
- 21
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 8.9% increase
in hand funct ion with
open surgery by trans-
verse incision of the
skin about 2-3 mm dis-
tally f rom the distal
palmar crease (23.35%
increase to 5.55% re-
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duct ion), and the rela-
t ive percentage change
translates to improve-
ment of 21.7% (13.54%
worse to 56.95%better)
3. NNTH n/ a4.
The dif ference of 8.
9 points in the DASH
score (DASH: 0 to 100
points; where 0 means
no disability and 100
means the most severe
disability) is not clini-
cally signif icant
Participant global as-
sessment of success
Not measured
See comment See comment - See comment Not measured in any
trial.
Recurrence
Not measured
See comment See comment - See comment Not measured in any
trial.
Adverse events Not
measured
See comment See comment - See comment Not measured in any
trial.
Neurovascular injury
Not measured
See comment See comment - See comment Not measured in any
trial.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect4
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Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The trial had methodological f laws; the authors did not describe how randomisat ion sequence was created and whether
allocat ion concealment was done; the outcome assessor was not blinded and the trial had select ive report ing. We opted
by double downgrade.
2 Imprecision: the total number of events was small, or the 95% conf idence interval includes both groups (transverse incision
of the skin about 2-3 mm distally f rom distal palmar crease and longitudinal incision of the skin).
3Basis for assumed risk was the mean baseline risk f rom the study in the meta-analysis.
4Number needed to treat to benef it (NNTB), or harm (NNTH) not applicable (n/ a) when result is not stat ist ically signif icant.
NNT for dichotomous outcomes calculated using Cates NNT calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous
outcomes calculated using Wells Calculator (CMSG editorial of f ice).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Open surgery by transverse incision of the skin in the distal palmar crease compared to open surgery by longitudinal incision of the skin for trigger finger
Patient or population: pat ients with trigger f inger
Setting: hospital
Intervention: open surgery by transverse incision of the skin in the distal palmar crease
Comparison: open surgery by longitudinal incision of the skin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Open surgery by longi-
tudinal incision of the
skin
Open surgery by trans-
verse incision of the
skin in the distal pal-
mar crease
Resolution of symp-
toms
Not measured
See comment See comment - See comment Not measured in any
trial.
Pain
(short-term)
Not measured
See comment See comment - See comment Not measured in any
trial.
Function
(DASH score: 0 to 100
points)
Follow-up: 12 months
The mean DASH score
in the control group was
15.3
The mean DASH score
in the intervent ion
group was 3.1 higher
(21.28 lower to 27.48
higher)
- 22
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute reduct ion: 3.
1% funct ion reduct ion
with open surgery by
transverse incision of
the skin in the distal
palmar crease (27.48%
reduct ion to 21.28% in-
crease), and the relat ive
percent change trans-
lates to worsening of 7.
56% (67.02% worse to
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51.9% better)3. NNTB
n/ a4.
The dif ference of 3.
1 points in the DASH
score (DASH: 0 to 100
points; where 0 means
no disability and 100
means the most severe
disability) is not clini-
cally signif icant
Participant global as-
sessment of success
Not measured
See comment See comment Not est imable - See comment Not measured in any
trial.
Recurrence
Not measured
See comment See comment Not est imable - See comment Not measured in any
trial.
Adverse events Not
measured
See comment See comment Not est imable - See comment Not measured in any
trial.
Neurovascular injury
Not measured
See comment See comment Not est imable - See comment Not measured in any
trial.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1 The trial had methodological f laws; the authors did not describe how randomisat ion sequence was created and whether
allocat ion concealment was done; the outcome assessor was not blinded and the trial had select ive report ing. We chose
to double downgrade.
2 Imprecision: the total number of events was small, or the 95% conf idence interval includes both groups (transverse incision
of the skin in the distal palmar crease and longitudinal incision of the skin).
3Basis for assumed risk was the mean baseline risk f rom the study in the meta-analysis.
4Number needed to treat to benef it (NNTB), or harm (NNTH) not applicable (n/ a) when result is not stat ist ically signif icant.
NNT for dichotomous outcomes calculated using Cates NNT calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous
outcomes calculated using Wells Calculator (CMSG editorial of f ice).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
5
3
S
u
rg
e
r
y
fo
r
trig
g
e
r
fi
n
g
e
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Open surgery by transverse incision of the skin in the distal palmar crease compared to open surgery by transverse incision of the skin about 2-3 mm distally from distal
palmar crease for trigger finger
Patient or population: pat ients with trigger f inger
Setting: hospital
Intervention: open surgery by transverse incision of the skin in the distal palmar crease
Comparison: open surgery by transverse incision of the skin about 2-3 mm distally f rom distal palmar crease
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Open surgery by trans-
verse incision of the
skin about 2-3 mm dis-
tally from distal palmar
crease
Open surgery by trans-
verse incision of the
skin in the distal pal-
mar crease
Resolution of symp-
toms
Not measured
See comment See comment - See comment Not measured in any
trial.
Pain
(short-term)
Not measured
See comment See comment - See comment Not measured in any
trial.
Function
(DASH score: 0 to 100
points)
Follow-up: 12 months
The mean DASH score
in the control group was
6.4
The mean DASH score
in the intervent ion
group was 12 higher
(8.84 lower to 32.84
higher)
- 21
(1 RCT)
⊕©©©
VERY LOW 1,2
Absolute risk dif f er-
ence: 12% decrease
in funct ion with open
surgery by transverse
incision of the skin
in the distal palmar
crease (32.84% re-
duct ion to 8.84% in-
crease), and the rela-
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t ive percentage change
translates to worsen-
ing of 61.22%(167.55%
worse to 45.1% better)
3. NNTH n/ a4.
Although an increase of
12 in the DASH score
(DASH: 0 to 100 points;
where 0 means no dis-
ability and 100 means
the most severe dis-
ability) may correspond
to clinical worsening,
there was no stat ist ical
dif f erence between the
groups and some par-
t icipants’ hand funct ion
improved)
Participant global as-
sessment of success
Not measured
See comment See comment - See comment Not measured in any
trial.
Recurrence
Not measured
See comment See comment - See comment Not measured in any
trial.
Adverse events Not
measured
See comment See comment - See comment Not measured in any
trial.
Neurovascular injury
Not measured
See comment See comment - See comment Not measured in any
trial.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The trial had methodological f laws; the authors did not describe how randomisat ion sequence was created and whether
allocat ion concealment was done; the outcome assessor was not blinded and the trial had select ive report ing. We chose
to double downgrade.
2 Imprecision: the total number of events was small, or the 95% conf idence interval includes both groups (transverse incision
of the skin in the distal palmar crease and transverse incision of the skin about 2-3 mm distally f rom distal palmar crease).
3Basis for assumed risk was the mean baseline risk f rom the study in the meta-analysis.
4Number needed to treat to benef it (NNTB), or harm (NNTH) not applicable (n/ a) when result is not stat ist ically signif icant.
NNT for dichotomous outcomes calculated using Cates NNT calculator (www.nntonline.net/ visualrx/ ). NNT for cont inuous
outcomes calculated using Wells Calculator (CMSG editorial of f ice).
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D I S C U S S I O N
Summary of main results
We included 14 single-centre trials (eleven randomised and three
quasi-randomised), involving 1361 fingers in 1260 participants,
which compared, with each other or with any other medical treat-
ment, the effectiveness of different surgical techniques for the treat-
ment of trigger finger. These 14 studies allowed nine comparisons:
open surgery versus steroid injection (two trials), in which one
of the studies used ultrasound to guide the application of corti-
costeroids, while the other made the injections without using ul-
trasound; percutaneous surgery versus steroid injection (five tri-
als); open surgery versus steroid injection plus ultrasound-guided
hyaluronic acid injection (one trial); percutaneous surgery plus
steroid injection versus steroid injection (one trial); percutaneous
surgery versus open surgery (five trials), in which one of the stud-
ies used ultrasound to guide the percutaneous surgery, while the
other four performed the procedure without using ultrasound; en-
doscopic surgery versus open surgery (one trial); open surgery by
transverse incision of the skin about 2-3 mm distally from distal
palmar crease versus open surgery by longitudinal incision of the
skin at the level of the A1-pulley without crossing the proximal
distal palmar crease (one trial); open surgery by transverse incision
of the skin in the distal palmar crease versus open surgery by lon-
gitudinal incision of the skin at the level of the A1-pulley without
the proximal crossing the distal palmar crease (one trial); and open
surgery by transverse incision of the skin in the distal palmar crease
versus open surgery by transverse incision of the skin about 2-3
mm distally from the distal palmar crease (one trial).
There are three ongoing studies (see Ongoing studies): NTR1135
compares open surgery versus steroid injection and they were
recruiting participants at the time of writing this review;
TCTR20140529001 compares percutaneous surgery with needle
versus percutaneous surgery with probe scalpel and recruitment
had not started; and TCTR20150416001 compares open surgery
versus percutaneous surgery and recruitment had started at the
time of writing this review.
In our global analysis comparing the different types of surgical
treatment for trigger finger, we present the results divided into nine
groups according to the type of comparison performed. When
possible, we present the results divided into subgroups according
to the elapsed time (short-, intermediate- and long-term); it was
not possible to sub-group the results according to the participants’
age or according to the presence or absence of comorbidities due
to lack of data in the included studies.
We did not assess all of the evidence for all outcomeswe considered
as important in all of the possible comparisons, due to the lack of
reporting of relevant outcomes in the studies; we could not carry
out analysis for the outcome ’patient satisfaction’.
In Comparison 1, the very low quality evidence leaves us uncertain
if open surgery results in improvement in the resolution of trig-
gering when compared with one or more steroid application (see
Summary of findings for the main comparison). Low quality ev-
idence indicates that open surgery may decrease triggering recur-
rence, although itmaymore painful.We are uncertain if there were
any differences between treatments for adverse events and neu-
rovascular injury due to the low number of events (see Summary
of findings for the main comparison). No studies measured hand
function or patient satisfaction. We downgraded evidence due to
risk of detection bias, imprecision and, for the outcome ’resolu-
tion’, high heterogeneity too (see Summary of findings for the
main comparison).
In Comparison 2, the very low quality evidence leaves us uncertain
if when compared with steroid application, percutaneous surgery
results in improvement in the resolution of triggering, pain relief
in the short term, increases adverse events or reduces recurrence
rates (see Summary of findings 2). Low quality evidence indicates
we are also uncertain if there was any difference in the risk of
neurovascular injury, due to the low number of events. No trials
measured hand function or patient satisfaction. We downgraded
evidence due to risk of bias, imprecision and, for some outcomes,
high heterogeneity (see Summary of findings 2).
The very low quality of evidence in Comparison 3 indicates we
are uncertain if there is any difference in the resolution of trigger-
ing, recurrence or adverse events between open surgery treatment
and steroid injection plus ultrasound-guided hyaluronic acid in-
jection (see Summary of findings 3). Reporting bias due to partial
publication made it impossible to analyze the data regarding pain
relief, functional improvement of the hand or patient satisfaction,
because the authors failed to report any measurement of variance
(standard deviation, standard errors, P values, or confidence in-
tervals). We were unable to assess if the surgical treatment had a
greater risk of neurovascular injury as the study did not report this
outcome. We downgraded evidence due to risk of bias (double
downgrade) and imprecision (see Summary of findings 3).
In Comparison 4, the very low quality of evidence of the study
indicates that we are uncertain if percutaneous surgery plus steroid
injection improves resolution of triggering, results in more adverse
events or an increased risk of neurovascular injury when com-
pared with steroid injection (see Summary of findings 4). Report-
ing bias due to partial publication made it impossible to analyze
the data regarding pain relief, because the authors failed to report
any measurement of variance (standard deviation, standard errors,
P values, or confidence intervals). The study did not report func-
tional measures, recurrence of triggering or patient satisfaction.
We downgraded evidence due to risk of bias (double downgrade)
and imprecision (see Summary of findings 4).
The very low to low quality of evidence in the studies in Com-
parison 5 indicates that we are uncertain if percutaneous surgery
resolves triggering, improves pain, reduces recurrence, increases
adverse events, or the risk of neurovascular injury when compared
to open surgery (see Summary of findings 5). Hand function and
patient satisfaction were not reported in the studies. We down-
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graded evidence due to risk of bias (double downgrade) and, for
some outcomes, imprecision (see Summary of findings 5).
The very low quality of evidence in the studies in Comparison 6
indicates that we are uncertain if endoscopic surgery improves the
resolution of triggering, decreases adverse events or the risk of neu-
rovascular injury when compared to open surgery (see Summary
of findings 6). Pain relief, functional hand improvement, recur-
rence of triggering and patient satisfaction were not reported. We
downgraded evidence was downgraded due to risk of bias (double
downgrade) and imprecision (see Summary of findings 6).
In Comparisons 7, 8 and 9, the very low quality of evidence anal-
ysis from a study comparing three different types of incision for
open surgery treatment of the trigger finger indicated that it is
uncertain if one of two types of transverse incision of the skin - on
the distal palmar crease, or two to three millimeters distally from
the distal palmar crease - improves hand function when compared
to longitudinal incision of the skin, and also showed to be uncer-
tain whether there is any difference in the function of the hand
when the transverse incision of the skin in the distal palmar crease
was compared with transverse incision of the skin about 2-3 mm
distally from the distal palmar crease (see Summary of findings 7;
Summary of findings 8; Summary of findings 9). The study did
not report data on resolution, pain, patient satisfaction, recurrence
of triggering, adverse events or neurovascular injury (see Summary
of findings 7; Summary of findings 8; Summary of findings 9).
We downgraded evidence due to risk of bias (double downgrade)
and imprecision.
Overall completeness and applicability of
evidence
The best recent evidence on surgery for trigger finger was obtained
from eleven randomised trials and three quasi-randomised trials,
which assessed only adult individuals with trigger finger (thumb
or other fingers) at any stage of the disease, totalling 1361 events in
1260 participants. The effectiveness of different types of surgical
treatment were compared and also compared with steroid infil-
tration, sub-grouping the results according to the follow-up time
(short-, intermediate- and long-term). Studies inwhich ultrasound
was used as a guide were analyzed in conjunction with studies in
which the same procedure was performed without ultrasound vis-
ibility, provided that the comparison was between the same treat-
ment methods (ex: open surgery versus ultrasound-guided steroid
injection and open surgery versus steroid injection were analyzed
in the same comparison). We were unable to sub-group the results
according to the age of the participants or the presence of associ-
ated comorbidities, due to the lack of data in the included studies.
No study reported all the important outcomes of the review: 10
trials reported the resolution of triggering and eight assessed pain,
although one trial assessed pain dichotomously and five trials re-
ported the data incompletely about pain. Three trials evaluated
functional status of the hand by validated instruments, but only
one reported complete data. No study reported complete data
about patient satisfaction; 10 studies assessed triggering recur-
rence. Thirteen studies reported adverse events and eight trials re-
ported full details of neurovascular injury.
A limitation of this review is that the resolution of triggering, con-
sidered as the main primary outcome, was defined differently in
the 10 studies that reported it, which can interfere in the interpre-
tation of the analyses of this outcome.
Quality of the evidence
In this review, the evidence was found to be of very low to low
quality for the results grouped in the nine possible comparisons,
and this was due to methodological flaws such as inadequate or
uncertain allocation concealment in most studies and the lack of
blinding of the outcomes assessed in 13 of 14 studies. Additionally,
the trials includeddidnot report data according to theCONSORT
statement (Moher 2001), and only three studies (Hansen 2017;
Nikolaou 2017; Sato 2012) published a protocol, but in Nikolaou
2017 and Sato 2012 it was dated after the study was finished.
In Comparison 1 (open surgery versus steroid injection), the evi-
dence found was of very low quality for the outcome ’resolution’,
justified by one downgrade due to methodological flaws related
to the risk of detection bias in the studies included in this com-
parison, one downgrade for imprecision due to the small number
of events, and one downgrade for inconsistency because of high
heterogeneity. As for the outcomes ’pain’, ’trigger recurrence’, ’ad-
verse events’ and ’neurovascular injury’ we obtained low quality
evidence, justified by a downgrade due to methodological flaws
related to the risk of detection bias in the studies included in this
comparison and a downgrade due to uncertainty related to the
small number of events. The degree of evidence for the outcomes
’hand function’ and ’participant satisfaction’ was not assessed due
to the lack of relevant data in the two studies included in this
comparison.
Very low quality evidence was found in Comparison 2 (percuta-
neous surgery versus steroid injection) for the outcomes ’resolu-
tion’, ’pain’, ’trigger recurrence’ and ’adverse events’, and the re-
sults of the outcomes ’resolution’ and ’pain’ received one down-
grade due to the methodological flaws of the studies related to
detection bias and selective reporting, one downgrade for impre-
cision due to the small number of events, and one downgrade for
inconsistency because of high heterogeneity; the outcomes ’trigger
recurrence’ and ’adverse events’ received two downgrades due to
significant methodological flaws related to bias selection (two tri-
als were quasi-randomised), the presence of detection bias and se-
lective reporting and one downgrade due to uncertainty related to
the small number of events. It is also emphasized that the outcome
’trigger recurrence’ also received a downgrade for inconsistency re-
lated to high heterogeneity. Low-quality evidence was obtained for
the outcome ’neurovascular injury’ which was downgraded due to
the methodological flaws in the studies related to detection bias
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and selective reporting, and downgraded for inaccuracy due to the
small number of events. It was not possible to assess the degree of
evidence for the outcomes ’hand function’ and ’participant satis-
faction’ due to the lack of relevant data in the five studies included
in this comparison.
In Comparison 3 (open surgery versus steroid injection plus
hyaluronic acid injection guided by ultrasound) evidence of very
low quality was found for the outcomes ’resolution’, ’trigger recur-
rence’ and ’adverse events’, justified by a double downgrade due
to significant methodological flaws of the study related to unclear
selection bias, the presence of detection bias and selective report-
ing; a third downgrade was justified for uncertainty due to the
small number of participants in this comparison. It was not possi-
ble to assess the degree of evidence for the outcomes ’pain’, ’hand
function’, ’participant satisfaction’ and ’neurovascular injury’ due
to the lack of relevant data in the only study included in this com-
parison.
Very low evidence was obtained in Comparison 4 (percutaneous
surgery plus steroid injection versus steroid injection) for the out-
comes ’resolution’, ’adverse events’ and ’neurovascular injury’, due
to a double downgrade for the methodological flaws of the stud-
ies related to unclear selection bias, detection bias and selective
reporting, in addition to one downgrade for inconsistency due to
the small number of events. It was not possible to assess the degree
of evidence for the outcomes ’pain’, ’hand function’, ’participant
satisfaction’ and ’trigger recurrence’ due to the lack of relevant data
in the only study included in this comparison.
In the comparisonbetweenpercutaneous surgery andopen surgery
(Comparison 5) we obtained low-quality evidence for the out-
come ’resolution’ due to a double downgrade for methodological
flaws of the studies related to selection bias, detection bias and
selective reporting. As for the outcomes ’pain’, ’recurrence of trig-
ger finger’, ’adverse events’ and ’neurovascular injury’ we obtained
very low quality evidence, justified by a double downgrade due to
the methodological flaws of the studies related to selection bias,
detection bias and selective reporting and one downgrade for im-
precision related to the small number events in the studies of this
comparison. It was not possible to assess the degree of evidence
for the outcomes ’hand function’ and ’participant satisfaction’ due
to the lack of relevant data in the four studies included in this
comparison.
We found very low quality evidence in Comparison 6 (endoscopic
surgery versus open surgery) for the outcomes ’resolution’, ’adverse
events’ and ’neurovascular injury’ due to a double downgrade for
the methodological flaws of the only study in this comparison,
related to lack of clarity regarding selection bias, and the presence
of detection bias and selective reporting, and one downgrade for
imprecision due to the small number of events in the study. It was
not possible to assess the degree of evidence for the outcomes ’pain’,
’hand function’, ’participant satisfaction’ and ’trigger recurrence’
due to the lack of relevant data in the only study included in this
comparison.
Very low-quality evidence was found in Comparisons 7 (open
surgery by transverse incision of the skin about 2-3 mm distally
from the distal palmar crease versus open surgery by longitudinal
incision of the skin), 8 (open surgery by transverse incision of the
skin in the distal palmar crease versus open surgery by longitudinal
incision of the skin) and 9 (open surgery by transverse incision of
the skin in the distal palmar crease versus open surgery by trans-
verse incision of the skin about 2-3 mm distally from the distal
palmar crease) for the outcome ’hand function’ which was double
downgraded due to the methodological flaws in the study related
to selection bias, detection bias and selective reporting, and down-
graded for inaccuracy due to the small number of events. It was not
possible to assess the degree of evidence for the outcomes ’resolu-
tion’, ’pain’, ’participant satisfaction’, ’trigger recurrence’, ’adverse
events’ and ’neurovascular injury’ due to the lack of relevant data
in the only study included in these comparisons.
Potential biases in the review process
This review started with a systematic search for potential studies
without any language restrictions, which included amanual search
in conference proceedings and in published articles and review
citations, as well as ongoing or recently completed research studies;
however, it is possible that we have missed some relevant studies,
but we underscore that we keep an open channel to contact the
author (HFJ) for continuous updates.
We conducted direct e-mail communicationwith all the authors of
the articles included in the review in order to try to obtain relevant
omitted data; however we received feedback from only one of the
authors (Sato 2012), who informed us about the exact number
of the thumbs, index, long, ring and little fingers included in the
study.
Whenever possible we followed the methods in our protocol. The
changes are described in Differences between protocol and review.
Agreements and disagreements with other
studies or reviews
We found some narrative reviews (Akhtar 2005; Fowler 2013;
Health Information 2013; McAuliffe 2010; Ryzewicz 2006); and
two systematic reviews which reported surgical treatment for trig-
ger finger in adults (Huisstede 2010;Wang 2013).Huisstede 2010
included randomised or quasi-randomised clinical trials and one
systematic review on steroid injections, whileWang 2013 included
only randomised or quasi-randomised clinical trials. Although our
results and conclusions are in partial agreement with these two re-
views, our conclusions are more comprehensive and our method-
ology consistently differs from these and other reviews.
Huisstede 2010 assessed seven studies (a systematic review and
six RCTs or quasi-RCTs) related to the subject of trigger finger
and the data reported showed the outcomes ’pain’, ’hand func-
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tion’ and ’recovery’; the systematic review and three RCTs only
reported the comparisons related to treatment with infiltration
(medication type, application site and number of applications).
One study (Topper 1997) randomised the participants into three
different types of surgery but changed all treatments during the
procedure, performing the same surgery in all participants; thus,
it was not characterized a randomised clinical trial (see Excluded
studies). Two studies (Dierks 2008; Gilberts 2001), totalling 136
fingers, reported percutaneous surgery versus open surgery, but
the authors did not perform quantitative analysis of the data in
the review. Huisstede 2010 concludes that there is moderate evi-
dence that steroid injection is effective in the short term (one to
four weeks), but not effective in the long term, and that surgi-
cal treatment may be regarded as a definitive treatment choice,
but there is still no evidence regarding which is the most effective
method (percutaneous or open). However Huisstede 2010 based
their findings on only two studies (Dierks 2008; Gilberts 2001),
while we included five studies in the same comparison (percuta-
neous surgery versus open surgery) (Bamroongshawgasame 2010;
Dierks 2008; Gilberts 2001; Nikolaou 2017; Sato 2012). The
results of this review are in agreement with those published by
Huisstede 2010, since our analyses indicate it was uncertain if
percutaneous surgery improves resolution of trigger finger during
the follow-up of two to six months, with low-quality evidence,
when compared to open surgery; and it was uncertain if there is
any difference between the percutaneous and open surgical meth-
ods in reducing pain intensity (follow-up of one week), recurrence
rate and risk of adverse events or neurovascular injury (follow-
up two to six months), with very low-quality evidence. However
there were methodological differences between the two reviews,
since Huisstede 2010 carried out only one qualitative analysis of
the data using the methodology described by Van Tulder 2003,
while we not only carried out a qualitative but also quantitative
analysis of the data (see Data and analyses), also highlighting the
fact that the outcomes we regarded as relevant (satisfaction, recur-
rence, adverse events and neurovascular injury) were not assessed
by Huisstede 2010.
Wang 2013 systematically assessed the effect of percutaneous
surgery compared with open surgery or with steroid injection,
basing the results on seven studies (six RCTs and one quasi-
RCT), totalling 676 participants (Bamroongshawgasame 2010;
Chao 2009; Dierks 2008; Gilberts 2001; Maneerit 2003; Sato
2012; Zyluk 2011). Four studies were included in the analysis
that compared percutaneous surgery versus steroid injection (Chao
2009; Maneerit 2003; Sato 2012; Zyluk 2011), which showed
favourable results for the treatment with percutaneous surgery for
the outcome ’failure of the treatment’ (no resolution of the trigger
after treatment or trigger relapse after temporary recovery with
treatment), but there were no differences between groups in the as-
sessment of complications. Four studies were included in the com-
parison analysis between percutaneous surgery versus open surgery
(Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001; Sato
2012), which showed no difference between percutaneous surgery
versus open surgery in the frequency of failure and complications
of the treatments. Although in the comparison between percu-
taneous surgery versus steroid injection our results for the out-
come ’adverse events’ were consistent with the results published
by Wang 2013, there are several differences between the two re-
views: while Wang 2013 analysed three studies - Chao 2009, Sato
2012 and Zyluk 2011 - that compared a single intervention in
each group (percutaneous surgery versus steroid injection) in con-
junction with the study of Maneerit 2003, which carried out co-
interventions in one of the comparison groups (analysing percu-
taneous surgery plus steroid injection versus steroid injection), we
included five studies - Aref 2014, Chao 2009, Sato 2012, Singh
2005 and Zyluk 2011 - that assessed only a single intervention in
each comparison group (percutaneous surgery versus steroid in-
jection). In another comparison group we analysed separately the
study of Maneerit 2003, because when one intervention is added
to the other we can change the outcome of the procedure. More-
over, Wang 2013 assessed the data only after one infiltration ap-
plication, while our assessment was after one or more application;
our results showed it is uncertain if when compared with one or
more applications of steroid injection, the percutaneous surgery
promotes increased resolution and decreased recurrence rates, ad-
verse events and neurovascular injury in the follow-up of six to
12 months, and also in pain relief in the follow-up of one month;
moreover, the outcomes we considered as relevant (pain and func-
tional status of the hand) were not assessed by Wang 2013. In
the comparison between percutaneous surgery versus open surgery
Wang 2013 found four studies - Bamroongshawgasame 2010,
Dierks 2008,Gilberts 2001 andSato 2012 -, whilewe includedfive
trials (Bamroongshawgasame 2010; Dierks 2008; Gilberts 2001;
Nikolaou 2017; Sato 2012), but our analysis obtained compati-
ble results, also showing that it is uncertain if one of the surgi-
cal methods is better than the other method with regard to res-
olution, recurrence, adverse events and neurovascular injury, in
the follow-up of two to six months. Wang 2013 did not use any
method to classify the evidence found, while we classified the ev-
idence as low quality (resolution) and as very low-quality (recur-
rence, adverse events and neurovascular injury), using the software
GRADEpro GDT. Unlike our study, Wang 2013 did not assess
studies that compared open surgery with steroid injection (with
or without hyaluronic acid plus) or studies that compared other
types of surgical treatments (e.g. endoscopic surgery) or different
kinds of incision for open surgery. Our assessment of the risk of
bias is less favourable than that assessed by Wang 2013, as this
study used scores to assess the internal validity of the studies, which
can yield questionable assessments (Detsky 1992), while we used
the Cochrane ’Risk of bias’ tool, which is more reliable (Higgins
2011a).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is very low to low-quality evidence for a set of 14 hetero-
geneous clinical trials regarding surgical treatment for finger trig-
ger in adults. It is uncertain if open surgery is better than steroid
injection in trigger resolution at six to 12 months following treat-
ment, due to very low quality evidence, although the open sur-
gical treatment provide a less recurrence rate (follow-up of six to
12 months), but it increases the incidence of pain during the first
follow-up week, with low-quality evidence. It is uncertain whether
there is any benefit in decreased adverse events or neurovascular
injury rates, with low-quality evidence. It is uncertain whether
when compared with steroid infiltration, the percutaneous surgery
has any benefits in the resolution of trigger finger, pain relief and
reduced recurrence rates or adverse events, with very low-quality
evidence. It is uncertain whether there is any benefit in decreased
neurovascular injury rates, with low-quality evidence. It is un-
certain whether the association of steroid infiltration with ultra-
sound-guided hyaluronic acid can increase its effectiveness when
compared with open surgery because the available evidence comes
from a small study of very low quality. It is uncertain if percu-
taneous surgery plus steroid injection is more effective than the
treatment with steroid injection in the resolution of trigger finger,
as the evidence was very low quality; it is also uncertain whether
there is any benefit in reducing adverse events and neurovascular
injury, as these were rarely reported, and the evidence was very low
quality. Percutaneous surgery has similar rates of symptom resolu-
tion as open surgery at two to six months’ follow-up (low-quality
evidence), and it is uncertain whether either surgery has any ad-
vantage in decreasing pain intensity (very low quality evidence),
trigger recurrence (very low quality evidence), adverse events (very
low quality evidence) and neurovascular injury (very low quality
evidence). It is uncertain whether endoscopic surgery has the same
effectiveness as open surgery in trigger resolution in follow-up at
three months, due to very low quality evidence; it is also uncertain
whether there is any benefit for the occurrence of adverse events or
neurovascular injury, with very low quality evidence. It is unclear
whether one of the three types of skin incision performed for open
surgery treatment (transverse incision about 2-3 mm distally from
the distal palmar crease, transverse incision in the distal palmar
crease or longitudinal incision) provides better functional results
of the hand when compared to each other, because the available
evidence comes from a small study of very low-quality.
Implications for research
More research is needed to elucidate the best approach for treat-
ing trigger finger in adults, as there is still no high-quality evi-
dence supporting any surgical method. Although three studies are
currently in progress (see Ongoing studies), more large studies of
good methodological quality are required to provide additional
evidence.
It is imperative that future studies should be randomised con-
trolled trials and comply with the CONSORT statement to for-
mulate and report non-pharmacological studies (Boutron 2008).
The creation of standard norms for future research can facilitate
the interpretation of results and speed up the process in order to
achieve more consistent evidence.
Future research should include adult participants with trigger fin-
ger at any stage, and should present data that enables sub-grouping
participants according to age, follow-up time (up to three months,
more than three to six months, and more than six months) and
trigger stage (using the classification of Quinnell 1980). Authors
should use the outcomes of this review to assess the treatment
methods, standardising resolution such as the harmonious slip of
the flexor tendons after performing the procedure, measuring pain
through the VAS score and assessing the functional status of the
hand by means of a validated questionnaire (such as the DASH
score), evaluating patient satisfaction using the Satisfaction Visual
Analog Scale (SVAS score, gradated from zero to 10) or measur-
ing participant-reported treatment success as a dichotomous out-
come, considering recurrence as triggering relapse after a period
of resolution and notifying any type of adverse events (including
neurovascular injury). Larger trials, preferably multicentric with
long follow-up periods, may allow the verification of differences
in the incidence of adverse events among the various treatment
methods. Cost assessment must also be performed because current
evidence has shown no differences between the types of surgical
treatments available and this can be a determining factor in choos-
ing the treatment.
We emphasise the importance of clearly describing the process
of randomisation and allocation concealment, and also reporting
the data completely by providing mean and standard deviations
for continuous data. We suggest that participants comply with
a minimum of one-year follow-up as there are several reports of
recurrence after six months. Finally, we recommend implementing
the same rehabilitation programme and the same form of analgesia
in both groups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aref 2014
Methods Study design: quasi-randomised controlled trial.
Duration of the study: from January 2011 to December 2013.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not registered.
Funding sources: none known.
Participants Place of study: Mazandaran University of Medical Sciences, Iran.
Number of participants assigned: 50 participants (50 fingers); 25 percutaneous surgery
and 25 steroid injection
Number of participants assessed: 50 participants (50 fingers); 25 percutaneous surgery
and 25 steroid injection
Inclusion criteria:
• Participants who presented with grade II or III trigger digit as classified by
Quinnell 1980.
Exclusion criteria:
• Participants with trigger thumbs were excluded.
Age:
• Total of participants (mean/range): 48/40 to 65 years.
Gender:
• Total of participants: 20 male; 30 female.
Side:
• Total of participants: 31 dominant hand and 19 non-dominant hand.
Digits:
• Total of participants: 9 index, 26 long, 10 ring and 5 little.
Classification of injury: trigger fingers were classified according to the Quinnell 1980
criteria (graded I to V).
Interventions Timing of intervention: not reported.
Duration of treatment: not reported.
Type of intervention:
• Percutaneous surgery
• Steroid injection: 1 mL of triamcinolone mixed with 1 mL of 1% lidocaine was
injected into the tendon sheath and around the nodule.
Rehabilitation: the authors did not clearly describe whether all study participants re-
ceived physiotherapy
Any co-interventions: analgesia was given for 3 days.
Outcomes Length of follow-up:
• Follow-up was 9 months.
• Participants were evaluated weekly for 6 consecutive weeks.
Loss of follow-up: not reported.
Primary outcomes:
Symptomatic relief: the authors did not clearly define what they considered as “symp-
tomatic relief ” and reported incomplete data, stating only that both groups showed im-
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proved symptoms within 2 weeks of follow-up, and after 2 weeks the response was better
in the steroid injection group
Patient satisfaction.
Complications (adverse events):
• Partial loss of movement.
• Dysaesthesia.
• Pulley or tendon injury.
• Skin atrophy or hypopigmentation.
Secondary outcomes:
Pain:measured by Visual Analog Scale (VAS)
Recurrence of triggering: the authors did not clearly definewhat they considered recurrence
Outcomes included in this review:
Pain: measured by Visual Analog Scale (VAS).
Patient satisfaction.
Recurrence of triggering
Adverse events:
• Partial loss of movement.
• Dysaesthesia.
• Pulley or tendon injury.
• Skin atrophy or hypopigmentation.
Notes • Pain and patient satisfaction were described incompletely (no numerical data were
reported), and we were unable to include these data in the results.
• We tried unsuccessfully to contact the authors to obtain further information on
pain (VAS-score) and patient satisfaction.
• The authors did not clearly report if there were losses to follow-up.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised controlled trial.
Participants were randomised to either
steroid injection or percutaneous surgery
using their birth year. Those with even
numberswere allocated to the steroid group
and uneven numbers to the percutaneous
group
Allocation concealment (selection bias) High risk Quasi-randomised controlled trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
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Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported. The authors did not clearly
described whether all study participants
completed follow-up
Selective reporting (reporting bias) High risk There was no protocol published.
Outcome of interest in the review (resolu-
tion of trigger finger and functional status
of the hand) were not reported. Pain was
reported incompletely, without numerical
values
Other bias Unclear risk The authors did not report data about base-
line balance, and they did not clearly report
about care providers and rehabilitation
Bamroongshawgasame 2010
Methods Study design: randomised controlled trial.
Duration of the study: 1 May 2007 to 31 December 2008.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none known.
Participants Place of study: Thailand.
Number of participants assigned: 142 participants (160 fingers); 80 percutaneous
surgery and 80 open surgery
Number of participants assessed: 142 participants (160 fingers); 80 percutaneous
surgery and 80 open surgery.
Inclusion criteria:
• Failure non-surgical treatment for 3 months.
• At least 1 local steroid injection.
• Grade II, III or IV trigger digit as classified by Froimson 1993.
Exclusion criteria:
• Clinically active osteoarthritis of the affected hand.
Age:
• Percutaneous surgery (mean/range): 48.6/22 to 72 years.
• Open surgery (mean/range): 46.2/24 to 76 years.
Gender:
• Percutaneous surgery: 28 male; 44 female.
• Open surgery: 30 male; 40 female.
Side: not reported.
Digits:
• Percutaneous surgery: 23 thumb, 8 index, 27 long, 20 ring and 2 little.
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• Open surgery: 26 thumb, 6 index, 24 long, 23 ring and 1 little.
Classification of injury:
Trigger fingers were graded according to Froimson’s modification of Quinnell’s classifi-
cation (graded I to IV) (Froimson 1993).
Interventions Timing of intervention: at least 3 months.
Duration of treatment
• Percutaneous surgery (mean operative time): 1.8 minutes.
• Open surgery (mean operative time): 2.2 minutes.
Type of intervention:
• Percutaneous surgery: a full handle knife 45º was inserted 2 mm proximal to the
proximal edge of the A1 pulley; when the distal edge was reached, the knife was moved
distally to proximally, releasing the A1 pulley.
• Open surgery: transverse incision was made over the involved metacarpal head,
and the A1 pulley was transected under direct observation.
Rehabilitation: not reported.
Any co-interventions: not reported.
Outcomes Length of follow-up:
• Follow-up was 8 weeks.
• Participants were evaluated at 1, 2, 3, 4, 6, and 8 weeks.
Loss of follow-up: none lost to follow-up.
Primary outcomes:
Operative time.
Range of motion of finger PIP or thumb IP.
Patient satisfaction score.
Patient pain score.
Surgical complications (adverse events):
• Section of all or a portion of the A2 pulley.
Neurovascular injury.
Outcomes included in this review:
Resolution of trigger finger: considered as the relief of pain and the cessation of finger
locking after the procedure. Although reported in the study, it was not considered as
primary outcome by the author
Pain (0 to 3 scale).
Satisfaction scores (0 to 3 scale).
Recurrence of triggering: the author did not clearly define what he considered recurrence.
Although reported in the study, it was not considered as primary outcome by the author
Adverse events measured by:
• Section of all or a portion of the A2 pulley.
Neurovascular injury.
Notes • Pain and satisfaction scores were presented graphically only, and we were unable
to include these data in the analyses.
• We tried unsuccessfully to contact the authors to obtain further information on
absolute numerical values and standard deviations for pain (VAS-score) and satisfaction
scores.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
Selective reporting (reporting bias) High risk No protocol was published.
Pain and satisfaction score were measured
by non-validated instruments and the re-
sults were exhibited in figures, with inac-
curate values and no measure of variance,
compromising the assessment
Other bias Low risk There was no baseline imbalance, and
no risk of bias was associated with care
providers or differences in rehabilitation
Callegari 2011
Methods Study design: randomised controlled trial.
Duration of the study: January 2007 to May 2007.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none known.
Participants Place of study: Varese, Italy.
Number of participants assigned: 30 participants (30 fingers); 15 open surgery and 15
steroid injection plus hyaluronic acid injection ultrasound-guided
Number of participants assessed: 30 participants (30 fingers); 15 open surgery and 15
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steroid injection plus hyaluronic acid injection ultrasound-guided
Inclusion criteria:
• Age between 35 and 70 years old.
• Clinical signs and symptoms of stenosing tenosynovitis of the flexor tendons and
in whom diagnosis was confirmed by ultrasound.
Exclusion criteria:
Trigger finger grade IV.
Comorbidities:
• Diabetes mellitus.
• Rheumatoid arthritis.
• Hypercholesterolemia.
• Hypotension.
• Hypertension.
Age:
• Open surgery (mean/range): 52.13/40 to 70 years.
• Injection group (mean/range): 52.86/35 to 69 years.
Gender:
• Open surgery: 4 male; 11 female.
• Injection group: 6 male; 9 female
Side: not reported.
Digits: 16 thumb, 7 ring and 7 long.
Classification of injury:
Trigger fingers were graded according to Froimson’s modification of Quinnell’s classifi-
cation (graded I to IV) (Froimson 1993).
Interventions Timing of intervention: average period: 3.5months of symptoms (range 1 to 6months)
Duration of treatment: the duration of the surgical procedure was not reported.
Hyaluronic acid injection was injected 10 days after steroid injection (injection group)
Type of intervention:
• Open surgery: patients underwent open surgery by conventional technique under
locoregional anaesthesia and a haemostatic pressure cuff inflated around the upper arm.
The procedure was carried out on a day surgery basis and patients were discharged in
the evening with a compression dressing to be kept in place for 4 days until it was
changed in the outpatient clinic. Sutures were removed 2 weeks after surgery.
• Injection group: inject methylprednisolone acetate 40 mg/1 mL with 0.8 mL
lidocaine chlorhydrate 2% into the sheath of the flexor tendons, distally to the A1
pulley, under ultrasound guidance. 10 days later, 1 mL 0.8% hyaluronic acid was
injected using the same technique.
Rehabilitation:
• Open surgery: the patients started mobilisation of the finger after 4 days.
• Injection group: therapy was not reported.
Any co-interventions: 10 patients in open surgery group needed physiotherapy and
local or oral analgesics for complete resolution of symptoms, which was approximately
30 to 40 days post surgery
Outcomes Length of follow-up: 1 year. Participants were evaluated before intervention, at 6 weeks
and at 3, 6, and 12 months
Loss of follow-up: none lost to follow-up.
Primary outcomes:
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Resolution of trigger finger: considered as the remission of symptoms within 6 weeks, with
no recurrence within 6 months
Recurrence of triggering: was considered the return of any degree of triggering after a full
remission period of trigger finger
Secondary outcomes:
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale).
Functional status of the hand: was used DASH (0 to 100%).
Satisfaction scores: measured by Satisfaction Visual Analog Scale (SVAS: 0 to 10 scale)
Outcomes included in this review:
Resolution of trigger finger
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale).
Functional status of the hand: measured by DASH (0 to 100%).
Satisfaction scores: measured by Satisfaction Visual Analog Scale (SVAS: 0 to 10 scale)
Recurrence of triggering:
Adverse event (Although reported in the study, it was not considered as primary outcome
by the authors):
• Partial loss of movement.
• Algodystrophic syndrome.
Notes • The authors did not report standard deviations on VAS, DASH and SVAS scores.
• We tried unsuccessfully to contact the authors to obtain further information on
standard deviations for pain (VAS-score), functional status of the hand (DASH-score)
and patient satisfaction (SVAS-score).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
Selective reporting (reporting bias) High risk No protocol was published.
Although outcomes of interest in the review
were reported, the authors failed to report
any measure of variance for the validated
instruments (VAS, DASH and SVAS)
Other bias High risk There were different rehabilitations in 2
groups.
In both groups, at the first follow-up visit,
participants were advised to mobilise the
finger, depending on the level of pain expe-
rienced, but 10participants in open surgery
groupneededphysiotherapy, and local and/
or oral analgesics for complete resolution
of symptoms
Chao 2009
Methods Study design: randomised controlled trial.
Duration of the study: January 2005 to February 2007.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none known.
Participants Place of study: China.
Number of participants assigned: 86 participants (97 trigger thumbs); 42 participants
(47 thumbs) in percutaneous surgery group and 44 patients (50 thumbs) in steroid
injection group
Number of participants assessed: 83 participants (93 trigger thumbs); 41 participants
(46 thumbs) in percutaneous surgery group and 42 patients (47 thumbs) in steroid
injection group
Inclusion criteria: idiopathic adult trigger thumbs with grade III-V on the Quinnell
classification
Exclusion criteria: patients who had rheumatoid arthritis, diabetes mellitus or chronic
systemic disease
Age:
• Percutaneous surgery: the average was 48 years ( 27 to 65).
• Steroid injection: the average age was 49 years (28 to 72).
Gender:
• Percutaneous surgery: 29 female and 12 male.
• Steroid injection: 28 female and 14 male.
Side:
• Percutaneous surgery: 33 right and 13 left.
• Steroid injection: 36 right and 11 left.
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Digits: 97 thumbs.
Classification of injury:
The trigger thumb was graded according to Quinnell classification (graded I to V)
(Quinnell 1980).
Interventions Timing of intervention: 4 months’ duration of the symptoms in both groups.
Duration of treatment: not reported.
Type of intervention:
• Percutaneous release with a new instrument called mini scalpel-needle (MSN),
based on acupuncture.
• Injection with 1 ml triamcinolone acetonide (10 mg/ml). Previous injection of
the 0.5 ml of 1% lidocaine was infiltrated into the skin and tissue around the tendon
sheath. When necessary a second injection at 1 week was realised.
Rehabilitation: did not have rehabilitation.
Any co-interventions: topical NSAIDs were administered for 3 days with the occasional
use of paracetamol for pain control in both groups when necessary
Outcomes Length of follow-up: 1 year
Loss of follow-up: 1 patient (1 thumb) in percutaneous surgery group and 2 patients
(3 thumbs) in steroid injection group were lost to follow-up at 12 months and were
excluded
Primary outcomes:
Successful procedure or satisfaction (resolution of trigger finger): “satisfactory” was con-
sidered to be participants who progressed with pain score lower than or equal to 1 (VAS
scale) and cessation of triggering
Pain:measured by Visual Analog Scale (VAS:0 to 10 scale).
Adverse events measured:
• Infection.
• Tendon bowstringing (tendon or pulley injury).
Neurovascular injury.
Outcomes included in this review:
Resolution of trigger finger: “satisfactory” was considered to be participants who progressed
with pain score lower than or equal to 1 (VAS scale) and cessation of triggering
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale).
Recurrence of triggering: the authors did not evaluate it as a study outcome, but they
published indirect data on recurrence
Adverse events measured:
• Infection.
• Tendon bowstringing (tendon or pulley injury).
Neurovascular injury.
Notes • The follow-up data were collected by clinical examination (69 participants) or by
telephone interview (14 participants).
• In the study, the authors use the words “satisfaction”, “success of procedure” and
“satisfactory results” as synonyms for trigger finger resolution.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk The patientswere randomly assignedby the
selection of number 1 or 2 from sealed en-
velopes in the presence of a witness
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced in
numbers across intervention groups; 1
thumb 1/47 (2%) in percutaneous release
group and 3 thumbs 3/50 (6%) in steroid
injection group were lost to follow up of 12
months and excluded; however they were
reported
Selective reporting (reporting bias) High risk No protocol was published.
Functional status (as primary outcome us-
ing validated instruments to measure hand
function) was not evaluated by the authors
Other bias Unclear risk There was no baseline imbalance, but
the authors did not describe about care
providers or rehabilitation
Dierks 2008
Methods Study design: quasi-randomised controlled trial.
Duration of the study: during the year 2003.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not registered.
Funding sources: none known.
Participants Place of study: Oldenburg, Germany.
Number of participants assigned: 36 participants (36 fingers); 20 percutaneous surgery
and 16 open surgery
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Number of participants assessed: 36 participants (36 fingers); 20 percutaneous surgery
and 16 open surgery
Inclusion criteria: patients with primary trigger finger and age between 18 and 80 years
Exclusion criteria: patients with trigger thumb, more than 1 trigger finger, previous
operations of the upper extremity, evidence of symptomatic synovitis, or diseases possibly
influencing pain scores or hand function (e.g. nerve entrapments, neuropathy, diabetes,
and rheumatoid arthritis), or patients with any joint extension lag
Age:
• Percutaneous surgery (mean): 62 years (41 to 79).
• Open surgery (mean): 64 years (39 to 88).
Gender:
• Percutaneous surgery: 9 male and 11 female.
• Open surgery: 7 male and 9 female.
Side: not reported.
Digits: not reported.
Classification of injury: not reported.
Interventions Timing of intervention:
• Percutaneous surgery (mean): 7 months (1 to 36).
• Open surgery (mean): 12 months (1 to 60).
Duration of treatment:
• Percutaneous surgery: 26 seconds.
• Open surgery: 4 min 17 seconds.
Type of intervention:
• Percutaneous surgery: the affected digit was placed in extension. At the proximal
level of the A1 pulley, a L15 blade scalpel was put through the skin and pushed palmar-
ward with the backside of the knife. Then the knife was positioned on top of the distal
end of the A1 pulley centred at the palmar axis of the tendon sheath, and the sharp side
of the knife was directed dorsally. External pressure from the surgeon’s finger on the
skin is performed to put the knife through the A1 pulley.
• Open surgery: a longitudinal incision was placed in a skin crease at the level of the
A1 pulley. The neurovascular structures were preserved by Langenbeck hooks. The A1
pulley was opened longitudinally. The skin was closed with 4.0 Ethylon sutures.
Rehabilitation:
A direct postoperative mobilization protocol was used in both groups. The authors did
not describe which protocol was used, nor for how long it was used
Any co-interventions: not reported.
Outcomes Length of follow-up: 12 weeks.
Loss of follow-up: none.
Primary outcomes:
Range of motion (ROM) of the PIP joint.
Grip strength.
Pain: mean score assessed using a scale from 1 to 6; 1 = no pain and 6 = extreme pain
Time of surgery.
Postoperative complications (adverse events and neurovascular injury).
Costs of the surgical techniques.
Outcomes included in this review:
Resolution of trigger finger: considered as complete relief of symptoms (the authors did not
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evaluate it as a study primary outcome, but they published indirect data on resolution)
Pain: mean score assessed using a scale from 1 to 6; 1 = no pain and 6 = extreme pain
Recurrence of triggering: the authors did not evaluate it as a study primary outcome, but
they published indirect data on recurrence
Adverse events:
• Inflammation.
Neurovascular injury.
Notes • The authors did not report on functional status of the hand and patients’
satisfaction.
• The authors reported inclusion criterion of participants aged 18 to 80 years, but
they presented results of participants aged 39 to 88 years.
• Open surgical technique was more expensive. The cost difference (personnel costs
excluded) was EURO 7 (7 euros).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised controlled trial.
Participants were randomised to either
open or percutaneous surgery using their
patient numbers. When their numbers
started with an uneven number, they were
treated percutaneously, but if their num-
bers started an even number, they were
treated by open surgery
Allocation concealment (selection bias) High risk Quasi-randomised controlled trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
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Selective reporting (reporting bias) High risk No protocol was published.
Functional status (as primary outcome us-
ing validated instruments to measure hand
function) was not evaluated by the authors
and pain was measured by non-validated
instrument
Other bias Low risk There was no baseline imbalance, and
no risk of bias was associated with care
providers or differences in rehabilitation
Gilberts 2001
Methods Study design: randomised controlled trial.
Duration of the study: between February 1993 and October 1994.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none known.
Participants Place of study: Rotterdam, the Netherlands.
Number of participants assigned:
96 participants (100 trigger digits); 54 percutaneous surgery and 46 open surgery
Number of participants assessed:
96 participants (100 trigger digits); 54 percutaneous surgery and 46 open surgery
Inclusion criteria:
Patients had to be older than 18 years and have symptoms of a trigger digit for at least
1 month
Exclusion criteria:
• Evidence of inflammation at the time of presentation (to exclude active
rheumatoid arthritis or other connective tissue disease).
• Previous surgery on the affected digit.
Age:
• Percutaneous surgery (mean): 62 years (24 to 88).
• Open surgery (mean): 60 years (24 to 81).
Gender:
• Percutaneous surgery: male/female = 1/1.5.
• Open surgery: male/female = 1/2.3.
Side: not reported.
Digits: although the authors assessed the results of 100 fingers, they reported data on
99 fingers
• Percutaneous surgery: 23 thumb, 2 index, 17 long, 7 ring and 5 little.
• Open surgery: 17 thumb, 4 index, 12 long, 12 ring and 0 little.
Classification of injury: not reported.
Interventions Timing of intervention:
Mean duration of symptoms:
• Percutaneous surgery: 6 months (1 to 24).
• Open surgery: 12 months (1 to 144).
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Duration of treatment:
• Percutaneous surgery: 7 minutes.
• Open surgery: 11 minutes.
Type of intervention:
Percutaneous surgery:
• The affected digit was placed in extension. At the level of the A1 pulley an 18-
gauge hypodermic needle was inserted into the flexor sheath with the opening directed
distally. After ascertaining that the flexor tendon was clear (active flexion shows no
movement of the needle), the needle was turned 90° to direct the bevelled edges
longitudinally. By moving the needle, using the skin as a pivot point, the flexor sheath
and the A1 pulley were divided, resulting in a typical grating sound. When necessary, a
second insertion of the needle was made to obtain full release of the trigger digit. Any
residual triggering was tested by active flexion of the affected digit. A compressive
bandage was applied.
Open surgery:
• A transverse incision was placed in a skin crease at the level of the metacarpal
head. The flexor sheath was opened longitudinally, incorporating the A1 pulley. Any
residual triggering was tested by active flexion of the affected digit. The skin was closed
with a 4.0 nylon suture. A compressive bandage was applied.
Rehabilitation:
• Exercises were started immediately in both groups.
• The authors did not describe which protocol was used, nor for how long it was
used.
Any co-interventions: not reported.
Outcomes Length of follow-up:
Follow-up was 12 weeks.
Patients were examined 10 days, 6 weeks, and 12 weeks after surgery
Loss of follow-up: not reported.
Primary outcomes:
Mean duration of surgery (minutes).
Mean duration of postoperative pain (days).
Recovery of motor function (days).
Return to work (days).
Success rate (resolution of trigger finger): considered as the cessation of triggering, with no
recurrence during follow-up (3 months)
Complications.
Outcomes included in this review:
Resolution of trigger finger: considered as the cessation of triggering, with no recurrence
during follow-up (3 months)
Pain: reported the average postoperative pain duration in days.
Recurrence of triggering: was reported in the study although it was not considered as
primary outcome by the authors; the authors did not clearly define what they considered
recurrence
Adverse event:
• Oedema.
• Hematoma and adherence.
Neurovascular injury.
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Notes • One adverse event that occurred in the percutaneous surgery group was not
clearly specified by the author.
• We tried unsuccessfully to contact the authors in order to obtain further
information to clearly specify what this adverse event was.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
Selective reporting (reporting bias) High risk No protocol was published.
Pain and functional status of the hand (as
primary outcomes, measured by validated
instruments) were not evaluated by the au-
thors
Other bias Low risk There was no baseline imbalance, and
no risk of bias was associated with care
providers or differences in rehabilitation
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Methods Study design: randomised controlled trial.
Duration of the study: January 2012 to May 2015.
Protocol was published before recruitment of patients: yes.
Details of trial registration: ClinicalTrials.gov, www.clinicaltrials.gov NCT01486420
Funding sources: the authors have declared no conflicts of interest.
Participants Place of study: Center for Planned Surgery, Regional Hospital Silkeborg, Silkeborg,
Denmark
Number of participants assigned: 165 participants (165 fingers); 84 open surgery and
81 steroid injection
Number of participants assessed: 153 participants (153 fingers); 76 open surgery and
77 steroid injection
Inclusion criteria:
• Patients were ≥ 18 years old.
• Patients with trigger finger classified as Quinnell Type IIb (history of uneven
movement with or without pain or discomfort) or greater.
Exclusion criteria:
Patients were excluded if they had insulin-dependent diabetes mellitus, rheumatoid
arthritis, amyloidosis, mucopolysaccharidosis, previous treatment of trigger finger in the
included digit, Dupuytren disease affecting the included digit, or medical contraindica-
tions to corticosteroid injection
Age:
• Open surgery (mean): 60 years.
• Steroid injection (mean): 60 years.
Gender:
• Open surgery: 27 male and 57 female.
• Steroid injection: 27 male and 54 female.
Side: 97 right and 68 left.
Digits: the allocated digit was the thumb in 39%, index in 5%, middle in 25%, ring in
25%, and little in 6%
Classification of injury:
The trigger finger was graded according to Quinnell’ classification modified by adding
a history of uneven movement with pain or discomfort at the A1 pulley (graded I to V)
(Quinnell 1980).
Interventions Timing of intervention:
• Open surgery (mean): 4 months.
• Steroid injection (mean): 5 months.
Duration of treatment: not reported.
Type of intervention:
• Open surgery was performed under local anesthesia with a tourniquet placed at
the upper arm. At the level of the A1 pulley, an incision was made and blunt dissection
was done down to the A1 pulley. A small, round-tipped dissection scissor was used to
split the A1 pulley. After securing free movement of the flexor tendons, the skin was
closed with nonabsorbable sutures, a light bandage was applied, and the tourniquet was
released. As standard procedure, digital nerves were not explored in any digits.
• Ultrasound-guided corticosteroid injection with a 23-gauge needle was performed
with a linear transducer placed in an axial direction to identify the flexor tendons. All
patients were injected with a corticosteroid solution containing 1 ml triamcinolone
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acetonide, 40 mg/ml (Kenalog; Bristol-Myers Squibb AB, New York) and 1ml
Llidocaine, 10mg/ml. After intra-sheath placement of 1 ml of the corticosteroid
solution, the needle was withdrawn just superficially to the A1 pulley, and the last 1 ml
was injected outside the sheath in close proximity to the A1 pulley.
Rehabilitation: not reported.
Any co-interventions: not reported.
Outcomes Length of follow-up: 12 months.
The patients were prospectively assessed after 3 and 12 months
Loss of follow-up: 1 patient in both groups were lost to follow-up at 3 months, and 1
participant in open surgery group and 2 participants in steroid injection group were lost
to follow-up at 12 months and were excluded
Six participants in open surgery group and one participant in steroid injection group did
not receive allocated intervention
Primary outcomes:
Resolution of trigger finger (cure): the authors considered normal movement with or with-
out pain or discomfort after 12 months of follow-up
Secondary outcomes:
Topical pain: defined as patient-reported pain when pressure was applied on the palmar
side of the hand at the level of the A1 pulley, assessed by a numerical rating scale from
1 to 10 (1 = no pain, and 10 = worst imaginable pain)
Complications (adverse events):
• Infection.
• Neuropathy.
• Bowstringing.
• Flare (defined as the worsening of symptoms in a short time after the injection).
• Failure (reported by patients at the 1-year follow-up interview).
• Fat necrosis at the injection site.
• Tendon rupture.
Outcomes included in this review:
Resolution of trigger finger.
Pain: assessed by a numerical rating scale from 1 to 10 (1 = no pain, and 10 = worst
imaginable pain)
Recurrence of triggering.
Adverse event:
• Infection.
• Bowstringing.
• Flare (defined as the worsening of symptoms in a short time after the injection).
• Fat necrosis at the injection site.
• Tendon rupture
Neurovascular injury.
Notes • If patients presented with more than one affected finger, a single finger was
arbitrarily chosen for inclusion based on the patient’s request.
• Outcomes were assessed at 3 months by personnel in the outpatient clinic, and at
12 months in a telephone interview by the first author.
• The authors did not report the mean and standard deviations on pain score. They
reported only the median and interquartile range (IQR).
• We tried unsuccessfully to contact the authors to obtain further information on
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mean and standard deviations for pain. In the analyses of results we using the median
as an approximate for the mean, and we calculate an approximate standard deviations
(SD) based on IQR (using the formula: SD = IQR/1.35).
• In the open surgery group eight allocated participants did not complete the
follow-up (six patients were allocated but they did not receive the treatment, and two
patients were operated but they were lost to follow-up at 12 months). In the steroid
injection group four allocated participants did not complete the follow-up (one patient
was allocated but he did not receive the treatment, and three patients were operated but
they were lost to follow-up at 12 months).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The schedule for randomization was gen-
erated by the randomization software Re-
search Randomizer (http://www.random-
izer.org). The authors used a block random-
ization with blocks of 5 patients
Allocation concealment (selection bias) Low risk Opaque sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced in
numbers across intervention groups; eight
participants 8/84 (9%) in open surgery
group and four participants 4/81 (5%) in
steroid injection group were allocated to
treatment, but they did not complete to
follow up of 12 months and they were ex-
cluded; however they were reported
Selective reporting (reporting bias) Low risk The study protocol was previously pub-
lished.No changes inmethodswere applied
after the trial commenced
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Other bias Unclear risk The groups were similar at baseline except
for lower alcohol consumption in the open
surgery group.The authors did not describe
about differences in care providers or reha-
bilitation
Kloeters 2016
Methods Study design: randomised controlled trial.
Duration of the study: between January 2013 and February 2014.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: the authors have declared no conflicts of interest.
Participants Place of study: Nijmegen, the Netherlands.
Number of participants assigned:
30 participants (32 trigger digits);
Open surgery by transversal incision of the skin in the distal palmar crease: 11 trigger
fingers
Open surgery by transversal incision of the skin about 2-3mmdistally from distal palmar
crease: 10 trigger fingers
Open surgery by longitudinal incision of the skin at the level of the A1-pulley without
crossing the distal palmar crease proximal: 11 trigger fingers
Number of participants assessed:
30 participants (32 trigger digits).
Open surgery by transversal incision of the skin in the distal palmar crease: 11 trigger
fingers
Open surgery by transversal incision of the skin about 2-3mmdistally from distal palmar
crease: 10 trigger fingers
Open surgery by longitudinal incision of the skin at the level of the A1-pulley without
crossing the distal palmar crease proximal: 11 trigger fingers
Inclusion criteria:
• Patients had to be 18 years or older.
• Diagnosis of at least grade II trigger finger according to the Quinnell classification
(Quinnell 1980).
• Duration of symptoms for at least 3 months.
• Absence of surgical treatment of the affected finger.
Exclusion criteria:
• Participants with trigger thumbs were excluded.
• More than one finger affected in one hand.
• History of severe hand trauma.
Age (mean): 61.77 years.
Gender: 13 male and 17 female.
Side:
• Dominant hand: 14.
• Non-dominant hand: 15.
• Unknown: 3.
Digits: 4 index, 17 long, 8 ring and 3 little finger.
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Classification of injury: The trigger finger was graded according to Quinnell classifica-
tion (Quinnell 1980).
Interventions Timing of intervention: at least 3 months.
Duration of treatment: not reported.
Type of intervention:
All participants were submitted to open surgery, and was randomised to one of three
kinds of skin incision:
• Transversal in the distal palmar crease.
• Transversal 2-3 mm distally from distal palmar crease.
• Longitudinally at the level of the A1-pulley without crossing the distal palmar
crease proximal.
All surgeries were performed under local anesthesia. Tourniquet was placed at the
Forearm at 250 mmHg and a incision pattern was carried out over a defined length of
15 mm. The A1-pulley was identified and fully opened by a longitudinal incision over
the pulley. Approximately 2-3 mm in width of the A1-pulley were resected to reduce the
risk for recurrence. The skin was then closed with Prolene 4-0
Rehabilitation:
• Directly after surgery, all patients were instructed to use the hand without any
specific limitations.
Any co-interventions: not reported.
Outcomes Length of follow-up:
Follow-up was 12 months.
Patients were examined 1, 3 and 12 months after surgery.
Loss of follow-up: not reported.
Primary outcomes:
Functional status of the hand: was used DASH score.
Scar volume: was measured using an high-resolution ultrasound.
Outcomes included in this review:
Functional status of the hand: was used DASH score.
Notes • The authors did not report standard deviations on DASH score or data about
how many participants evolved with hypertrophic scar or keloid, but they reported the
mean standard error on DASH score.
• We tried unsuccessfully to contact the authors to obtain further information on
standard deviations for functional status of the hand (DASH-score), and about how
many participants presented hypertrophic scar or keloid in yours hands. So we used the
mean standard error in the forest plots calculator to get the standard deviations in
analyses about DASH score.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Unclear risk Not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
Unclear risk The authors did not assess or report any
objective outcome.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
Selective reporting (reporting bias) High risk No protocol was published.
Outcomes of interest in the review (reso-
lution of trigger finger and pain) were not
reported
Other bias High risk There was baseline imbalance.
The authors reported there was a signifi-
cant difference in baselineDASHscores be-
tween groups
Maneerit 2003
Methods Study design: randomised controlled trial.
Duration of the study: October 1998 to December 2001.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none known.
Participants Place of study: Bangkok, Thailand.
Number of participants assigned:
• 115 participants (127 triggering thumbs).
• Percutaneous surgery with steroid injection: 66 thumbs in 60 participants.
• Steroid injection alone: 61 thumbs in 55 participants.
Number of participants assessed:
• 125 triggering thumbs in 113 participants.
• Percutaneous release with steroid injection: 65 thumbs in 59 participants.
• Steroid injection alone: 60 thumbs in 54 participants.
Inclusion criteria:
Idiopathic adult trigger thumb grade II (actively correctable) III (passively correctable)
or IV (fixed in flexion) according to the Quinnell classification (Quinnell 1980).
Exclusion criteria:
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• Participants with history of trauma.
• Participants with carpal tunnel syndrome were excluded.
Age:
• Percutaneous release with steroid injection (mean): 52 years (31 to 68).
• Steroid injection alone (mean): 53 years (31 to 76).
Gender:
• Percutaneous release with steroid injection: 61 female and 4 male.
• Steroid injection alone: 55 female and 5 male.
Side:
Percutaneous release with steroid injection:
• Thumb affected (R/L): 31/34.
• Hand dominance (R/L): 57/8.
Steroid injection alone:
• Thumb affected (R/L): 28/32.
• Hand dominance (R/L): 55/5.
Digits: 127 thumbs.
Classification of injury:
The trigger thumb was graded according to Quinnell classification (graded 0 to IV)
(Quinnell 1980).
Interventions Timing of intervention:
Percutaneous release with steroid injection (mean): 4 months (1 to 36)
Steroid injection alone (mean): 4 months (1 to 20).
Duration of treatment: not reported.
Type of intervention:
Percutaneous release with steroid injection:
• The release was done with an 18-gauge needle inserted at a point 1 mm to 2 mm
distal to metacarpophalangeal joint crease, keeping the thumb in hyperextension
position. After release the flexor tendon sheath was injected with 1 ml triamcinolone
acetonide, 10 mg/ml.
Steroid injection alone:
• Participants were treated simply by injection of 1 ml triamcinolone acetonide and
1 ml of 1% lidocaine.
Rehabilitation: not reported.
Any co-interventions:
• All participants in both groups received 20 paracetamol tablets for home
medication. They were told to take the medicine only if they felt pain.
• The mean paracetamol requirement in the first 2 weeks was 4 tablets in
percutaneous release with steroid injection and 3 tablets in steroid injection.
Outcomes Length of follow-up: range 23 months (6 to 42 months).
Participants were evaluated at 2 and 6 weeks, and 6 or more months
Loss of follow-up:
1 participant (1 thumb) was lost to follow-up at 6 months in both groups
Primary outcomes:
Resolution of trigger finger: “satisfactory” was considered to be participants who progressed
with pain score lower than or equal to 1 (VAS scale) and cessation of triggering
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale) and paracetamol requirement
in the first 2 weeks
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Outcomes included in this review:
Resolution of trigger finger
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale).
Adverse events: were reported in the study although not considered as primary outcomes
by the author
Superficial infection (cellulitis).
Partial loss of movement.
Neurovascular injury: was reported in the study although not considered as primary
outcome by the author
Notes • The authors did not report standard deviations on VAS score.
• We tried unsuccessfully to contact the authors to obtain further information on
standard deviations for pain (VAS-score).
• The follow-up data were collected by clinical examination (78 participants) or by
telephone interview (35 participants) between 6 and 42 (mean, 23) months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced in
numbers across intervention groups. 1
thumbwas lost in both groups at 6months:
in percutaneous surgery plus steroid injec-
tion group 1/66 (1.5%); and in steroid in-
jection 1/61 (1.6%)
Selective reporting (reporting bias) High risk No protocol was published.
The authors did not report standard de-
viations on VAS score, and the functional
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status of the hand (using validated instru-
ments) was not evaluated
Other bias Unclear risk There was no baseline imbalance and
no risk of bias was associated with care
providers, but the author did not report
about rehabilitation
Nikolaou 2017
Methods Study design: randomised controlled trial.
Duration of the study: not reported.
Protocol was published before recruitment of patients: yes.
Details of trial registration: clinicaltrials.gov/ct2/show/study/NCT02830672.
Funding sources: the authors have declared no conflicts of interest.
Participants Place of study: National and Kapodistrian University of Athens, Greece.
Number of participants assigned: 32 participants (32 fingers); 16 ultrasound-guided
percutaneous surgery and 16 open surgery
Number of participants assessed: 32 participants (32 fingers); 16 ultrasound-guided
percutaneous surgery and 16 open surgery
Inclusion criteria:
• Participants affected by trigger finger or trigger thumb clinically and
ultrasonographically examined.
• Failure non-surgical treatment for 3 months.
• Grade II, III or IV trigger digit as classified by Froimson 1993.
Exclusion criteria:
• Individuals under 18 years old.
• Patients who were treated with a previous operation or a corticosteroid injection.
• Individuals with inflammatory arthritis, tumor or autoimmune disease.
• Patients with multiple trigger fingers.
Age: mean age of 32 patients: 45.5 years old.
• Percutaneous surgery (mean/range): not reported.
• Open surgery (mean/range): not reported.
Gender: 12 male; 20 female.
• Percutaneous surgery (mean/range): not reported.
• Open surgery (mean/range): not reported.
Side: not reported.
Digits: not reported.
Classification of injury:
Trigger fingers were graded according to Froimson’s modification of Quinnell’s classifi-
cation (graded I to IV) (Froimson 1993).
Interventions Timing of intervention: at least 3 months.
Duration of treatment: not reported.
Type of intervention:
• Percutaneous surgery: under continuous sonographic imaging of the digit, an
ophthalmic corneal/scleral V-Lance knife (Alcon, Novartis company) was inserted
percutaneously, over flexor tendons proximally to the A1 pulley and towards their
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longitudinal axis. Then, the knife was advanced distally, just below A1 pulley and
pressed palmary so as to loosen the thicken pulley. Thus, after having withdrawn the
V-Lance knife, a thin hook with a long neck was introduced under the - now extended
- A1 pulley. The hook penetrated the annular ligamentous structure facing palmary in
order to protect the flexor tendons and subsequently removed proximally (in a steady
quick move) carrying along and dissecting the A1 pulley. Intraoperatively and right
after the performed dissection, each patient was clinically and sonographically
evaluated for the achieved resolution of the triggering.
• Open surgery: the section of the A1 pulley was done through a 10-15 mm skin
incision.
Any co-interventions: not reported.
Outcomes Length of follow-up:
• Follow-up was 12 weeks.
• Participants were evaluated at 2, 4 and 12 weeks.
Loss of follow-up: none lost to follow-up.
Primary outcomes:
Resolution of triggering was expressed as the “success rate” per digit.
The time for taking postoperative pain killers.
QuickDASH score.
Range of motion recovery.
Return to normal activities (including work).
Complications (adverse events).
Cosmetic results.
Outcomes included in this review:
Resolution of triggering was expressed as the “success rate” per digit.
Pain: postoperative pain duration (measured by mean time in days for taking postoper-
ative pain killers)
Functional status of the hand: QuickDASH score.
Adverse events measured by:
• Infections.
• Partial loss of movement.
Notes • The authors did not report standard deviations on QuickDASH score.
• We tried unsuccessfully to contact the authors to obtain further information on
standard deviations for functional status of the hand (QuickDASH-score).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Low risk Closed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
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Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
Low risk The self-reported subjective outcomes as-
sessors were blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
Selective reporting (reporting bias) Unclear risk Although results were evaluated and ex-
plained according to protocol published in
July 6, 2016 and the study was published in
February 18, 2017, the paper was received
in the World Journal of Orthopedics’ ed-
itorial in July 4, 2016 before date of the
protocol publication
Although the protocol published by au-
thors estimated the enrollment of 60 pa-
tients in the study, the sample of the paper
was only 32 participants
Other bias Unclear risk The authors did not report data about base-
line balance, and they did not clearly report
about care providers and rehabilitation
Pegoli 2008
Methods Study design: randomised controlled trial.
Duration of the study: October 2005 to March 2006.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none known.
Participants Place of study: University of Milan, Italy.
Number of participants assigned:
200 participants (231 fingers);
Endoscopic surgery: 114 trigger fingers in 100 participants.
Open surgery: 117 trigger fingers in 100 participants.
Number of participants assessed:
200 participants (231 fingers).
Endoscopic surgery: 114 trigger fingers in 100 participants.
Open surgery: 117 trigger fingers in 100 participants.
Inclusion criteria:
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Participants affected by trigger finger, despite other concomitant disease
Exclusion criteria: not reported.
Age:
• Endoscopic surgery (mean): 56 years (23 to 82).
• Open surgery (mean): 61 years (33 to 79).
Gender:
• Endoscopic surgery: 33 male and 67 female.
• Open surgery: 27 male and 73 female.
Side:
The authors reported data incompletely; in the endoscopic surgery group they reported
the affected side in relation to the fingers, while in the open surgery group they reported
the affected side in relation to the participants
Endoscopic surgery: 71 (fingers) right hand and 43 (fingers) left hand
Open surgery: 69 (participants) right hand and 31 (participants) left hand
Digits:
• Endoscopic surgery: 12 thumb, 23 index, 37 long, 34 ring and 8 little.
• Open surgery: 13 thumb, 25 index, 31 long, 38 ring and 10 little.
Classification of injury: not reported.
Interventions Timing of intervention: not reported
Duration of treatment:
Endoscopic surgery (mean): 4 min and 30 seconds (range: 2 to 9 min)
Open surgery (mean): 5 min (range: 2 to 7 min).
Type of intervention:
Endoscopic surgery:
• Under local anaesthesia, with 2 sites of transverse incision that were distally at the
level of the digital-palmar crease of the finger and proximally at the level of the palmar
crease, corresponding to the metacarpophalangeal joint of the finger. A 2.7-mm
diameter endoscope was introduced through the proximal incision while a retrograde
knife was introduced from the distal incision. Skin suture was done with steri-strips
and a moderate compressing dressing was applied.
Open surgery:
• Under local anaesthesia, with longitudinal incision of 1 cm length made on the
volar aspect of the hand, in the palmar crease overlying the metacarpophalangeal joint
of the involved digit. The incision was closed in a single layer with 4.0 Vycril and a
moderate compressive dressing was applied.
Rehabilitation:
• Post-operative rehabilitation protocol consisted of 2 therapy sessions: 1 on the day
after surgery, in which tendon gliding exercises and oedema control were taught, and
the other after removal of the dressing, after 7 days for the endoscopic surgery group
and after 12 days for the open surgery group. The participants were briefed on how to
treat the operative site, with massage of the scar and tendon gliding exercises. Both
groups used a dynamic extension splint for the proximal interphalangeal and
metacarpophalangeal joints at night for 1 month.
Any co-interventions: not reported.
Outcomes Length of follow-up: 90 days.
Follow-up at 7, 30 and 90 days. The first follow-up was excluded because the dressing
still present in open surgery group did not allow a proper evaluation
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Loss of follow-up: none.
Primary outcome:
Resolution of trigger finger: considered as the disappearance of triggering after the proce-
dure
Pain: reported the average postoperative pain duration in days.
Adverse event:
• Infection.
• Dysesthesia.
Neurovascular injury.
Outcomes included in this review:
Resolution of trigger finger.
Pain: reported the average postoperative pain duration in days.
Adverse event:
• Infection.
• Dysesthesia.
Neurovascular injury.
Notes • Included were participants with carpal tunnel syndrome (28 cases in open surgery
group and 12 in endoscopic surgery group), de Quervain’s syndrome (4 cases in open
surgery group and 2 in endoscopic surgery group) and carpometacarpal joint arthritis
(6 cases in open surgery group).
• The authors treated trigger finger and others associated pathologies in the same
surgical procedure.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of generating the random se-
quence was not reported
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
Selective reporting (reporting bias) High risk No protocol was published.
Pain and functional status of the hand (as
primary outcomes, measured by validated
instruments) were not evaluated by the au-
thors
Other bias High risk There was baseline imbalance.
Several participants in both groups had as-
sociated pathologies in hand and under-
went surgery.
In the open surgery group 38% (38/
100 participants) had associated patholo-
gies in hand: 28 had carpal tunnel syn-
drome, 4 had de Quervain’s syndrome and
6 rizartroses. In the endoscopic surgery
group 14% (14/100 participants) had as-
sociated pathologies in hand: 12 had carpal
tunnel syndrome and 2 had de Quervain’s
syndrome
Sato 2012
Methods Study design: randomised controlled trial.
Duration of the study: November 2002 to March 2007.
Protocol was published before recruitment of patients: yes.
Details of trial registration: Current Controlled Trials, www.controlled-trials.com/ IS-
RCTN19255926
Funding sources: the authors have declared no conflicts of interest.
Participants Place of study: Federal University of São Paulo, Brazil.
Number of participants assigned:
137 participants (150 fingers); 45 percutaneous surgery, 56 open surgery and 49 steroid
injection
Number of participants assessed:
137 participants (150 fingers); 45 percutaneous surgery, 56 open surgery and 49 steroid
injection
Inclusion criteria:
• Patients were ≥ 15 years old.
• Patients with trigger finger who had not undergone previous treatment of any
type and were classified as Quinnell Types II
IV.
Exclusion criteria:
• Individuals with type I trigger fingers.
• Congenital trigger fingers.
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• Secondary to the partial lesion to the tendon.
Age:
• Percutaneous surgery (mean): 54.40 years.
• Open surgery (mean): 53.4 years.
• Steroid injection (mean): 55.29 years.
Gender:
• Percutaneous surgery: 5 male and 40 female.
• Open surgery: 10 male and 46 female.
• Steroid injection: 3 male and 46 female.
Side: not reported.
Digits: 31 thumb, 4 index, 77 long, 35 ring and 3 little.
Classification of injury:
The trigger finger was graded according to Quinnell classification (graded 0 to IV)
(Quinnell 1980).
Interventions Timing of intervention:
• Percutaneous surgery (mean): 14.96 months.
• Open surgery (mean): 10.5 months.
• Steroid injection (mean): 11.80 months.
Duration of treatment: not reported.
Type of intervention:
• Percutaneous surgery consisted of release of the A1 pulley with a 40 × 12 needle,
using longitudinal movements, in the direction of the axis of the flexor tendon, and
this release was introduced at the site corresponding to the A1 pulley.
• Open surgery consisted of an incision of 2 cm in the skin transverse to the axis of
the finger at the palmar skin fold, followed by subcutaneous dissection and
longitudinal opening of the A1 pulley.
• Steroid injection consisted of an injection of 2 ml of methylprednisolone acetate
40 mg/ml at the site corresponding to the A1 pulley, attempting to inject the solution
within the osteofibrous canal.
Rehabilitation: not reported.
Any co-interventions: not reported.
Outcomes Length of follow-up: 6 months.
The patients were prospectively assessed after 1, 2 weeks, 1, 2, 4 and 6 months
Loss of follow-up: none.
Primary outcomes:
Resolution of trigger finger (cure): the authors considered the remission of symptoms with
the cessation of blockage with no recurrence within 6 months
Recurrence of triggering: the authors defined recurrence (relapse) as the return of finger
locking within 6 months of follow-up
Secondary outcomes:
Topical pain.
Articular pain.
Total active motion (TAM) of the fingers.
Complications (adverse events):
• Infection.
• Tendon injury.
Neurovascular injury.
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Outcomes included in this review:
Resolution of trigger finger.
Pain: assessed through presence or not presence of the pain (topical or articular) in the
hand
Recurrence of triggering.
Adverse event:
• Infection.
• Tendon injury.
Neurovascular injury.
Notes • For the injection group, all participants received a single injection initially, then a
second injection was performed if there was no resolution after the first infiltration.
Those that received a second injection were followed for 6 months starting from the
second intervention.
• In cases in which the patient presented with 2 trigger fingers, each finger received
its own order number regardless of whether the fingers were on the same or different
hands; 11 patients participated in the study on 2 occasions, and 1 participated on 3
occasions.
• After contacting the main author of the study, we were informed about the exact
number of thumbs, index, long, ring and little fingers included in each comparison
group of the study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was done by means of
a 6-sided die with 2 sides representing 1 of
the 3 treatments.
The draw was conducted before the study
by a person independent of the research
Allocation concealment (selection bias) Low risk The result of each draw was placed in an
opaque envelope, which was then sealed;
envelopes were numbered from 1 to 150.
None of the project participants had prior
access to the envelope contents
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
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Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors did not report missing data.
All participants received treatment and
were followed.
Selective reporting (reporting bias) Unclear risk Although results were evaluated and ex-
plained according to previous protocol
published in October 2010, the study
started in November 2002 and finished in
March 2007
Other bias Unclear risk There was no baseline imbalance or differ-
ences in care providers, but the authors did
not describe rehabilitation
Singh 2005
Methods Study design: quasi-randomised controlled trial.
Duration of the study: from January 2005 to June 2005.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not registered.
Funding sources: none known.
Participants Place of study: Penang General Hospital, Malaysia.
Number of participants assigned: 26 participants (26 fingers); 14 percutaneous surgery
and 12 steroid injection
Number of participants assessed: 26 participants (26 fingers); 14 percutaneous surgery
and 12 steroid injection
Inclusion criteria:
• Participants who presented with grade II or III trigger digit as classified by
Quinnell.
Exclusion criteria:
• Participants with trigger thumbs were excluded.
Age:
• Total of participants (mean): 57 years.
Gender:
• Total of participants: 9 male; 17 female.
Side:
• Total of participants: 14 dominant hand and 12 non-dominant hand.
Digits:
• Total of participants: 4 index, 11 long and 11 ring. There was no involvement of
the little finger.
Classification of injury:
The trigger finger was graded according to Quinnell classification (graded 0 to IV)
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(Quinnell 1980).
Interventions Timing of intervention: not reported.
Duration of treatment: not reported.
Type of intervention:
• Percutaneous surgery: after 1m of lidocaine 1% was infiltrated around A1 pulley,
a 20-gauge needle was inserted with the sharp bevel parallel to the tendon, in position
correlating with the middle of the A1 pulley. The needle was stroked longitudinally,
proximally and distally to transect the A1 pulley.
• Steroid injection: after 1m of lidocaine 1% was infiltrated around A1 pulley, was
injected 1 mL of triamcinolone mixed with 1 mL of 1% lidocaine into the tendon
sheath and around the nodule.
Rehabilitation: the authors did not clearly describe if all study participants did phys-
iotherapy. They reported that in percutaneous surgery group 2 participants developed
stiffness of digit which responded to aggressive physiotherapy
Any co-interventions: analgesia was given for 3 days in steroid injection group.
Outcomes Length of follow-up:
• Follow-up was 1 year.
• Participants were evaluated weekly for 1 month and 3-monthly for a year.
Loss of follow-up: not reported.
Primary outcomes:
Pain.
Patient satisfaction.
Recurrence of triggering: the authors did not clearly definewhat they considered recurrence
Adverse events:
• Partial loss of movement.
• Dysaesthesia.
• Pulley or tendon injury.
Outcomes included in this review:
Pain.
Patient satisfaction.
Recurrence of triggering
Adverse events:
• Partial loss of movement.
• Dysaesthesia.
• Pulley or tendon injury.
Notes • Pain and patient satisfaction were described incompletely (no numerical data was
reported), and we were unable to include these data in the results.
• We tried unsuccessfully to contact the authors to obtain further information on
pain.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk Quasi-randomised controlled trial.
Patients were randomised to either steroid
injection or percutaneous surgery using
their birth year. Those with even numbers
were allocated to the steroid group and un-
even numbers to the percutaneous group
Allocation concealment (selection bias) High risk Quasi-randomised controlled trial.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
High risk The self-reported subjective outcomes as-
sessors were not blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
High risk The objective outcome assessors were not
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
Selective reporting (reporting bias) High risk No protocol was published.
Outcomes of interest in the review (resolu-
tion of trigger finger and functional status
of the hand) were not reported. Pain was
reported incompletely, without numerical
values
Other bias Unclear risk The authors did not report data about base-
line balance, and they did not clearly report
about care providers and rehabilitation
Zyluk 2011
Methods Study design: randomised controlled trial.
Duration of the study: January 2008 to May 2009.
Protocol was published before recruitment of patients: not reported.
Details of trial registration: not reported.
Funding sources: none declared.
Participants Place of study: Pomeranian Medical University in Szczecin, Poland.
Number of participants assigned: 115 participants.
Number of participants assessed: 95 participants (105 digits); 43 participants (46
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digits) percutaneous surgery and 52 participants (59 digits) steroid injection
Inclusion criteria: participants with trigger digits.
Exclusion criteria: not reported.
Age:
• Percutaneous surgery (mean): 55 years.
• Steroid injection (mean): 58 years.
Gender:
• Percutaneous surgery: 27 female and 16 male.
• Steroid injection: 40 female and 12 male.
Side:
• Percutaneous surgery: 24 left and 19 right.
• Steroid injection: 34 left and 18 right.
Digits:
• Total of digits assessed: 39 thumb, 1 index, 22 long, 35 ring and 8 little.
Classification of injury:
Trigger fingers were graded according to Froimson’s modification of Quinnell’s classifi-
cation (graded I to IV) (Froimson 1993).
Interventions Timing of intervention:
• Percutaneous surgery (mean): 5 months.
• Steroid injection (mean): 6 months.
Duration of treatment: not reported.
Type of intervention:
• Percutaneous A1 pulley release was performed in the outpatient clinic, using a 19
gauge hypodermic needle, after preparation of the skin and injection of 1 ml 2% plain
lidocaine.
• The steroid injection of 1 ml of betamethasone into the flexor tendon sheath was
also performed in the outpatient clinic.
Rehabilitation: not reported.
Any co-interventions: not reported.
Outcomes Length of follow-up:
6 months (at 1 and 6 months).
Loss of follow-up:
20 participants (12 in the percutaneous surgery group and 8 in the steroid injection
group)
Primary outcomes:
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale).
Active range of motion (AROM) of the affected digit.
Total grip strength: expressed as a proportion of the strength of the contralateral, healthy
hand
Recurrence of triggering: considered as the return to the baseline grade, after a period of
total or partial improvement of the trigger finger
Adverse event:
• Partial loss of movement.
• Neurovascular injury.
Outcomes included in this review:
Pain: measured by Visual Analog Scale (VAS: 0 to 10 scale).
Recurrence of triggering.
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Adverse event:
• Partial loss of movement.
Neurovascular injury.
Notes • The authors reported pain, adverse events and neurovascular injury incompletely.
They did not report standard deviations on VAS score, and they reported that
infection, algodystrophic syndrome and neurovascular injury did not occur in the
steroid injection group, but did not mention whether these adverse events occurred in
the percutaneous surgery group.
• Twenty of 115 patients (17%) who were recruited did not attend follow-up (12 in
the group treated operatively and 8 in the group treated by injection).
• We tried unsuccessfully to contact the authors to obtain further information on
standard deviations for pain (VAS-score), and missing data on adverse events and
neurovascular injury; asked also for further information on total patients’ fingers lost to
follow-up. In analysis we used the same standard deviation reported by Chao 2009 for
pain (VAS-score), as foreseen in our protocol Ventin 2014.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned to the
groups by drawing slips of paper marked 1
(percutaneous release) or 2 (steroid injec-
tion) from a sealed envelope in the presence
of a witness
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias) - subjective outcomes (e.g. resolution,
recurrence, pain, function, satisfaction)
All outcomes
Low risk The self-reported subjective outcomes as-
sessors were blinded
Blinding of outcome assessment (detec-
tion bias) - objective outcomes (e.g. adverse
events, neurovascular injury)
All outcomes
Low risk The objective outcome assessors were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 20 of 115 patients (17%) who were re-
cruited did not attend follow-up and were
excluded (12 participants in the percuta-
neous surgery group and 8 in the steroid
injection group). The authors did not de-
scribe how many fingers were affected in
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these 20 patients
Selective reporting (reporting bias) High risk No protocol was published.
Outcomes of interest in the review (resolu-
tion of trigger finger and functional status
of the hand)were not reported. Painwas re-
ported incompletely, without any measure
of variance for the validated instruments
(VAS)
Other bias Unclear risk There was no baseline imbalance and
no risk of bias was associated with care
providers, but the author did not report
about rehabilitation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abe 2016 Design of study not relevant: not a randomised or quasi-randomised controlled trial
Benson 1997 Design of study not relevant: retrospective comparative study
Durand 2011 Design of study not relevant: narrative review.
Guler 2013 Design of study not relevant: retrospective comparative study
Kolind-Sorensen 1970 Design of study not relevant: not a randomised or quasi-randomised controlled trial
Lin 2016 Design of study not relevant: retrospective comparative study
Liu 2016 Intervention is steroid injection plus percutaneous surgery versus percutaneous surgery alone
NCT01781130 Intervention is steroid injection plus percutaneous surgery versus percutaneous surgery alone
Patel 1992 Design of study not relevant: not a randomised or quasi-randomised controlled trial
Patel 1997 Design of study not relevant: not a randomised or quasi-randomised controlled trial
Paul 1992 Design of study not relevant: not a randomised or quasi-randomised controlled trial
Rojo-Manaute 2012a Design of study not relevant: not a randomised or quasi-randomised controlled trial
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Rojo-Manaute 2012b This study was not included because none of the outcomes of interest in this review (resolution of trigger
finger, severity of pain or tenderness at the base of the digit on the palm of the hand, functional status of the
hand, participant-reported treatment success or satisfaction, frequency of recurrence of triggering, number
of patients experiencing any adverse event or neurovascular injury) were assessed. The authors defined a
surgical model as the combination of a procedure (sonographically guided, wide awake, or classic) and a
setting (day surgery or office-based), and they assessed the outcomes turnover analysis and economic analysis
for each model
Topper 1997 Although the author randomised 3 different surgical treatments in trigger finger initially (surgical release
of the third proximal, middle and distal pulley A1), there was intraoperative change in all patients after it
was observed that the partial release of one-third pulley A1 was not curative treatment for trigger finger.
So the authors chose to perform the complete open release of the A1 pulley in all cases. Thus, it was not
characterized a randomised clinical trial
Uçar 2012 Design of study not relevant: not a randomised or quasi-randomised controlled trial
Characteristics of ongoing studies [ordered by year of study]
NTR1135
Trial name or title The efficacy of Trigger Finger treatment: a randomised, controlled, prospective clinical multicentre trial
Methods Study design: randomized controlled trial.
Random sequence generation: not reported.
Allocation concealment: not reported.
Masking: open label.
Participants Location: plastic surgery outpatient clinic in the UMCUtrecht, The Hand Clinic Amsterdam, Diakonessen-
huis Zeist, the Mesos Medical Center Utrecht, the St. Antonius Hospital Nieuwegein, the Zuwe Hofpoort
Hospital Woerden and the Meander Medical Center Amersfoort, the Netherlands.
Target sample size (N): 490 participants.
Inclusion criteria: adults with trigger finger.
Exclusion criteria:
• Incapacitated patients
• Patients less than 18 years of age;
• Women who would like to become pregnant during the period of the trial;
• Pregnant women;
• Lactating women.
Interventions Type of surgical intervention: open surgery.
Type of conservative intervention: local corticosteroid injections (triamcinolone acetonide).
Outcomes Primary outcomes:
• Success of the treatment.
• Pain.
Secondary outcomes:
• The complications which occur after treatment.
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NTR1135 (Continued)
Timing of outcomes measurement: not reported.
Starting date Main ID: NTR1135
Date of registration: 18 November 2007.
Last refreshed on: 30 April 2017.
Date of first enrolment: 1 January 2008.
Status: recruiting.
Estimated Study Completion date: January 2011.
Contact information Name: A.S.E. Esschendal.
Address: Postbus 85500 , Secretariaat Plastische Chirurgie UMC Utrecht kamer G04.122 Utrecht, the
Netherlands
Telephone: +31 30 250 6954
Email: Eva Esschendal@hotmail.com
Affiliation: not reported.
Notes
TCTR20150416001
Trial name or title A1-Pulley release using open conventional technique or percutaneously with a modified Kirschner wire: a
prospective randomised-controlled trial
Methods Study design: randomised controlled trial.
Random sequence generation: not reported.
Allocation concealment: not reported.
Masking: open label.
Participants Location: Department of Orthopedics, Faculty of Medicine, Khonkaen University, Thailand
Target sample size (N): 51 participants.
Inclusion criteria:
• Patients who had failed non-operative treatment of the trigger digits.
• Age minimum: 18 years.
• Age maximum: 70 years.
• Gender: both.
Exclusion criteria:
• Congenital trigger digits.
• Secondary trigger digits from underlying causes
• Rheumatoid arthritis.
• Patients who had previous surgery in the palm.
Interventions Type of surgical intervention: open surgery.
Type of conservative intervention: percutaneous release by using a modified Kirschner wire.
Outcomes Primary outcomes: time to return to work.
Secondary outcomes: pain score.
Timing of outcomes measurement: 1 year.
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TCTR20150416001 (Continued)
Starting date Main ID: TCTR20150416001.
Date of registration: 16 April 2015.
Last refreshed on: 11 September 2017.
Date of first enrolment: 16 April 2015.
Status: recruiting.
Estimated Study Completion date: 31 December 2016.
Contact information Name: Surut Jianmongkol, M.D.
Address: Department of Orthopedics, Faculty ofMedicine, Khonkaen University Khonkaen 40002 Thailand
Telephone: 6643348398
Email: surutmd@yahoo.com
Affiliation: not reported.
Notes
TCTR20140529001
Trial name or title Percutaneous trigger finger release, probe knife compared with 18-gauge needle : A randomized control trial
Methods Study design: randomised controlled trial.
Random sequence generation: not reported.
Allocation concealment: not reported.
Masking: single blind (masked roles: outcomes assessor).
Participants Location: Songklanakarin Hospital, Thailand.
Target sample size (N): 128 participants.
Inclusion criteria:
• Painful triggering finger.
• Locking finger.
• Age minimum: 30 years.
• Age maximum: 80 years.
• Gender: both.
Exclusion criteria:
• Previous hand disease and hand injury
Interventions Type of surgical intervention: percutaneous release with needle.
Type of surgical intervention: percutaneous release with probe scalpel.
Outcomes Primary outcomes:
• Post-operative pain (VAS score).
Secondary outcomes:
• Operative time.
• Time return to work.
• Adverse events.
• Patient satisfaction.
• Pinch strength (metric/method of measurement: Questionnaire, tip pinch gauge).
Timing of outcomes measurement: not reported.
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TCTR20140529001 (Continued)
Starting date Main ID: TCTR20140529001
Date of registration: May 29, 2014.
Last refreshed on: September 11, 2017.
Date of first enrolment: May 30, 2014.
Status: Active, not recruiting.
Estimated Study Completion date: not reported.
Contact information Name: Sittichoke Anuntaseree, M.D.
Address: Songklanakarin Hospital, Hat Yai 90110 Thailand.
Telephone: 66869691017
Email: asittich@medicine.psu.ac.th
Affiliation: Faculty of Medicine, PSU.
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Open surgery versus steroid injection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of trigger finger 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Resolution of symptoms
after one or more injections (six
to 12 months)
2 270 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.79, 2.76]
2 Pain on the palm of the hand 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Pain short-term (one
week)
1 105 Risk Ratio (M-H, Random, 95% CI) 3.69 [1.99, 6.85]
2.2 Pain intermediate-term
(six months)
1 105 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 1.77]
3 Pain (1 to 10 scale) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Pain short-term (three
months)
1 156 Mean Difference (IV, Random, 95% CI) 0.0 [-0.23, 0.23]
3.2 Pain long-term (12
months)
1 153 Mean Difference (IV, Random, 95% CI) -2.0 [-2.68, -1.32]
4 Frequency of recurrence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Recurrence (range six to
12 months)
2 270 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.09, 0.33]
5 Adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Infection 2 270 Risk Ratio (M-H, Random, 95% CI) 2.65 [0.88, 7.99]
5.2 Tendon or pulley injury 1 105 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Flare around procedure
site
1 165 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.23, 1.15]
5.4 Cutaneous discomfort
around procedure site (after 12
months)
1 165 Risk Ratio (M-H, Random, 95% CI) 3.62 [1.25, 10.44]
5.5 Fat necrosis at the
procedure site
1 165 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.47, 3.54]
5.6 Total adverse events 2 270 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.57, 1.84]
6 Neurovascular injury 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Neurovascular injury 2 270 Risk Ratio (M-H, Random, 95% CI) 2.17 [0.70, 6.77]
7 Subgroup analyses for resolution 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Resolution short-term 1 165 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.96, 1.21]
7.2 Resolution intermediate-
term
1 105 Risk Ratio (M-H, Random, 95% CI) 1.17 [1.04, 1.31]
7.3 Resolution long-term 1 165 Risk Ratio (M-H, Random, 95% CI) 1.90 [1.49, 2.43]
8 Subgroup analyses for recurrence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Recurrence intermediate-
term (six months)
1 105 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.00, 1.00]
8.2 Recurrence long-term (12
months)
1 165 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.09, 0.36]
108Surgery for trigger finger (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 2. Percutaneous surgery versus steroid injection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of trigger finger 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Resolution of symptoms
after one or more injections (six
to 12 months)
2 191 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.31, 14.51]
2 Pain (VAS: 0 to 10 scale) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Pain short-term (one
month)
2 198 Mean Difference (IV, Random, 95% CI) -1.80 [-5.72, 2.12]
2.2 Pain long-term (12
months)
1 93 Mean Difference (IV, Random, 95% CI) -6.5 [-7.25, -5.75]
3 Pain on the palm of the hand 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Pain short-term (one
week)
1 94 Risk Ratio (M-H, Random, 95% CI) 3.63 [1.94, 6.78]
3.2 Pain intermediate-term
(six months)
1 94 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.01, 2.18]
4 Frequency of recurrence 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Recurrence (range six to
12 months)
5 392 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.21, 1.59]
5 Adverse events 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Infection 2 191 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.29]
5.2 Partial loss of movement 3 201 Risk Ratio (M-H, Random, 95% CI) 3.09 [0.87, 10.97]
5.3 Tendon or pulley injury 4 267 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.21, 4.81]
5.4 Dysaesthesia 2 76 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.02, 1.67]
5.5 Skin atrophy or
hypopigmentation
1 50 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.63]
5.6 Total adverse events 5 392 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.91, 2.75]
6 Neurovascular injury 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Neurovascular injury 2 191 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.29]
7 Subgroup analyses for resolution 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Resolution short-term 1 97 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.55, 3.05]
7.2 Resolution intermediate-
term
1 94 Risk Ratio (M-H, Random, 95% CI) 1.16 [1.03, 1.31]
7.3 Resolution long-term 1 97 Risk Ratio (M-H, Random, 95% CI) 3.90 [2.37, 6.42]
8 Subgroup analyses for recurrence 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Recurrence short-term
(one month)
1 125 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.76, 3.94]
8.2 Recurrence intermediate-
term (six months)
2 219 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.02, 5.50]
8.3 Recurrence long-term
(range nine to 12 months)
3 173 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.10, 2.99]
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Comparison 3. Open surgery versus steroid injection plus hyaluronic acid injection guided by ultrasound
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of trigger finger 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Resolution of symptoms
long-term (12 months)
1 30 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.98, 1.85]
1.2 Resolution of symptoms
intermediate-term (six month)
1 30 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.89, 1.28]
2 Frequency of recurrence 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Recurrence long-term (12
months)
1 30 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.55]
2.2 Recurrence intermediate-
term (six months)
1 30 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Partial loss of movement 1 30 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.20, 19.78]
3.2 Algodystrophic syndrome 1 30 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 68.26]
3.3 Total adverse events 1 30 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.35, 25.68]
Comparison 4. Percutaneous surgery plus steroid injection versus steroid injection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of trigger finger 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Resolution of symptoms
after one or more injections
(range 6 to 42 months)
1 127 Risk Ratio (M-H, Random, 95% CI) 1.51 [1.21, 1.90]
2 Adverse events 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Infection 1 127 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.04, 4.97]
2.2 Partial loss of movement 1 127 Risk Ratio (M-H, Random, 95% CI) 1.85 [0.17, 19.87]
2.3 Total adverse events 1 127 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.13, 6.36]
3 Neurovascular injury 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Neurovascular injury 1 127 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.06, 14.46]
Comparison 5. Percutaneous surgery versus open surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of trigger finger 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Resolution of symptoms
(range 2 to 6 months)
5 429 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.97, 1.02]
2 Pain (1 to 6 scale) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Pain short-term (1 week) 1 36 Mean Difference (IV, Random, 95% CI) 0.30 [-0.34, 0.94]
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2.2 Pain short-term (12
weeks)
1 36 Mean Difference (IV, Random, 95% CI) 0.0 [-0.52, 0.52]
3 Pain on the palm of the hand 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Pain short-term (one
week)
1 101 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.75, 1.29]
3.2 Pain intermediate-term
(six months)
1 101 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Frequency of recurrence 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Recurrence (range 2 to 6
months)
4 397 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.83]
5 Adverse events 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Infection 2 133 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Partial loss of movement 1 32 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Tendon or pulley injury 2 261 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.4 Edema or inflammation
or hematoma
2 136 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.12, 5.30]
5.5 Adherence 1 100 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.83]
5.6 Others (it did not
specified)
1 100 Risk Ratio (M-H, Random, 95% CI) 2.56 [0.11, 61.45]
5.7 Total adverse events 5 429 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.17, 3.68]
6 Subgroup analyses for resolution 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Resolution of symptoms
(short-term)
4 328 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.97, 1.02]
6.2 Resolution of symptoms
(intermediate-term)
1 101 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.96, 1.04]
7 Subgroup analyses for recurrence 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Recurrence short-term
(eight to 12 weeks)
3 296 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.83]
7.2 Recurrence intermediate-
term (six months)
1 101 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Endoscopic surgery versus open surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of trigger finger 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Resolution of symptoms
(three months)
1 231 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.98, 1.02]
2 Adverse events 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Infection 1 231 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Dysesthesia 1 231 Risk Ratio (M-H, Random, 95% CI) 2.74 [0.74, 10.06]
2.3 Total adverse events 1 231 Risk Ratio (M-H, Random, 95% CI) 2.74 [0.74, 10.06]
3 Neurovascular injury 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Neurovascular injury 1 231 Risk Ratio (M-H, Random, 95% CI) 3.08 [0.13, 74.79]
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Comparison 7. Open surgery by transverse incision of the skin about 2-3 mm distally from distal palmar crease
versus open surgery by longitudinal incision of the skin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DASH score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 DASH score short-term
(one month)
1 21 Mean Difference (IV, Random, 95% CI) -1.5 [-19.19, 16.19]
1.2 DASH score short-term
(three months)
1 21 Mean Difference (IV, Random, 95% CI) -2.0 [-16.45, 12.45]
1.3 DASH score long-term
(12 months)
1 21 Mean Difference (IV, Random, 95% CI) -8.9 [-23.35, 5.55]
Comparison 8. Open surgery by transverse incision of the skin in the distal palmar crease versus open surgery by
longitudinal incision of the skin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DASH score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 DASH score short-term
(one month)
1 22 Mean Difference (IV, Random, 95% CI) 5.20 [-16.67, 27.07]
1.2 DASH score short-term
(three months)
1 22 Mean Difference (IV, Random, 95% CI) 1.60 [-15.27, 18.47]
1.3 DASH score long-term
(12 months)
1 22 Mean Difference (IV, Random, 95% CI) 3.10 [-21.28, 27.48]
Comparison 9. Open surgery by transverse incision of the skin in the distal palmar crease versus open surgery by
transverse incision of the skin about 2-3 mm distally from distal palmar crease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DASH score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 DASH score short-term
(one month)
1 21 Mean Difference (IV, Random, 95% CI) 6.70 [-13.67, 27.07]
1.2 DASH score short-term
(three months)
1 21 Mean Difference (IV, Random, 95% CI) 3.60 [-12.84, 20.04]
1.3 DASH score long-term
(12 months)
1 21 Mean Difference (IV, Random, 95% CI) 12.00 [-8.84, 32.84]
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Analysis 1.1. Comparison 1 Open surgery versus steroid injection, Outcome 1 Resolution of trigger finger.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 1 Resolution of trigger finger
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms after one or more injections (six to 12 months)
Hansen 2017 (1) 75/84 38/81 48.6 % 1.90 [ 1.49, 2.43 ]
Sato 2012 56/56 42/49 51.4 % 1.17 [ 1.04, 1.31 ]
Subtotal (95% CI) 140 130 100.0 % 1.48 [ 0.79, 2.76 ]
Total events: 131 (Open surgery), 80 (Steroid injection)
Heterogeneity: Tau2 = 0.19; Chi2 = 21.29, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.23 (P = 0.22)
0.1 0.2 0.5 1 2 5 10
Favours steroid injection Favours open surgery
(1) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they did not have a positive outcome.
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Analysis 1.2. Comparison 1 Open surgery versus steroid injection, Outcome 2 Pain on the palm of the hand.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 2 Pain on the palm of the hand
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pain short-term (one week)
Sato 2012 38/56 9/49 100.0 % 3.69 [ 1.99, 6.85 ]
Subtotal (95% CI) 56 49 100.0 % 3.69 [ 1.99, 6.85 ]
Total events: 38 (Open surgery), 9 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 4.15 (P = 0.000033)
2 Pain intermediate-term (six months)
Sato 2012 0/56 4/49 100.0 % 0.10 [ 0.01, 1.77 ]
Subtotal (95% CI) 56 49 100.0 % 0.10 [ 0.01, 1.77 ]
Total events: 0 (Open surgery), 4 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.12)
Test for subgroup differences: Chi2 = 5.79, df = 1 (P = 0.02), I2 =83%
0.005 0.1 1 10 200
Favours open surgery Favours steroid injection
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Analysis 1.3. Comparison 1 Open surgery versus steroid injection, Outcome 3 Pain (1 to 10 scale).
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 3 Pain (1 to 10 scale)
Study or subgroup Open surgery Steroid injection
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Pain short-term (three months)
Hansen 2017 77 1 (0.74) 79 1 (0.74) 100.0 % 0.0 [ -0.23, 0.23 ]
Subtotal (95% CI) 77 79 100.0 % 0.0 [ -0.23, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Pain long-term (12 months)
Hansen 2017 76 1 (0.74) 77 3 (2.96) 100.0 % -2.00 [ -2.68, -1.32 ]
Subtotal (95% CI) 76 77 100.0 % -2.00 [ -2.68, -1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.75 (P < 0.00001)
-4 -2 0 2 4
Favours open surgery Favours steroid injection
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Analysis 1.4. Comparison 1 Open surgery versus steroid injection, Outcome 4 Frequency of recurrence.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 4 Frequency of recurrence
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence (range six to 12 months)
Hansen 2017 (1) 8/84 43/81 94.4 % 0.18 [ 0.09, 0.36 ]
Sato 2012 0/56 7/49 5.6 % 0.06 [ 0.00, 1.00 ]
Subtotal (95% CI) 140 130 100.0 % 0.17 [ 0.09, 0.33 ]
Total events: 8 (Open surgery), 50 (Steroid injection)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 5.20 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours open surgery Favours steroid injection
(1) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had recurrence.
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Analysis 1.5. Comparison 1 Open surgery versus steroid injection, Outcome 5 Adverse events.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 5 Adverse events
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection
Hansen 2017 (1) 11/84 4/81 100.0 % 2.65 [ 0.88, 7.99 ]
Sato 2012 0/56 0/49 Not estimable
Subtotal (95% CI) 140 130 100.0 % 2.65 [ 0.88, 7.99 ]
Total events: 11 (Open surgery), 4 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
2 Tendon or pulley injury
Sato 2012 0/56 0/49 Not estimable
Subtotal (95% CI) 56 49 Not estimable
Total events: 0 (Open surgery), 0 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Flare around procedure site
Hansen 2017 (2) 8/84 15/81 100.0 % 0.51 [ 0.23, 1.15 ]
Subtotal (95% CI) 84 81 100.0 % 0.51 [ 0.23, 1.15 ]
Total events: 8 (Open surgery), 15 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
4 Cutaneous discomfort around procedure site (after 12 months)
Hansen 2017 (3) 15/84 4/81 100.0 % 3.62 [ 1.25, 10.44 ]
Subtotal (95% CI) 84 81 100.0 % 3.62 [ 1.25, 10.44 ]
Total events: 15 (Open surgery), 4 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
5 Fat necrosis at the procedure site
Hansen 2017 (4) 8/84 6/81 100.0 % 1.29 [ 0.47, 3.54 ]
Subtotal (95% CI) 84 81 100.0 % 1.29 [ 0.47, 3.54 ]
Total events: 8 (Open surgery), 6 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
6 Total adverse events
Hansen 2017 (5) 18/84 17/81 100.0 % 1.02 [ 0.57, 1.84 ]
0.01 0.1 1 10 100
Favours open surgery Favours steroid injection
(Continued . . . )
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(. . . Continued)
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sato 2012 0/56 0/49 Not estimable
Subtotal (95% CI) 140 130 100.0 % 1.02 [ 0.57, 1.84 ]
Total events: 18 (Open surgery), 17 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
0.01 0.1 1 10 100
Favours open surgery Favours steroid injection
(1) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had an adverse event.
(2) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had an adverse event.
(3) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had an adverse event.
(4) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had an adverse event.
(5) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had an adverse event.
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Analysis 1.6. Comparison 1 Open surgery versus steroid injection, Outcome 6 Neurovascular injury.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 6 Neurovascular injury
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Neurovascular injury
Sato 2012 0/56 0/49 Not estimable
Hansen 2017 (1) 9/84 4/81 100.0 % 2.17 [ 0.70, 6.77 ]
Subtotal (95% CI) 140 130 100.0 % 2.17 [ 0.70, 6.77 ]
Total events: 9 (Open surgery), 4 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
0.001 0.01 0.1 1 10 100 1000
Favours open surgery Favours steroid injection
(1) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had an neurovascular injury.
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Analysis 1.7. Comparison 1 Open surgery versus steroid injection, Outcome 7 Subgroup analyses for
resolution.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 7 Subgroup analyses for resolution
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution short-term
Hansen 2017 (1) 76/84 68/81 100.0 % 1.08 [ 0.96, 1.21 ]
Subtotal (95% CI) 84 81 100.0 % 1.08 [ 0.96, 1.21 ]
Total events: 76 (Open surgery), 68 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
2 Resolution intermediate-term
Sato 2012 56/56 42/49 100.0 % 1.17 [ 1.04, 1.31 ]
Subtotal (95% CI) 56 49 100.0 % 1.17 [ 1.04, 1.31 ]
Total events: 56 (Open surgery), 42 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 2.53 (P = 0.011)
3 Resolution long-term
Hansen 2017 (2) 75/84 38/81 100.0 % 1.90 [ 1.49, 2.43 ]
Subtotal (95% CI) 84 81 100.0 % 1.90 [ 1.49, 2.43 ]
Total events: 75 (Open surgery), 38 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 5.19 (P < 0.00001)
Test for subgroup differences: Chi2 = 17.14, df = 2 (P = 0.00), I2 =88%
0.5 0.7 1 1.5 2
Favours steroid injection Favours open surgery
(1) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they did not have a positive outcome.
(2) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they did not have a positive outcome.
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Analysis 1.8. Comparison 1 Open surgery versus steroid injection, Outcome 8 Subgroup analyses for
recurrence.
Review: Surgery for trigger finger
Comparison: 1 Open surgery versus steroid injection
Outcome: 8 Subgroup analyses for recurrence
Study or subgroup Open surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence intermediate-term (six months)
Sato 2012 0/56 7/49 100.0 % 0.06 [ 0.00, 1.00 ]
Subtotal (95% CI) 56 49 100.0 % 0.06 [ 0.00, 1.00 ]
Total events: 0 (Open surgery), 7 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 Recurrence long-term (12 months)
Hansen 2017 (1) 8/84 43/81 100.0 % 0.18 [ 0.09, 0.36 ]
Subtotal (95% CI) 84 81 100.0 % 0.18 [ 0.09, 0.36 ]
Total events: 8 (Open surgery), 43 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 4.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours open surgery Favours steroid injection
(1) There was follow-up loss in this trial; eight participants in open surgery group and four participants in steroid injection group were follow-up loss and we assumed
they had recurrence.
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Analysis 2.1. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 1 Resolution of trigger
finger.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 1 Resolution of trigger finger
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms after one or more injections (six to 12 months)
Chao 2009 (1) 44/47 12/50 49.2 % 3.90 [ 2.37, 6.42 ]
Sato 2012 45/45 42/49 50.8 % 1.16 [ 1.03, 1.31 ]
Subtotal (95% CI) 92 99 100.0 % 2.11 [ 0.31, 14.51 ]
Total events: 89 (Percutaneous surgery), 54 (Steroid injection)
Heterogeneity: Tau2 = 1.90; Chi2 = 56.49, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.76 (P = 0.45)
0.002 0.1 1 10 500
Favours steroid injection Favours percutaneous surgery
(1) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they did not have a positive outcome.
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Analysis 2.2. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 2 Pain (VAS: 0 to 10
scale).
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 2 Pain (VAS: 0 to 10 scale)
Study or subgroup Percutaneous surgery Steroid injection
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Pain short-term (one month)
Chao 2009 46 0.8 (0.6) 47 4.6 (1.8) 50.0 % -3.80 [ -4.34, -3.26 ]
Zyluk 2011 46 1.2 (0.6) 59 1 (1.8) 50.0 % 0.20 [ -0.29, 0.69 ]
Subtotal (95% CI) 92 106 100.0 % -1.80 [ -5.72, 2.12 ]
Heterogeneity: Tau2 = 7.93; Chi2 = 114.69, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Pain long-term (12 months)
Chao 2009 46 0.4 (0.3) 47 6.9 (2.6) 100.0 % -6.50 [ -7.25, -5.75 ]
Subtotal (95% CI) 46 47 100.0 % -6.50 [ -7.25, -5.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 17.02 (P < 0.00001)
-10 -5 0 5 10
Favours percutaneous surgery Favours steroid injection
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Analysis 2.3. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 3 Pain on the palm of
the hand.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 3 Pain on the palm of the hand
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pain short-term (one week)
Sato 2012 30/45 9/49 100.0 % 3.63 [ 1.94, 6.78 ]
Subtotal (95% CI) 45 49 100.0 % 3.63 [ 1.94, 6.78 ]
Total events: 30 (Percutaneous surgery), 9 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 4.04 (P = 0.000053)
2 Pain intermediate-term (six months)
Sato 2012 0/45 4/49 100.0 % 0.12 [ 0.01, 2.18 ]
Subtotal (95% CI) 45 49 100.0 % 0.12 [ 0.01, 2.18 ]
Total events: 0 (Percutaneous surgery), 4 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
0.001 0.01 0.1 1 10 100 1000
Favours percutaneous surgery Favours steroid injection
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Analysis 2.4. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 4 Frequency of
recurrence.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 4 Frequency of recurrence
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence (range six to 12 months)
Aref 2014 7/25 5/25 26.9 % 1.40 [ 0.51, 3.82 ]
Chao 2009 (1) 1/47 12/50 15.2 % 0.09 [ 0.01, 0.66 ]
Sato 2012 0/45 7/49 9.6 % 0.07 [ 0.00, 1.23 ]
Singh 2005 2/14 2/12 17.1 % 0.86 [ 0.14, 5.20 ]
Zyluk 2011 (2) 12/58 14/67 31.2 % 0.99 [ 0.50, 1.97 ]
Subtotal (95% CI) 189 203 100.0 % 0.57 [ 0.21, 1.59 ]
Total events: 22 (Percutaneous surgery), 40 (Steroid injection)
Heterogeneity: Tau2 = 0.75; Chi2 = 10.62, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 1.07 (P = 0.28)
0.01 0.1 1 10 100
Favours percutaneous surgery Favours steroid injection
(1) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they had recurrence.
(2) There was follow-up loss in this trial; twelve participant in percutaneous surgery group and eight participants in steroid injection group were follow-up loss and we
assumed they had recurrence.
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Analysis 2.5. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 5 Adverse events.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 5 Adverse events
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection
Chao 2009 (1) 1/47 3/50 100.0 % 0.35 [ 0.04, 3.29 ]
Sato 2012 0/45 0/49 Not estimable
Subtotal (95% CI) 92 99 100.0 % 0.35 [ 0.04, 3.29 ]
Total events: 1 (Percutaneous surgery), 3 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Partial loss of movement
Aref 2014 8/25 0/25 16.8 % 17.00 [ 1.03, 279.53 ]
Singh 2005 2/14 0/12 15.4 % 4.33 [ 0.23, 82.31 ]
Zyluk 2011 (2) 13/58 8/67 67.8 % 1.88 [ 0.84, 4.21 ]
Subtotal (95% CI) 97 104 100.0 % 3.09 [ 0.87, 10.97 ]
Total events: 23 (Percutaneous surgery), 8 (Steroid injection)
Heterogeneity: Tau2 = 0.45; Chi2 = 2.75, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.75 (P = 0.081)
3 Tendon or pulley injury
Aref 2014 1/25 0/25 24.8 % 3.00 [ 0.13, 70.30 ]
Chao 2009 (3) 1/47 3/50 49.7 % 0.35 [ 0.04, 3.29 ]
Sato 2012 0/45 0/49 Not estimable
Singh 2005 1/14 0/12 25.5 % 2.60 [ 0.12, 58.48 ]
Subtotal (95% CI) 131 136 100.0 % 1.00 [ 0.21, 4.81 ]
Total events: 3 (Percutaneous surgery), 3 (Steroid injection)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
4 Dysaesthesia
Aref 2014 0/25 3/25 53.3 % 0.14 [ 0.01, 2.63 ]
Singh 2005 0/14 1/12 46.7 % 0.29 [ 0.01, 6.50 ]
Subtotal (95% CI) 39 37 100.0 % 0.20 [ 0.02, 1.67 ]
Total events: 0 (Percutaneous surgery), 4 (Steroid injection)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
0.05 0.2 1 5 20
Favours percutaneous surgery Favours steroid injection
(Continued . . . )
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(. . . Continued)
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 Skin atrophy or hypopigmentation
Aref 2014 0/25 3/25 100.0 % 0.14 [ 0.01, 2.63 ]
Subtotal (95% CI) 25 25 100.0 % 0.14 [ 0.01, 2.63 ]
Total events: 0 (Percutaneous surgery), 3 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
6 Total adverse events
Aref 2014 9/25 6/25 40.2 % 1.50 [ 0.63, 3.59 ]
Chao 2009 (4) 1/47 3/50 6.2 % 0.35 [ 0.04, 3.29 ]
Sato 2012 0/45 0/49 Not estimable
Singh 2005 3/14 1/12 6.8 % 2.57 [ 0.31, 21.59 ]
Zyluk 2011 (5) 13/58 8/67 46.9 % 1.88 [ 0.84, 4.21 ]
Subtotal (95% CI) 189 203 100.0 % 1.58 [ 0.91, 2.75 ]
Total events: 26 (Percutaneous surgery), 18 (Steroid injection)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.13, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 8.89, df = 5 (P = 0.11), I2 =44%
0.05 0.2 1 5 20
Favours percutaneous surgery Favours steroid injection
(1) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they had an adverse event.
(2) There was follow-up loss in this trial; twelve participant in percutaneous surgery group and eight participants in steroid injection group were follow-up loss and we
assumed they had an adverse event.
(3) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they had an adverse event.
(4) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they had an adverse event.
(5) There was follow-up loss in this trial; twelve participant in percutaneous surgery group and eight participants in steroid injection group were follow-up loss and we
assumed they had an adverse event.
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Analysis 2.6. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 6 Neurovascular injury.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 6 Neurovascular injury
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Neurovascular injury
Chao 2009 (1) 1/47 3/50 100.0 % 0.35 [ 0.04, 3.29 ]
Sato 2012 0/45 0/49 Not estimable
Subtotal (95% CI) 92 99 100.0 % 0.35 [ 0.04, 3.29 ]
Total events: 1 (Percutaneous surgery), 3 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
0.01 0.1 1 10 100
Favours percutaneous surgery Favours steroid injention
(1) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they had neurovascular injury.
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Analysis 2.7. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 7 Subgroup analyses
for resolution.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 7 Subgroup analyses for resolution
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution short-term
Chao 2009 (1) 43/47 21/50 100.0 % 2.18 [ 1.55, 3.05 ]
Subtotal (95% CI) 47 50 100.0 % 2.18 [ 1.55, 3.05 ]
Total events: 43 (Percutaneous surgery), 21 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 4.53 (P < 0.00001)
2 Resolution intermediate-term
Sato 2012 45/45 42/49 100.0 % 1.16 [ 1.03, 1.31 ]
Subtotal (95% CI) 45 49 100.0 % 1.16 [ 1.03, 1.31 ]
Total events: 45 (Percutaneous surgery), 42 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.014)
3 Resolution long-term
Chao 2009 (2) 44/47 12/50 100.0 % 3.90 [ 2.37, 6.42 ]
Subtotal (95% CI) 47 50 100.0 % 3.90 [ 2.37, 6.42 ]
Total events: 44 (Percutaneous surgery), 12 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 30.82, df = 2 (P = 0.00), I2 =94%
0.05 0.2 1 5 20
Favours steroid injection Favours percutaneous surgery
(1) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they did not have a positive outcome.
(2) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they did not have a positive outcome.
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Analysis 2.8. Comparison 2 Percutaneous surgery versus steroid injection, Outcome 8 Subgroup analyses
for recurrence.
Review: Surgery for trigger finger
Comparison: 2 Percutaneous surgery versus steroid injection
Outcome: 8 Subgroup analyses for recurrence
Study or subgroup Percutaneous surgery Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence short-term (one month)
Zyluk 2011 (1) 12/58 8/67 100.0 % 1.73 [ 0.76, 3.94 ]
Subtotal (95% CI) 58 67 100.0 % 1.73 [ 0.76, 3.94 ]
Total events: 12 (Percutaneous surgery), 8 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
2 Recurrence intermediate-term (six months)
Sato 2012 0/45 7/49 37.8 % 0.07 [ 0.00, 1.23 ]
Zyluk 2011 (2) 12/58 14/67 62.2 % 0.99 [ 0.50, 1.97 ]
Subtotal (95% CI) 103 116 100.0 % 0.37 [ 0.02, 5.50 ]
Total events: 12 (Percutaneous surgery), 21 (Steroid injection)
Heterogeneity: Tau2 = 2.94; Chi2 = 3.65, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Recurrence long-term (range nine to 12 months)
Aref 2014 7/25 5/25 40.6 % 1.40 [ 0.51, 3.82 ]
Chao 2009 (3) 1/47 12/50 28.6 % 0.09 [ 0.01, 0.66 ]
Singh 2005 2/14 2/12 30.9 % 0.86 [ 0.14, 5.20 ]
Subtotal (95% CI) 86 87 100.0 % 0.55 [ 0.10, 2.99 ]
Total events: 10 (Percutaneous surgery), 19 (Steroid injection)
Heterogeneity: Tau2 = 1.59; Chi2 = 6.97, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Chi2 = 2.30, df = 2 (P = 0.32), I2 =13%
0.002 0.1 1 10 500
Favours percutaneous surgery Favours steroid injection
(1) There was follow-up loss in this trial; twelve participant in percutaneous surgery group and eight participants in steroid injection group were follow-up loss and we
assumed they had recurrence.
(2) There was follow-up loss in this trial; twelve participant in percutaneous surgery group and eight participants in steroid injection group were follow-up loss and we
assumed they had recurrence.
(3) There was follow-up loss in this trial; one participant in percutaneous surgery group and three participants in steroid injection group were follow-up loss and we
assumed they had recurrence.
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Analysis 3.1. Comparison 3 Open surgery versus steroid injection plus hyaluronic acid injection guided by
ultrasound, Outcome 1 Resolution of trigger finger.
Review: Surgery for trigger finger
Comparison: 3 Open surgery versus steroid injection plus hyaluronic acid injection guided by ultrasound
Outcome: 1 Resolution of trigger finger
Study or subgroup Open surgery
Steroid injection plus hyaluronic
acid injection guided by
ultrasound Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms long-term (12 months)
Callegari 2011 15/15 11/15 100.0 % 1.35 [ 0.98, 1.85 ]
Subtotal (95% CI) 15 15 100.0 % 1.35 [ 0.98, 1.85 ]
Total events: 15 (Open surgery), 11 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
2 Resolution of symptoms intermediate-term (six month)
Callegari 2011 15/15 14/15 100.0 % 1.07 [ 0.89, 1.28 ]
Subtotal (95% CI) 15 15 100.0 % 1.07 [ 0.89, 1.28 ]
Total events: 15 (Open surgery), 14 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 1.54, df = 1 (P = 0.22), I2 =35%
0.5 0.7 1 1.5 2
Favours steroid injection plus hyaluronic acid injection guided by ultrasound Favours open surgery
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Analysis 3.2. Comparison 3 Open surgery versus steroid injection plus hyaluronic acid injection guided by
ultrasound, Outcome 2 Frequency of recurrence.
Review: Surgery for trigger finger
Comparison: 3 Open surgery versus steroid injection plus hyaluronic acid injection guided by ultrasound
Outcome: 2 Frequency of recurrence
Study or subgroup Open surgery
Steroid injection plus hyaluronic
acid injection guided by
ultrasound Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence long-term (12 months)
Callegari 2011 0/15 3/15 100.0 % 0.14 [ 0.01, 2.55 ]
Subtotal (95% CI) 15 15 100.0 % 0.14 [ 0.01, 2.55 ]
Total events: 0 (Open surgery), 3 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Recurrence intermediate-term (six months)
Callegari 2011 0/15 0/15 Not estimable
Subtotal (95% CI) 15 15 Not estimable
Total events: 0 (Open surgery), 0 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours steroid injection plus hyaluronic acid injection guided by ultrasound Favours open surgery
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Analysis 3.3. Comparison 3 Open surgery versus steroid injection plus hyaluronic acid injection guided by
ultrasound, Outcome 3 Adverse events.
Review: Surgery for trigger finger
Comparison: 3 Open surgery versus steroid injection plus hyaluronic acid injection guided by ultrasound
Outcome: 3 Adverse events
Study or subgroup Open surgery
Steroid injection plus hyaluronic
acid injection guided by
ultrasound Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Partial loss of movement
Callegari 2011 2/15 1/15 100.0 % 2.00 [ 0.20, 19.78 ]
Subtotal (95% CI) 15 15 100.0 % 2.00 [ 0.20, 19.78 ]
Total events: 2 (Open surgery), 1 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 Algodystrophic syndrome
Callegari 2011 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Open surgery), 0 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Total adverse events
Callegari 2011 3/15 1/15 100.0 % 3.00 [ 0.35, 25.68 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.35, 25.68 ]
Total events: 3 (Open surgery), 1 (Steroid injection plus hyaluronic acid injection guided by ultrasound)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
0.05 0.2 1 5 20
Favours steroid injection plus hyaluronic acid injection guided by ultrasound Favours open surgery
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Analysis 4.1. Comparison 4 Percutaneous surgery plus steroid injection versus steroid injection, Outcome 1
Resolution of trigger finger.
Review: Surgery for trigger finger
Comparison: 4 Percutaneous surgery plus steroid injection versus steroid injection
Outcome: 1 Resolution of trigger finger
Study or subgroup
Percutaneous
surgery plus steroid
injection Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms after one or more injections (range 6 to 42 months)
Maneerit 2003 (1) 59/66 36/61 100.0 % 1.51 [ 1.21, 1.90 ]
Subtotal (95% CI) 66 61 100.0 % 1.51 [ 1.21, 1.90 ]
Total events: 59 (Percutaneous surgery plus steroid injection), 36 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 3.62 (P = 0.00030)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours steroid injection Favours percutaneous surgery plus steroid injection
(1) There was follow-up loss in this trial; one participant in percutaneous surgery plus steroid injection group and one participant in steroid injection group were follow-up
loss and we assumed they did not have a positive outcome.
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Analysis 4.2. Comparison 4 Percutaneous surgery plus steroid injection versus steroid injection, Outcome 2
Adverse events.
Review: Surgery for trigger finger
Comparison: 4 Percutaneous surgery plus steroid injection versus steroid injection
Outcome: 2 Adverse events
Study or subgroup
Percutaneous
surgery plus steroid
injection Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection
Maneerit 2003 (1) 1/66 2/61 100.0 % 0.46 [ 0.04, 4.97 ]
Subtotal (95% CI) 66 61 100.0 % 0.46 [ 0.04, 4.97 ]
Total events: 1 (Percutaneous surgery plus steroid injection), 2 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Partial loss of movement
Maneerit 2003 (2) 2/66 1/61 100.0 % 1.85 [ 0.17, 19.87 ]
Subtotal (95% CI) 66 61 100.0 % 1.85 [ 0.17, 19.87 ]
Total events: 2 (Percutaneous surgery plus steroid injection), 1 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 Total adverse events
Maneerit 2003 (3) 2/66 2/61 100.0 % 0.92 [ 0.13, 6.36 ]
Subtotal (95% CI) 66 61 100.0 % 0.92 [ 0.13, 6.36 ]
Total events: 2 (Percutaneous surgery plus steroid injection), 2 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.65, df = 2 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours percutaneous surgery plus steroid injection Favours steroid injection
(1) There was follow-up loss in this trial; one participant in percutaneous surgery plus steroid injection group and one participant in steroid injection group were follow-up
loss and we assumed they had an adverse event.
(2) There was follow-up loss in this trial; one participant in percutaneous surgery plus steroid injection group and one participant in steroid injection group were follow-up
loss and we assumed they had an adverse event.
(3) There was follow-up loss in this trial; one participant in percutaneous surgery plus steroid injection group and one participant in steroid injection group were follow-up
loss and we assumed they had an adverse event.
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Analysis 4.3. Comparison 4 Percutaneous surgery plus steroid injection versus steroid injection, Outcome 3
Neurovascular injury.
Review: Surgery for trigger finger
Comparison: 4 Percutaneous surgery plus steroid injection versus steroid injection
Outcome: 3 Neurovascular injury
Study or subgroup
Percutaneous
surgery plus steroid
injection Steroid injection Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Neurovascular injury
Maneerit 2003 (1) 1/66 1/61 100.0 % 0.92 [ 0.06, 14.46 ]
Subtotal (95% CI) 66 61 100.0 % 0.92 [ 0.06, 14.46 ]
Total events: 1 (Percutaneous surgery plus steroid injection), 1 (Steroid injection)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
0.01 0.1 1 10 100
Favours percutaneous surgery plus steroid injection Favours steroid injection
(1) There was follow-up loss in this trial; one participant in percutaneous surgery plus steroid injection group and one participant in steroid injection group were follow-up
loss and we assumed they had neurovascular injury.
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Analysis 5.1. Comparison 5 Percutaneous surgery versus open surgery, Outcome 1 Resolution of trigger
finger.
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 1 Resolution of trigger finger
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms (range 2 to 6 months)
Bamroongshawgasame 2010 79/80 80/80 43.7 % 0.99 [ 0.95, 1.02 ]
Dierks 2008 20/20 16/16 4.6 % 1.00 [ 0.90, 1.11 ]
Gilberts 2001 54/54 45/46 15.6 % 1.02 [ 0.97, 1.08 ]
Nikolaou 2017 15/16 16/16 1.8 % 0.94 [ 0.79, 1.11 ]
Sato 2012 45/45 56/56 34.3 % 1.00 [ 0.96, 1.04 ]
Subtotal (95% CI) 215 214 100.0 % 1.00 [ 0.97, 1.02 ]
Total events: 213 (Percutaneous surgery), 213 (Open surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.60, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
0.5 0.7 1 1.5 2
Favours open surgery Favours percutaneous surgery
137Surgery for trigger finger (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Percutaneous surgery versus open surgery, Outcome 2 Pain (1 to 6 scale).
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 2 Pain (1 to 6 scale)
Study or subgroup Percutaneous surgery Open surgery
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Pain short-term (1 week)
Dierks 2008 20 2.8 (0.8) 16 2.5 (1.1) 100.0 % 0.30 [ -0.34, 0.94 ]
Subtotal (95% CI) 20 16 100.0 % 0.30 [ -0.34, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Pain short-term (12 weeks)
Dierks 2008 20 1.8 (0.9) 16 1.8 (0.7) 100.0 % 0.0 [ -0.52, 0.52 ]
Subtotal (95% CI) 20 16 100.0 % 0.0 [ -0.52, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
-4 -2 0 2 4
Favours percutaneous surgery Favours open surgery
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Analysis 5.3. Comparison 5 Percutaneous surgery versus open surgery, Outcome 3 Pain on the palm of the
hand.
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 3 Pain on the palm of the hand
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pain short-term (one week)
Sato 2012 30/45 38/56 100.0 % 0.98 [ 0.75, 1.29 ]
Subtotal (95% CI) 45 56 100.0 % 0.98 [ 0.75, 1.29 ]
Total events: 30 (Percutaneous surgery), 38 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
2 Pain intermediate-term (six months)
Sato 2012 0/45 0/56 Not estimable
Subtotal (95% CI) 45 56 Not estimable
Total events: 0 (Percutaneous surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours percutaneous surgery Favours open surgery
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Analysis 5.4. Comparison 5 Percutaneous surgery versus open surgery, Outcome 4 Frequency of recurrence.
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 4 Frequency of recurrence
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence (range 2 to 6 months)
Bamroongshawgasame 2010 0/80 0/80 Not estimable
Dierks 2008 0/20 0/16 Not estimable
Gilberts 2001 0/54 1/46 100.0 % 0.28 [ 0.01, 6.83 ]
Sato 2012 0/45 0/56 Not estimable
Subtotal (95% CI) 199 198 100.0 % 0.28 [ 0.01, 6.83 ]
Total events: 0 (Percutaneous surgery), 1 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.01 0.1 1 10 100
Favours percutaneous surgery Favours open surgery
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Analysis 5.5. Comparison 5 Percutaneous surgery versus open surgery, Outcome 5 Adverse events.
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 5 Adverse events
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection
Nikolaou 2017 0/16 0/16 Not estimable
Sato 2012 0/45 0/56 Not estimable
Subtotal (95% CI) 61 72 Not estimable
Total events: 0 (Percutaneous surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Partial loss of movement
Nikolaou 2017 0/16 0/16 Not estimable
Subtotal (95% CI) 16 16 Not estimable
Total events: 0 (Percutaneous surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Tendon or pulley injury
Sato 2012 0/45 0/56 Not estimable
Bamroongshawgasame 2010 0/80 0/80 Not estimable
Subtotal (95% CI) 125 136 Not estimable
Total events: 0 (Percutaneous surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Edema or inflammation or hematoma
Gilberts 2001 1/54 2/46 63.7 % 0.43 [ 0.04, 4.55 ]
Dierks 2008 1/20 0/16 36.3 % 2.43 [ 0.11, 55.89 ]
Subtotal (95% CI) 74 62 100.0 % 0.80 [ 0.12, 5.30 ]
Total events: 2 (Percutaneous surgery), 2 (Open surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
5 Adherence
Gilberts 2001 0/54 1/46 100.0 % 0.28 [ 0.01, 6.83 ]
Subtotal (95% CI) 54 46 100.0 % 0.28 [ 0.01, 6.83 ]
Total events: 0 (Percutaneous surgery), 1 (Open surgery)
Heterogeneity: not applicable
0.005 0.1 1 10 200
Favours percutaneous surgery Favours open surgery
(Continued . . . )
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(. . . Continued)
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.77 (P = 0.44)
6 Others (it did not specified)
Gilberts 2001 1/54 0/46 100.0 % 2.56 [ 0.11, 61.45 ]
Subtotal (95% CI) 54 46 100.0 % 2.56 [ 0.11, 61.45 ]
Total events: 1 (Percutaneous surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
7 Total adverse events
Bamroongshawgasame 2010 0/80 0/80 Not estimable
Nikolaou 2017 0/16 0/16 Not estimable
Sato 2012 0/45 0/56 Not estimable
Gilberts 2001 2/54 3/46 76.3 % 0.57 [ 0.10, 3.25 ]
Dierks 2008 1/20 0/16 23.7 % 2.43 [ 0.11, 55.89 ]
Subtotal (95% CI) 215 214 100.0 % 0.80 [ 0.17, 3.68 ]
Total events: 3 (Percutaneous surgery), 3 (Open surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.78)
Test for subgroup differences: Chi2 = 0.92, df = 3 (P = 0.82), I2 =0.0%
0.005 0.1 1 10 200
Favours percutaneous surgery Favours open surgery
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Analysis 5.6. Comparison 5 Percutaneous surgery versus open surgery, Outcome 6 Subgroup analyses for
resolution.
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 6 Subgroup analyses for resolution
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms (short-term)
Bamroongshawgasame 2010 79/80 80/80 66.5 % 0.99 [ 0.95, 1.02 ]
Dierks 2008 20/20 16/16 7.0 % 1.00 [ 0.90, 1.11 ]
Gilberts 2001 54/54 45/46 23.7 % 1.02 [ 0.97, 1.08 ]
Nikolaou 2017 15/16 16/16 2.8 % 0.94 [ 0.79, 1.11 ]
Subtotal (95% CI) 170 158 100.0 % 1.00 [ 0.97, 1.02 ]
Total events: 168 (Percutaneous surgery), 157 (Open surgery)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
2 Resolution of symptoms (intermediate-term)
Sato 2012 45/45 56/56 100.0 % 1.00 [ 0.96, 1.04 ]
Subtotal (95% CI) 45 56 100.0 % 1.00 [ 0.96, 1.04 ]
Total events: 45 (Percutaneous surgery), 56 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
0.5 0.7 1 1.5 2
Favours open surgery Favours percutaneous surgery
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Analysis 5.7. Comparison 5 Percutaneous surgery versus open surgery, Outcome 7 Subgroup analyses for
recurrence.
Review: Surgery for trigger finger
Comparison: 5 Percutaneous surgery versus open surgery
Outcome: 7 Subgroup analyses for recurrence
Study or subgroup Percutaneous surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Recurrence short-term (eight to 12 weeks)
Bamroongshawgasame 2010 0/80 0/80 Not estimable
Dierks 2008 0/20 0/16 Not estimable
Gilberts 2001 0/54 1/46 100.0 % 0.28 [ 0.01, 6.83 ]
Subtotal (95% CI) 154 142 100.0 % 0.28 [ 0.01, 6.83 ]
Total events: 0 (Percutaneous surgery), 1 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 Recurrence intermediate-term (six months)
Sato 2012 0/45 0/56 Not estimable
Subtotal (95% CI) 45 56 Not estimable
Total events: 0 (Percutaneous surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours percutaneous surgery Favours open surgery
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Analysis 6.1. Comparison 6 Endoscopic surgery versus open surgery, Outcome 1 Resolution of trigger finger.
Review: Surgery for trigger finger
Comparison: 6 Endoscopic surgery versus open surgery
Outcome: 1 Resolution of trigger finger
Study or subgroup Endoscopic surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Resolution of symptoms (three months)
Pegoli 2008 114/114 117/117 100.0 % 1.00 [ 0.98, 1.02 ]
Subtotal (95% CI) 114 117 100.0 % 1.00 [ 0.98, 1.02 ]
Total events: 114 (Endoscopic surgery), 117 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours open surgery Favours endoscopic surgery
145Surgery for trigger finger (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.2. Comparison 6 Endoscopic surgery versus open surgery, Outcome 2 Adverse events.
Review: Surgery for trigger finger
Comparison: 6 Endoscopic surgery versus open surgery
Outcome: 2 Adverse events
Study or subgroup Endoscopic surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infection
Pegoli 2008 0/114 0/117 Not estimable
Subtotal (95% CI) 114 117 Not estimable
Total events: 0 (Endoscopic surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Dysesthesia
Pegoli 2008 8/114 3/117 100.0 % 2.74 [ 0.74, 10.06 ]
Subtotal (95% CI) 114 117 100.0 % 2.74 [ 0.74, 10.06 ]
Total events: 8 (Endoscopic surgery), 3 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
3 Total adverse events
Pegoli 2008 8/114 3/117 100.0 % 2.74 [ 0.74, 10.06 ]
Subtotal (95% CI) 114 117 100.0 % 2.74 [ 0.74, 10.06 ]
Total events: 8 (Endoscopic surgery), 3 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.02 0.1 1 10 50
Favours endoscopic surgery Favours open surgery
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Analysis 6.3. Comparison 6 Endoscopic surgery versus open surgery, Outcome 3 Neurovascular injury.
Review: Surgery for trigger finger
Comparison: 6 Endoscopic surgery versus open surgery
Outcome: 3 Neurovascular injury
Study or subgroup Endoscopic surgery Open surgery Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Neurovascular injury
Pegoli 2008 1/114 0/117 100.0 % 3.08 [ 0.13, 74.79 ]
Subtotal (95% CI) 114 117 100.0 % 3.08 [ 0.13, 74.79 ]
Total events: 1 (Endoscopic surgery), 0 (Open surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours endoscopic surgery Favours open surgery
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Analysis 7.1. Comparison 7 Open surgery by transverse incision of the skin about 2-3 mm distally from
distal palmar crease versus open surgery by longitudinal incision of the skin, Outcome 1 DASH score.
Review: Surgery for trigger finger
Comparison: 7 Open surgery by transverse incision of the skin about 2 3 mm distally from distal palmar crease versus open surgery by longitudinal incision of the skin
Outcome: 1 DASH score
Study or subgroup
Transverse incision distally
from distal palmar crease Longitudinal incision
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 DASH score short-term (one month)
Kloeters 2016 10 23 (18.025) 11 24.5 (23.2164) 100.0 % -1.50 [ -19.19, 16.19 ]
Subtotal (95% CI) 10 11 100.0 % -1.50 [ -19.19, 16.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
2 DASH score short-term (three months)
Kloeters 2016 10 11.3 (15.9063) 11 13.3 (17.8766) 100.0 % -2.00 [ -16.45, 12.45 ]
Subtotal (95% CI) 10 11 100.0 % -2.00 [ -16.45, 12.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 DASH score long-term (12 months)
Kloeters 2016 10 6.4 (7.9373) 11 15.3 (22.9842) 100.0 % -8.90 [ -23.35, 5.55 ]
Subtotal (95% CI) 10 11 100.0 % -8.90 [ -23.35, 5.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.58, df = 2 (P = 0.75), I2 =0.0%
-100 -50 0 50 100
Favours transverse incision distally from distal palmar crease Favours longitudinal incision
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Analysis 8.1. Comparison 8 Open surgery by transverse incision of the skin in the distal palmar crease
versus open surgery by longitudinal incision of the skin, Outcome 1 DASH score.
Review: Surgery for trigger finger
Comparison: 8 Open surgery by transverse incision of the skin in the distal palmar crease versus open surgery by longitudinal incision of the skin
Outcome: 1 DASH score
Study or subgroup
Transverse incision in
the distal palmar
crease Longitudinal incision
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 DASH score short-term (one month)
Kloeters 2016 11 29.7 (28.8215) 11 24.5 (23.2164) 100.0 % 5.20 [ -16.67, 27.07 ]
Subtotal (95% CI) 11 11 100.0 % 5.20 [ -16.67, 27.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 DASH score short-term (three months)
Kloeters 2016 11 14.9 (22.2546) 11 13.3 (17.8766) 100.0 % 1.60 [ -15.27, 18.47 ]
Subtotal (95% CI) 11 11 100.0 % 1.60 [ -15.27, 18.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 DASH score long-term (12 months)
Kloeters 2016 11 18.4 (34.2607) 11 15.3 (22.9842) 100.0 % 3.10 [ -21.28, 27.48 ]
Subtotal (95% CI) 11 11 100.0 % 3.10 [ -21.28, 27.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.07, df = 2 (P = 0.97), I2 =0.0%
-100 -50 0 50 100
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Analysis 9.1. Comparison 9 Open surgery by transverse incision of the skin in the distal palmar crease
versus open surgery by transverse incision of the skin about 2-3 mm distally from distal palmar crease,
Outcome 1 DASH score.
Review: Surgery for trigger finger
Comparison: 9 Open surgery by transverse incision of the skin in the distal palmar crease versus open surgery by transverse incision of the skin about 2 3 mm distally
from distal palmar crease
Outcome: 1 DASH score
Study or subgroup
Transverse incision in
the distal palmar
crease
Transverse incision distally
from distal palmar crease
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 DASH score short-term (one month)
Kloeters 2016 11 29.7 (28.8215) 10 23 (18.025) 100.0 % 6.70 [ -13.67, 27.07 ]
Subtotal (95% CI) 11 10 100.0 % 6.70 [ -13.67, 27.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 DASH score short-term (three months)
Kloeters 2016 11 14.9 (22.2546) 10 11.3 (15.9063) 100.0 % 3.60 [ -12.84, 20.04 ]
Subtotal (95% CI) 11 10 100.0 % 3.60 [ -12.84, 20.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 DASH score long-term (12 months)
Kloeters 2016 11 18.4 (34.2607) 10 6.4 (7.9373) 100.0 % 12.00 [ -8.84, 32.84 ]
Subtotal (95% CI) 11 10 100.0 % 12.00 [ -8.84, 32.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.82), I2 =0.0%
-50 -25 0 25 50
Favours transverse incision in the distal palmar crease Favours transverse incision distally from distal palmar crease
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A P P E N D I C E S
Appendix 1. CENTRAL via the Cochrane Library
#1 MeSH descriptor: [Trigger Finger Disorder] explode all trees
#2 trigger finger
#3 trigger thumb
#4 trigger digit
#5 snap* near finger
#6 snap* near thumb
#7 snap* near digit
#8 lock* near finger
#9 lock* near thumb
#10 lock* near digit
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
Appendix 2. MEDLINE (1946 to August 2, 2017)
1 Trigger Finger Disorder/ (401)
2 (trigger adj (finger$ or thumb$ or digit$)).tw. (812)
3 (snapping adj (finger$ or thumb$ or digit$)).tw. (38)
4 (locking adj (finger$ or thumb$ or digit$)).tw. (7)
5 or/1-4 (925)
6 Orthopedics/ (19436)
7 exp Orthopedic Procedures/ (258870)
8 su.fs. (1821619)
9 (surger$ or surgical$ or operat$).tw. (2163875)
10 or/6-9 (3136300)
11 5 and 10 (571)
12 randomized controlled trial.pt. (470060)
13 controlled clinical trial.pt. (94456)
14 randomized.ab. (403594)
15 placebo.ab. (189089)
16 drug therapy.fs. (2021488)
17 randomly.ab. (280473)
18 trial.ab. (423411)
19 groups.ab. (1725392)
20 or/12-19 (4122380)
21 (animals not (humans and animals)).sh. (4409922)
22 20 not 21 (3559665)
23 11 and 22 (100)
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Appendix 3. Embase (1947 to February 14, 2013)
1 Trigger Finger Disorder/ (429)
2 (trigger adj (finger$ or thumb$ or digit$)).tw. (1203)
3 (snapping adj (finger$ or thumb$ or digit$)).tw. (78)
4 (locking adj (finger$ or thumb$ or digit$)).tw. (15)
5 or/1-4 (1389)
6 Orthopedics/ (33367)
7 exp Orthopedic Procedures/ (553613)
8 su.fs. (3137208)
9 (surger$ or surgical$ or operat$).tw. (3905446)
10 or/6-9 (5717763)
11 5 and 10 (872)
12 randomized controlled trial.pt. (340614)
13 controlled clinical trial.pt. (85208)
14 randomized.ab. (599068)
15 placebo.ab. (327198)
16 drug therapy.fs. (1578084)
17 randomly.ab. (427551)
18 trial.ab. (626990)
19 groups.ab. (2866231)
20 or/12-19 (5271971)
21 (animals not (humans and animals)).sh. (3671560)
22 20 not 21 (4829703)
23 11 and 22 (111)
Appendix 4. Embase (February 14, 2013 to August 02, 2017)
1 Trigger Finger Disorder/ (303)
2 (trigger adj (finger$ or thumb$ or digit$)).tw. (907)
3 (snapping adj (finger$ or thumb$ or digit$)).tw. (57)
4 (locking adj (finger$ or thumb$ or digit$)).tw. (11)
5 or/1-4 (1042)
6 Orthopedics/ (21203)
7 exp Orthopedic Procedures/ (427572)
8 su.fs. (1928203)
9 (surger$ or surgical$ or operat$).tw. (3007712)
10 or/6-9 (4139807)
11 5 and 10 (653)
12 random$.tw. (1235025)
13 factorial$.tw. (31365)
14 crossover$.tw. (63828)
15 cross over.tw. (28105)
16 cross-over.tw. (28105)
17 placebo$.tw. (263813)
18 (doubl$ adj blind$).tw. (184847)
19 (singl$ adj blind$).tw. (19969)
20 assign$.tw. (323523)
21 allocat$.tw. (120056)
22 volunteer$.tw. (228710)
23 crossover procedure/ (53097)
24 double blind procedure/ (143773)
25 randomized controlled trial/ (465603)
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26 single blind procedure/ (28838)
27 or/12-26 (1926861)
28 11 and 27 (53)
29 limit 28 to dd=20130214-20170802 (9)
Appendix 5. LILACS
Keyword: trigger finger
Appendix 6. ClinicalTrials.gov
Keyword: trigger finger
Appendix 7. WHO International Clinical Trials Registry Platform
Keyword: trigger finger
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27 March 2012 Amended CMSG ID A054-P
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